Compositions and methods for treating hepatitis b virus infection
The introduction of changes to the HBV genome through the base editor system has solved the limitations of existing HBV infection treatment methods, improved treatment efficiency and reduced costs, reduced transplantation needs, and achieved effective treatment of HBV infection.
Patent Information
- Application Number
- CN202280077560.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-08-16
- Filing Date
- 2022-09-27
- Publication Date
- 2024-11-22
Smart Images

Figure CN119013394A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to and the benefit of U.S. Provisional Application No. 63 / 371,634, filed on August 16, 2022, U.S. Provisional Application No. 63 / 357,623, filed on June 30, 2022, and U.S. Provisional Application No. 63 / 248,938, filed on September 27, 2021, the entire contents of which are incorporated herein by reference.
[0003] References to electronic sequence listings
[0004] The contents of the electronic sequence listing (180802_053004_PCT_SL.xml; size: 10,086,238 bytes; and creation date: September 26, 2022) are incorporated herein by reference in their entirety. Background Art
[0005] Hepatitis B is a serious liver infection caused by the hepatitis B virus (HBV). HBV is a small, DNA, hepatotropic virus that replicates via an RNA intermediate and can persist in infected cells by integrating into the host genome. Approximately 257 million people worldwide, including 850,000 to 2.2 million in the United States, are chronically infected with HBV. Chronic HBV infection manifests as chronic hepatitis, cirrhosis, and / or hepatocellular carcinoma. 20% to 30% of adults with chronic HBV infection will develop hepatocellular carcinoma or cirrhosis. HBV infection causes 600,000 to 1,000,000 deaths annually.
[0006] Current treatments for HBV infection have serious limitations. Antiviral drugs, such as tenofovir (a nucleotide reverse transcriptase inhibitor), can reduce viral replication but cannot cure patients with HBV infection. These antiviral therapies can cost patients as much as $500 to $1,500 per month. Due to the extent of liver damage caused by HBV, a transplant is sometimes necessary. In addition to the inherent risks of organ transplantation, the cost can also be prohibitive. Therefore, improved methods for treating HBV infection are urgently needed. Summary of the Invention
[0007] As described below, the present invention features compositions and methods for treating hepatitis B virus (HBV) infection by introducing changes into the HBV genome. In a specific embodiment, the present invention provides a base editor system (e.g., a fusion protein comprising a programmable DNA binding protein, a nucleobase editor, and a gRNA) for modifying the HBV genome to introduce changes, such as premature stop codons or deamination of nucleobases in the coding sequence of HBV or in HBV covalently closed circular DNA (cccDNA).
[0008] In one aspect, the invention of the present disclosure features a method for editing the nucleobases of the hepatitis B virus (HBV) genome. The method involves contacting the HBV genome with one or more guide RNAs and a base editor containing a polynucleotide programmable DNA binding domain and an adenosine deaminase. The guide RNA targets the base editor to achieve changes in the nucleobases of the HBV genome. The one or more guide RNAs contain a nucleotide sequence from 5′ to 3′ selected from one or more of the following, or 5′ and / or 3′ truncated fragments thereof of 1, 2, 3, 4, or 5 nucleotides: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO: 414), NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO: 416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO: 417).
[0009] On the other hand, the invention of the present disclosure features a method for editing the nucleobases of the hepatitis B virus (HBV) genome. The method involves (i) contacting cells containing the HBV genome with one or more guide RNAs and a base editor containing a polynucleotide programmable DNA binding domain and an adenosine deaminase or a cytidine deaminase. The guide RNA targets the base editor to achieve changes in the nucleobases of the HBV genome, thereby editing the nucleobases in the HBV genome. The method also includes (ii) contacting the cells with antiretroviral drugs. Relative to reference cells that have not been contacted with antiretroviral drugs, contacting the cells with antiretroviral drugs is associated with an increase in base editing efficiency.
[0010] On the other hand, the invention of the present disclosure features a method for editing the nucleobases of the hepatitis B virus (HBV) genome. The method involves (i) contacting cells containing the HBV genome with mRNA encoding BE4 and guide RNAs (gRNA37 and gRNA40). The guide RNA targets the base editor to achieve changes in the nucleobases of the HBV genome, thereby editing the nucleobases in the HBV genome. The method also involves (ii) contacting the cells with lamivudine. Contacting the cells with antiretroviral drugs is associated with an increase in base editing efficiency relative to reference cells that have not been exposed to antiretroviral drugs.
[0011] On the other hand, the invention of the present disclosure features a method for editing the nucleobases of the hepatitis B virus (HBV) genome. The method involves contacting a cell containing the HBV genome with an mRNA encoding a base editor and a guide RNA, wherein the base editor comprises a polynucleotide programmable DNA binding domain and an adenosine deaminase or a cytidine deaminase, and the guide RNA comprises the sequence GAAAGCCCAGGAUGAUGGGA (SEQ ID NO: 657) and CCAUGCCCCAAAGCCACCCA (SEQ ID NO: 662). The guide RNA targets the base editor to achieve changes in the nucleobases of the HBV genome, thereby editing the nucleobases in the HBV genome.
[0012] On the other hand, the invention of the present disclosure features a method for treating hepatitis B virus (HBV) infection in a subject. The method involves administering a fusion protein, a protein complex, or a polynucleotide encoding the fusion protein or protein complex to a subject in need. The fusion protein or protein complex contains a polynucleotide programmable DNA binding domain and a base editing domain that is an adenosine deaminase domain, and one or more guide RNAs that target the base editor domain to achieve a change of A·T to G·C of the nucleobase of the HBV genome. The one or more guide RNAs contain a nucleotide sequence from 5′ to 3′ selected from one or more of the following, or 5′ and / or 3′ truncated fragments thereof of 1, 2, 3, 4, or 5 nucleotides: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), CCCAAGGUCUUAC AUAAGAG (SEQ ID NO: 414), NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO: 416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO: 417).
[0013] In another aspect, the disclosed invention features a method of treating hepatitis B virus (HBV) infection in a subject. The method involves administering to a subject in need thereof one or more polynucleotides encoding a polynucleotide programmable DNA binding domain and a base editor domain that is an adenosine deaminase domain, and one or more guide RNAs that target the base editor domain to effect a change of an A·T nucleobase of the HBV genome to a G·C nucleobase. The one or more guide RNAs contain a nucleotide sequence from 5′ to 3′ selected from one or more of the following, or 5′ and / or 3′ truncated fragments thereof of 1, 2, 3, 4, or 5 nucleotides: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO: 414), NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO: 416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO: 417).
[0014] On the other hand, the invention of the present disclosure features a method for treating hepatitis B virus (HBV) infection in a subject. The method involves administering one or more guide RNAs and a base editor containing a polynucleotide programmable DNA binding domain and an adenosine deaminase or a cytidine deaminase to a subject in need. The one or more guide RNAs contain the sequences GAAAGCCCAGGAUGAUGGGA (SEQ ID NO: 657) and CCAUGCCCCAAAGCCACCCA (SEQ ID NO: 662), which target the base editor to effect a change in the nucleobases of the HBV genome, thereby editing the nucleobases in the HBV genome.
[0015] In another aspect, the disclosed invention features a composition containing a base editor bound to a guide RNA. The guide RNA contains a nucleotide sequence from 5′ to 3′ selected from one or more of the following, or a 5′ and / or 3′ truncated fragment of 1, 2, 3, 4 or 5 nucleotides thereof: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO: 414), NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO: 416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO: 417).
[0016] In another aspect, the invention of the present disclosure features a pharmaceutical composition for treating HBV infection. The composition comprises (i) a base editor or a nucleic acid encoding the base editor and one or more guide RNAs (gRNAs) comprising a nucleic acid sequence complementary to an HBV gene in a pharmaceutically acceptable excipient. The one or more guide RNAs contain a nucleotide sequence from 5′ to 3′ selected from one or more of the following, or 5′ and / or 3′ truncated fragments thereof of 1, 2, 3, 4, or 5 nucleotides: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO: 414), NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO: 416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO: 417).
[0017] In another aspect, the invention of the present disclosure features a method of treating HBV infection. The method involves administering a composition of any of the above aspects to a subject in need thereof.
[0018] In another aspect, the disclosed invention features a method of treating HBV infection, the method involving administering to a subject in need thereof a pharmaceutical composition of any of the above aspects.
[0019] In another aspect, the disclosed invention features the use of any of the above-described compositions for treating HBV infection in a subject.
[0020] In another aspect, the disclosed invention features the use of the pharmaceutical composition of any of the above aspects for treating HBV infection in a subject.
[0021] In another aspect, the disclosed invention features a guide RNA containing a nucleotide sequence from 5′ to 3′ selected from one or more of the following: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), or 1, 2, 3, 4, or 5 nucleotide 5′ and / or 3′ truncated fragments thereof. NO: 413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO: 416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO: 417).
[0022] In another aspect, the disclosed invention features a pharmaceutical composition containing (i) a nucleic acid encoding a base editor; and (ii) the guide RNA of any of the above aspects.
[0023] In any of the above aspects, the antiretroviral drug is selected from one or more of lamivudine, entecavir, tenofovir, interferon and pegylated interferon. In any of the above aspects, the retroviral drug is lamivudine.
[0024] In any of the above aspects, step (i) precedes step (ii), or step (ii) precedes step (i). In any of the above aspects, the cell is first contacted with an antiretroviral drug about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, or 14 days prior to step (i). In any of the above aspects, the cell has not been previously contacted with an antiretroviral drug. In any of the above aspects, the cell is in vivo. In any of the above aspects, the contacting is performed in a eukaryotic cell, a mammalian cell, or a human cell. In any of the above aspects, the cell is in vivo or ex vivo. In any of the above aspects or embodiments thereof, the subject is a mammal or a human. In any of the above aspects or embodiments thereof, the subject is a mammal. In any of the above aspects or embodiments thereof, the subject is a human.
[0025] In any of the above aspects, the HBV genome is contacted with two or more guide RNAs simultaneously.
[0026] In any of the above aspects, the guide RNA is selected from one or more of the following: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAACAAGAAAAACCCC (SEQ ID NO: 413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO: 414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO: 415). NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO:417).
[0027] In any of the above aspects, the one or more guide RNAs contain a spacer sequence selected from the sequences listed in Table 2A, Table 2B, Table 2C and / or SEQ ID NOs: 3105-5485 and 8220-10830.
[0028] In any of the above aspects, the one or more guide RNAs contain a spacer comprising the nucleotide sequence GAAAGCCCAGGAUGAUGGGA (SEQ ID NO: 657) and CCAUGCCCCAAAGCCACCCA (SEQ ID NO: 662). In any of the above aspects, the one or more guide RNAs contain the nucleotide sequence mG*mA*mA*AGCCCAGGAUGAUGGGAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUmU*mU*mU*(SEQ ID NO: 424) and mC*mC*mA*UGCCCCAAAGCCACCCAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGUGCUmU*mU*mU*(SEQ ID NO: 422).
[0029] In any of the above aspects, the base editing efficiency is increased by at least about 5%, 10%, 15% or 20%.
[0030] In any of the above aspects, the adenosine deaminase converts target A·T to G·C in the hepatitis B virus (HBV) genome.
[0031] In any of the above aspects, the nucleobase is located in a polynucleotide encoding an HBV protein. In any of the above aspects, the nucleobase is located in a polynucleotide sequence encoding an HBV protein selected from HBV core protein (Core), HBV polymerase (Pol), HBV surface protein or HBV protein X. In the embodiments of any of the above aspects, the change of the nucleobase in the polynucleotide encoding the HBV protein leads to a missense mutation. In the embodiments of any of the above aspects, the change of the nucleobase is associated with a decrease in transcription of the polynucleotide sequence encoding the HBV protein. In the embodiments of any of the above aspects, the HBV protein is HBV polymerase (Pol) and / or HBV protein X. In the embodiments of any of the above aspects, the missense mutation is located in the HBV pol gene. In embodiments of any of the foregoing aspects, the missense mutation results in E24G, L25F, P26F, R27C, V48A, V48I, S382F, V378I, V378A, V379I, V379A, L377F, D380G, D380N, F381P, R376G, A422T, F423P, A432V, M433V, P434S, D540G, A688V, D689G, A717T, E718K, P713S, P713L or L719P in the HBV polymerase protein encoded by the HBV pol gene. In embodiments of any of the foregoing aspects, the missense mutation is located in the HBV core gene. In embodiments of any of the above aspects, the missense mutation results in T160A, T160A, P161F, S162L, C183R, or *184Q in the HBV core protein encoded by the HBV core gene. In embodiments of any of the above aspects, the missense mutation is located in the HBV X gene. In embodiments of any of the above aspects, the missense mutation results in H86R, W120R, E122K, E121K, or L141P in the HBV X protein encoded by the HBV X gene. In embodiments of any of the above aspects, the missense mutation is located in the HBV S gene. In embodiments of any of the above aspects, the missense mutation results in S38F, L39F, W35R, W36R, T37I, T37A, R78Q, S34L, F80P, or D33G in the HBV S protein encoded by the HBV S gene.
[0032] In any of the above aspects, the nucleobase is associated with a transcription site. In embodiments of any of the above aspects, the transcription site is selected from one or more of enhancer II box A, enhancer I, and HBX promoter.
[0033] In any of the above aspects, the polynucleotide programmable DNA binding domain contains a Cas12 polypeptide. In any of the above aspects, the polynucleotide programmable DNA binding domain contains Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h or Cas12i. In any of the above aspects, the polynucleotide programmable DNA binding domain contains a sequence having at least about 85% amino acid sequence identity with Bacillus hisashii Cas12b, Bacillus thermoamylovorans Cas12b, Bacillus sp. V3-13Cas12b or Alicyclobacillus acidiphilus Cas12b. In any of the above aspects, the polynucleotide programmable DNA binding domain contains a sequence having at least about 85% amino acid sequence identity with Bacillus hisashii Cas12b (bhCas12b). In any of the above aspects, the polynucleotide programmable DNA binding domain contains a nuclease-inactive variant or a nickase variant. In an embodiment of any of the above aspects, the nuclease-inactive variant or the nickase variant contains a nuclease-activated bhCas12b containing amino acid substitutions D952A, S893R, K846R and E837G or their corresponding amino acid substitutions. In any of the above aspects, the base editor contains bhCas12b or a bhCas12b variant containing amino acid substitutions D952A, S893R, K846R and E837G.
[0034] In any of the above aspects, the base editor contains an adenosine deaminase. In any of the above aspects or embodiments thereof, the adenosine deaminase domain is capable of deaminating adenine in deoxyribonucleic acid (DNA). In any of the above aspects or embodiments thereof, the adenosine deaminase is a TadA deaminase. In an embodiment of any of the above aspects, the TadA deaminase is TadA*7.10, TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7, TadA*8.8, TadA*8.9, TadA*8.10, TadA*8.1 1. TadA*8.12, TadA*8.13, TadA*8.14, TadA*8.15, TadA*8.16, TadA*8.17, TadA *8.18, TadA*8.19, TadA*8.20, TadA*8.21, TadA*8.22, TadA*8.23 or TadA*8.24. In embodiments of any of the above aspects, the TadA deaminase is TadA*8.13.
[0035] In any of the above aspects, the one or more guide RNAs contain CRISPR RNA (crRNA) and trans-encoded small RNA (tracrRNA), wherein the crRNA contains a nucleic acid sequence complementary to the HBV nucleic acid sequence. In any of the above aspects, the one or more guide RNAs target three, four or five nucleobases of the HBV genome.
[0036] In any of the above aspects, the base editor forms a complex with a single guide RNA (sgRNA) containing a nucleic acid sequence complementary to the HBV nucleic acid sequence.
[0037] In any of the above aspects, the method involves editing two or more nucleobases.
[0038] In any of the above aspects, the method involves contacting the HBV genome with two or more guide RNAs targeting two or more HBV nucleic acid sequences. In any of the above aspects, the method involves delivering a fusion protein, a polynucleotide encoding a fusion protein, or one or more polynucleotides encoding a polynucleotide programmable DNA binding domain and a base editor domain, and one or more guide RNAs to a cell of a subject. In any of the above aspects or embodiments thereof, the cell is a hepatocyte.
[0039]
[0040] In any of the above aspects, the composition or pharmaceutical composition further comprises a lipid. In an embodiment of any of the above aspects, the lipid is a cationic lipid.
[0041] In any of the above aspects, the composition contains a pharmaceutically acceptable excipient.
[0042] In any of the above aspects, one or more gRNAs and base editors are formulated together. In any of the above aspects, one or more gRNAs and base editors are formulated separately.
[0043] In any of the above aspects, the composition or pharmaceutical composition further comprises a vector suitable for expression in mammalian cells, wherein the vector comprises a polynucleotide encoding a base editor. In any of the above aspects or embodiments thereof, the vector is a viral vector. In any of the above aspects or embodiments thereof, the viral vector is a retroviral vector, an adenoviral vector, a lentiviral vector, a herpes virus vector or an adeno-associated virus vector (AAV). In any of the above aspects or embodiments thereof, the composition or pharmaceutical composition further comprises ribonucleoprotein particles suitable for expression in mammalian cells.
[0044] In any of the above aspects, the HBV has genotype A or genotype D. In any of the above aspects, the method reduces the level of one or more markers selected from the group consisting of hepatitis B surface antigen, hepatitis B E antigen, hepatitis B virus total DNA, hepatitis B 3.5kb RNA, and hepatitis B covalently closed circular DNA. In any of the above aspects, the method edits the hepatitis B S antigen site and the precore (PreCore) site. In any of the above aspects or embodiments thereof, the editing efficiency is about 30% at the S antigen site and about 60% at the precore site.
[0045] In any of the above aspects, the nucleic acid encoding the base editor is mRNA.
[0046] In any of the above aspects, the one or more guide RNAs comprise the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcusususu (SEQ ID NO: 317), wherein a, c, u, or g represents a base with a 2′O-methyl (M) modification, and as, cs, us, or gs represents a base with a 2′-O-methyl 3′-phosphorothioate (MS) modification. In any of the above aspects, the one or more guide RNAs comprise the following nucleotide sequence: gsasasAGCCCAGGAUGAUGGGAgUUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcusususu (SEQ ID NO: 424) and
[0047] cscsasUGCCCCAAAGCCACCCAgUUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcusususu (SEQ ID NO: 422), wherein a, c, u, or g represents an A, C, U, or G nucleotide containing a 2′-O-methyl (M) modification, respectively; and as, cs, us, or gs represents an A, C, U, or G nucleotide containing a 2′-O-methyl 3′-phosphorothioate (MS) modification, respectively.
[0048] In any of the above aspects, cells are contacted with one or more guide RNAs and base editors at a first time point and a second time point. In embodiments, the first and second contacting of cells are at least one week apart. In embodiments, the first and second contacting of cells are at least two weeks apart.
[0049] In any of the above aspects, the base editor is BE4. In any of the above aspects, the gRNA comprises GAAAGCCCAAGAUGAUGGGA (SEQ ID NO. 10834).
[0050] The compositions and articles defined herein are isolated or otherwise prepared in conjunction with the examples provided below. Other features and advantages of the invention will be apparent from the detailed description and from the claims.
[0051] definition
[0052] Unless otherwise defined, all technical and scientific terms used herein have the meanings commonly understood by those skilled in the art to which the invention belongs. The following references provide general definitions of many of the terms used in the present invention for those skilled in the art: Singleton et al., Dictionary of Microbiology and Molecular Biology (2nd ed., 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); The Glossary of Genetics, 5th ed., R. Rieger et al. (eds.), Springer Verlag (1991); and Hale & Marham, The Harper Collins Dictionary of Biology (1991). Unless otherwise specified, the following terms as used herein have the meanings described below.
[0053] By "BE4 polypeptide" is meant a polypeptide having at least about 85% identity to the following amino acid sequence, or a fragment thereof having cytidine deaminase activity:
[0054]
[0055] "BE4 polynucleotide" means a polynucleotide encoding a BE4 polypeptide.
[0056] "HBV polymerase (pol) protein" means a polypeptide having at least about 95% identity to a wild-type HBV polymerase amino acid sequence or a fragment thereof that functions in hepatitis B virus infection. In one embodiment, the HBV polymerase is encoded by genotype HBV A, B, C, D, E, F, G, or H. In one embodiment, the HBV polymerase amino acid sequence is provided in UniPro Accession No. Q8B5R0-1, reproduced below.
[0057] MPLSYQHFRRLLLLDDEAGPLEEELPRLADEGLNRRVAEDLNLGNLNVSIPWTHKVGNFTGLYSSTVPVFNPHWKTPSFPNIHLHQDIIKKCEQFVGPLTVNEKRRLQLIMPARFYPKVTKYLPLDKGIKPYYPEHLVNHYFQTRHYLHTLWKAGILYKRETTHSASFCGSPYSWEQDLQHGAESFHQQS(SEQ ID NO: 370).
[0058] Mutations in HBV polymerase include: E24G, L25F, P26F, R27C, V48A, V48I, S382F, V378I, V378A, V379I, V379A, L377F, D380G, D380N, F381P, R376G, A422T, F423P, A432V, M433V, P434S, D540G, A688V, D689G, A717T, E718K, P713S, P713L, or L719P.
[0059] Other exemplary HBV DNA polymerases include, for example, NCBI Accession No. AAB59972.1, which has the following sequence:
[0060] MPLSYQHFRKLLLLDDEAGPLEEELPRLADEGLNRRVAEDLNLGNLNVSIPWTHKVGNFTGLYSSTVPVFNPHWKTPSFPNIHLHQDIIKKCEQFVGPLTVNEKRRLQLIMPARFYPKVTKYLPLDKGIKPYYPEHLVNHYFQTRHYLHTLWKAGILYKRETTHSASFCGSPYSWEQDLQHGAESFHQQSSGILSRPPVGSSLQSKHSKSRLGLQSQQGHLARRQQGRSWSIRAGFHPTARRPFGVEPSGSGHTTNFASKSASCLHQSPDRKAAYPAVSTFEKHSSSGHAVEFHNLSPNSARSQSERPVFPCWWLQFRSSKPCSDYCLSLIVNLLEDWGPCAEHGEHHIRIPRTPSRVTGGVFLVDKNPHNTAESRLVVDFSQFSRGNYRVSWPKFAVPNLQSLTNLLSSNLSWLSLDVSAAFYHLPLHPAAMPHLLVGSSGLSRYVARLSSNSRILNHQHGTMPNLHDYCSRNLYVSLLLLYQTFGRKLHLYSHPIILGFRKIPMGVGLSPFLLAQFTSAICSVVRRAFPHCLAFSYMDDVVLGAKSVQHLESLFTAVTNFLLSLGIHLNPNKTKRWGYSLNFMGYVIGSYGSLPQEHIIQKIKECFRKLPINRPIDWKVCQRIVGLLGFAAPFTQCGYPALMPLYACIQSKQAFTFSPTYKAFLCKQYLNLYPVARQRPGLCQVFADATPTGWGLVMGHQRVRGTFSAPLPIHTAELLAACFARSRSGANIIGTDNSVVLSRKYTSYPWLLGCAANWILRGTSFVYVPSALNPADDPSRGRLGLSRPLLRLPFRPTTGRTSLYADSPSVPSHLPDRVHFASPLHVAWRPP(SEQ ID NO: 371).
[0061] "HBV polymerase gene" means a polynucleotide encoding HBV polymerase.
[0062] "Hepatitis B surface antigen (HBsAg) polypeptide" or "HBV surface protein (S)" means an antigenic protein or fragment thereof having at least about 85% identity to NCBI Accession No. AAB59969.1 that plays a role in HBV viral infection. An exemplary HBsAg amino acid sequence is provided below:
[0063] MENITSGFLGPLLVLQAGFFLLTRILTIPQSLDSWWTSLNFLGGTTVCLGQNSQSPTSNHSPTSCPPTTCPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLIPGSST TSTGPCRTCMTTAQGTSMYPSCCCTKPSDGNCTCIPIPSSWAFGKFLWEWASARFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFFCLWVYI(SEQ ID NO: 372).
[0064] "HBsAg polynucleotide" means a polynucleotide encoding the HBsAg protein.
[0065] "HBV X-protein" or "HBV protein X" means a polypeptide or fragment thereof having at least about 85% identity to NCBI Accession No. AAB59970.1 that plays a role in HBV viral infection. An exemplary amino acid sequence is provided below:
[0066] MAARLCCQLDPARDVLCLRPVGAESCGRPFSGSLGTLSSPSPSAVPTDHGAHLSLRGLPVCAFSSAGPCALRFTSARRMETTVNAHRMLPKVLHKRTLGLSAMSTTDLEAYFKDCLFKDWEELGEEIRLKVFVLGGCRHKLVCAPAPCNFFTSA (SEQ ID NO: 373).
[0067] "Core antigen precursor," "precore protein," or "hepatitis B e antigen (HBeAg)" means a polypeptide or fragment thereof having at least about 85% identity to NCBI Accession No. AAB59971.1 reproduced below that plays a role in HBV viral infection.
[0068] MQLFHLCLIISCSCPTVQASKLCLGWLWGMDIDPYKEFGATVELLSFLPSDFFPSVRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMTLATWVGVNLEDP ASRDLVVSYVNTNMGLKFRQLLWFHISCLTFGRETVIEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQSPRRRRSQSREPQC(SEQ IDNO: 10831).
[0069] "HBV core protein," "HBc," or "core protein" means a polypeptide that is at least about 95% identical to a wild-type HBV core protein amino acid sequence or a fragment thereof. In one embodiment, the HBV core protein plays a role in hepatitis B virus infection. In one embodiment, the HBV core protein is encoded by an HBV A, B, C, D, E, F, G, or H genotype. In one embodiment, the HBV core protein amino acid sequence is provided in NCBI GenBank Accession No. AXG50928.1 and is provided below:
[0070] MDIDPYKEFGASVELLSFLPSDFFPSIRDLLDTASALYREALESPEHCSPHHTALRQAILCWGELMNLATWVGSNLEDPASRELVVSYVNVNMGLKIRQLLWFHISCLTFGRETVLEYLVSFGVWIRTPPAYRPPNAPILSTLPETTVVRRRGRSPRRRTPSPRRRRSQSPRRRRSQSRESQC (SEQ ID NO: 374). "HBV X protein" means a polynucleotide encoding an HBV X protein.
[0071] "HBV X protein (genotype B)" means a polypeptide having at least about 95% identity to the wild-type HBV genotype BX protein amino acid sequence or a fragment thereof. In one embodiment, the HBV X protein plays a role in hepatitis B virus infection. In one embodiment, the HBV genotype BX protein amino acid sequence is provided in NCBI GenBank Accession No. BAQ95575.1 and is provided below:
[0072] MAARLCCQLDPARDVLCLRPVGAESRGRPLPGPLGALPPASPPVVPSDHGAHLSLRGLPVCAFSSXGPCALRFTSARRMETTVNAHRNLPKVLHKRTLGLSAMSTTDLEAYFKDCVFXEWEELGEEXRLKVFVLGGCRHKLVCSPAPCNFFTSA (SEQ ID NO: 375).
[0073] "HBV X protein (genotype C)" means a polypeptide having at least about 95% identity to the wild-type HBV genotype CX protein amino acid sequence or a fragment thereof. In one embodiment, the HBV X protein plays a role in hepatitis B virus infection. In one embodiment, the HBV genotype CX protein amino acid sequence is provided in NCBI GenBank Accession No. BAQ95563.1 and is provided below:
[0074] MAARVCCQLDPARDVLCLRPVGAESRGRPVSGPFGPLPSSSAVPADYGAHLSLRGLPVCAFSSAGPCALRFTSARRMETTVNAHQVLPKLLHKRTLGLSAMSTTDLEAYFKDCLFKDWEELGEEIRLKVFVLGGCRHKLVCSPAPCNFFTSA (SEQ ID NO: 376).
[0075] "HBV S protein" means a polypeptide having at least about 95% identity to the wild-type HBV S protein amino acid sequence or a fragment thereof. In one embodiment, the HBV S protein plays a role in hepatitis B virus infection. In one embodiment, the HBV S protein is encoded by HBV A, B, C, D, E, F, G, or H genotypes. In one embodiment, the HBV S protein amino acid sequence is provided in NCBI GenBank Accession No. ABV02793.1 and is provided below:
[0076] MENTTSGFLGPLLVLQAGFFLLTRNLTIPQSLDSWWTSLNFLGGAPTCPGQNSQSPTSNHSPTSCPPICPGYRWMCLRRFIIFLFILLLCLIFLLVLLDYQGMLPVCPLLPGTST TSTGPCKTCTIPAQGTSMFPSCCCTKPSDGNCTCIPIPSSWAFARFLWEWASVRFSWLSLLVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYNILSPFLPLLPIFFCLWVYI(SEQ ID NO: 377).
[0077] The complete genome of hepatitis B virus subtype ayw, i.e., the complete genome, including polynucleotides encoding HBV polymerase, HBsAg protein, HBV X protein, and core antigen precursor, is provided in GenBank accession number U95551.1, reproduced below. The nucleotide positions of regions corresponding to regulatory elements (e.g., enhancer I, enhancer II box A, HBX promoter) and polypeptide-encoding sequences in the hepatitis B virus genome are known in the art (see, e.g., Panjaworayan et al. "HBVRegDB: Annotation, comparison, detection and visualization of regulatory elements in hepaitis B virus sequences," Virol. J., 4:136, DOI: 10.1186 / 1743-422X-4-136).
[0078]
[0079] "Adenine" or "9H-purine-6-amine" means a purine having the molecular formula C5H5N5 and the structure and corresponds to the purine nucleobase with CAS number 73-24-5.
[0080] "Adenosine" or "4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2(1H)-one" means a glycosidic bond attached to a ribose sugar having the structure And corresponds to the adenine molecule with CAS number 65-46-3. Its molecular formula is C 10 H 13 N5O4.
[0081] "Adenosine deaminase" or "adenine deaminase" means a polypeptide or fragment thereof that can catalyze the hydrolytic deamination of adenine or adenosine. In some embodiments, the deaminase or deaminase domain is an adenosine deaminase that catalyzes the hydrolytic deamination of adenosine to inosine or the hydrolytic dehydrogenation of deoxyadenosine to deoxyinosine. In some embodiments, the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA). Adenosine deaminase provided herein (e.g., engineered adenosine deaminase, evolved adenosine deaminase) can be from any organism (e.g., eukaryotes, prokaryotes), including but not limited to algae, bacteria, fungi, plants, invertebrates (e.g., insects) and vertebrates (e.g., amphibians, mammals). In some embodiments, the adenosine deaminase is an adenosine deaminase variant with one or more changes, and is capable of deaminating adenine and cytosine in a target polynucleotide (e.g., DNA, RNA). In some embodiments, the target polynucleotide is single-stranded or double-stranded. In some embodiments, the adenosine deaminase variants are capable of deaminating adenine and cytosine in DNA. In some embodiments, the adenosine deaminase variants are capable of deaminating adenine and cytosine in single-stranded DNA. In some embodiments, the adenosine deaminase variants are capable of deaminating adenine and cytosine in RNA.
[0082] "Adenosine deaminase activity" means catalyzing the deamination of adenine or adenosine to guanine in a polynucleotide. In some embodiments, adenosine deaminase variants as provided herein retain adenosine deaminase activity (e.g., at least about 30%, 40%, 50%, 60%, 70%, 80%, 90% or more of the activity of a reference adenosine deaminase (e.g., TadA*8.20 or TadA*8.19)).
[0083] "Adenosine base editor (ABE)" means a base editor comprising an adenosine deaminase.
[0084] "Adenosine base editor (ABE) polynucleotide" means a polynucleotide encoding an ABE. "Adenosine deaminase base editor 8 (ABE8) polynucleotide" or "ABE8" means a base editor comprising an adenosine deaminase variant as defined herein, comprising one or more alterations listed in Table 15, one of the combinations of alterations listed in Table 15, or an alteration at one or more positions listed in Table 15 (e.g., 82 and / or 166), relative to the following reference sequence: MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1).
[0085] In some embodiments, ABE8 comprises further alterations relative to the reference sequence, as described herein.
[0086] "Adenosine deaminase base editor 8 (ABE8) polynucleotide" means a polynucleotide encoding ABE8.
[0087] "Administering" herein refers to providing one or more of the compositions described herein to a patient or subject.
[0088] By "agent" is meant any small molecule chemical compound, antibody, nucleic acid molecule or polypeptide or a fragment thereof.
[0089] By "alteration" is meant a change (increase or decrease) in the level, structure, or activity of an analyte, gene, or polypeptide as detected by standard art-known methods (such as those described herein). As used herein, an alteration includes a 10% change in expression level, a 25% change in expression level, a 40% change, and a 50% or greater change. In some embodiments, the alteration includes an insertion, deletion, or substitution of a nucleobase or amino acid.
[0090] The term "improve" means to reduce, inhibit, alleviate, attenuate, prevent or stabilize the development or progression of a disease.
[0091] The term "analog" refers to a molecule that is not identical but has similar functional or structural features. For example, a polypeptide analog retains the biological activity of the corresponding naturally occurring polypeptide while having certain biochemical modifications that enhance the analog's function relative to the naturally occurring polypeptide. Such biochemical modifications may increase the analog's protease resistance, membrane permeability, or half-life without altering, for example, ligand binding. Analogs may include unnatural amino acids.
[0092] The so-called "base editor (BE)" or "nucleobase editor polypeptide (NBE)" refers to an agent that binds to a polynucleotide and has nucleobase modification activity. In various embodiments, the base editor comprises a nucleobase modification polypeptide (e.g., a deaminase) and a polynucleotide programmable nucleotide binding domain (e.g., Cas9 or Cpf1) bound to a guide polynucleotide (e.g., a guide RNA (gRNA)). Representative nucleic acid and protein sequences of base editors are provided in the sequence listing as SEQ ID NOs: 2-11.
[0093] "Base editing activity" means an action that chemically changes a base within a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is cytidine deaminase activity, for example, converting the target C·G to T·A. In another embodiment, the base editing activity is adenosine or adenine deaminase activity, for example, converting A·T to G·C.
[0094] The term "base editor system" refers to an intermolecular complex for editing the core bases of a target nucleotide sequence. In various embodiments, the base editor (BE) system includes (1) a polynucleotide programmable nucleotide binding domain, a deaminase domain (e.g., cytidine deaminase or adenosine deaminase) for deaminating the core bases in the target nucleotide sequence; and (2) one or more guide polynucleotides (e.g., guide RNA) bound to the polynucleotide programmable nucleotide binding domain. In various embodiments, the base editor (BE) system includes a core base editor domain selected from adenosine deaminase or cytidine deaminase, and a domain with nucleic acid sequence-specific binding activity. In some embodiments, the base editor system includes (1) a base editor (BE), which includes a polynucleotide programmable DNA binding domain and a deaminase domain for deaminating one or more core bases in the target nucleotide sequence; and (2) one or more guide RNAs bound to the nucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the base editor is a cytidine base editor (CBE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE). In some embodiments, the base editor is an adenine or adenosine base editor (ABE) or a cytidine base editor (CBE).
[0095] The so-called "base editing activity" means the effect of chemically changing a base within a polynucleotide. In one embodiment, a first base is converted to a second base. In one embodiment, the base editing activity is cytidine deaminase activity, for example, converting the target C·G to T·A. In another embodiment, the base editing activity is adenosine deaminase activity, for example, converting A·T to G·C.
[0096] The term "Cas9" or "Cas9 domain" refers to an RNA-guided nuclease that comprises a Cas9 protein or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9 and / or a gRNA binding domain of Cas9). Cas9 nucleases are sometimes also referred to as casn1 nucleases or CRISPR (clustered regularly interspaced short palindromic repeats)-associated nucleases.
[0097] The term "conservative amino acid substitution" or "conservative mutation" refers to the replacement of one amino acid by another amino acid having common properties. A functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, GE and Schirmer, RH, Principles of Protein Structure, Springer-Verlag, New York (1979)). Based on this type of analysis, groups of amino acids can be defined in which the amino acids within the group are preferentially exchanged with each other and are therefore most similar to each other in terms of their effect on the overall protein structure (Schulz, GE and Schirmer, RH, supra). Non-limiting examples of conservative mutations include amino acid substitutions of amino acids, such as lysine for arginine, and conversely, so that a positive charge can be maintained; glutamic acid for aspartic acid, and conversely, so that a negative charge can be maintained; serine for threonine, so that free -OH can be maintained; and glutamine for asparagine, so that free -NH2 can be maintained.
[0098] The terms "coding sequence" or "protein coding sequence," used interchangeably herein, refer to a segment of a polynucleotide that encodes a protein. A coding sequence may also be referred to as an open reading frame. The region or sequence is bounded by a start codon closer to the 5' end and a stop codon closer to the 3' end. Useful stop codons for the base editors described herein include the following:
[0099] Glutamine CAG→TAG stop codon
[0100] CAA→TAA
[0101] Arginine CGA→TGA
[0102] Tryptophan TGG→TGA
[0103] TGG→TAG
[0104] TGG→TAA
[0105] So-called “complex” means a combination of two or more molecules whose interaction depends on intermolecular forces. Non-limiting examples of intermolecular forces include covalent and non-covalent interactions. Non-limiting examples of non-covalent interactions include hydrogen bonds, ionic bonds, halogen bonds, hydrophobic bonds, van der Waals interactions (e.g., dipole-dipole interactions, dipole-induced dipole interactions, and London dispersion forces) and π-effects. In one embodiment, the complex comprises a polypeptide, a polynucleotide, or a combination of one or more polypeptides and one or more polynucleotides. In one embodiment, the complex comprises one or more polypeptides and polynucleotides (e.g., guide RNA) that associate to form a base editor (e.g., a base editor comprising a nucleic acid programmable DNA binding protein (such as Cas9) and a deaminase). In one embodiment, the complex is held together by hydrogen bonds. It should be understood that one or more components of a base editor (e.g., a deaminase or a nucleic acid programmable DNA binding protein) may be covalently or non-covalently associated. As an example, a base editor may include a deaminase covalently linked (e.g., by a peptide bond) to a nucleic acid programmable DNA binding protein. Alternatively, the base editor may comprise a non-covalently associated deaminase and a nucleic acid programmable DNA binding protein (e.g., wherein one or more components of the base editor are provided in trans and associated directly or via another molecule such as a protein or nucleic acid). In one embodiment, one or more components of the complex are held together by hydrogen bonds.
[0106] "Cytosine" or "4-aminopyrimidin-2(1H)-one" means a cytosine having the molecular formula C4H5N3O and the structure and corresponds to the purine nucleobase with CAS number 71-30-7.
[0107] "Cytidine" means a cytidine having the structure And it corresponds to the cytosine molecule with CAS number 65-46-3. Its molecular formula is C9H 13 N3O5.
[0108] "Cytidine base editor (CBE)" means a base editor comprising a cytidine deaminase.
[0109] "Cytidine base editor (CBE) polynucleotide" means a polynucleotide comprising a CBE.
[0110] "Cytidine deaminase" or "cytosine deaminase" means a polypeptide or fragment thereof that is capable of deaminating cytidine or cytosine. In one embodiment, the cytidine deaminase converts cytosine to uracil or converts 5-methylcytosine to thymine. The terms "cytidine deaminase" and "cytosine deaminase" are used interchangeably throughout this application. Sea lamprey (Petromyzon marinus) cytosine deaminase 1 (PmCDA1) (SEQ ID NOs: 13-14), activation-induced cytidine deaminase (AICDA) (SEQ ID NOs: 15-21), and APOBEC (SEQ ID NOs: 12-61) are exemplary cytidine deaminases. Other exemplary cytidine deaminase (CDA) sequences are provided in the sequence listing as SEQ ID NOs: 62-66 and SEQ ID NOs: 67-189. In embodiments, the cytidine deaminase is BE4, rrA3F, or ppApo.
[0111] By "rra3F polypeptide" is meant a cytidine deaminase having cytidine deaminase activity, whose amino acid sequence has about or at least about 85%, 90%, 95%, 99%, or 100% sequence identity to:
[0112] MKPQIRDHRPNMEAMYPHIFYFHFENLEKAYGRNETWLCFTVEIIKQYLPVPWKKGVFRNQVDPETHCHAEKCFLSWFCNNTLSPKKNYQVTWYTSWSPCPECAGEVAEFLAEHSNVKLTIYTARLYYFWDTDYQEGLRSLSEEGASVEIMDYEDFQYCWENFVYDDGEPFKRWKGLKYNFQSLTRRLREILQ(SEQ ID NO: 67).
[0113] "ppAPOBEC-1 (ppApo)" means a cytidine deaminase having cytidine deaminase activity, whose amino acid sequence has about or at least about 85%, 90%, 95%, 99%, or 100% sequence identity to:
[0114] MTSEKGPSTGDPTLRRRIESWEFDVFYDPRELRKETCLLYEIKWGMSRKIWRSSGKNTTNHVEVNFIKKFTSERRFHSSISCSITWFLSWSPCWECSQAIREFLSQHPGVTLVIYVARLF WHMDQRNRQGLRDLVNSGVTIQIMRASEYYHCWRNFVNYPPGDEAHWPQYPPLWMMLYALELHCIILSLPPCLKISRRWQNHLAFFRLHLQNCHYQTIPPHILLATGLIHPSVTWR(SEQ ID NO: 23).
[0115] "Cytosine" means a pyrimidine nucleobase having the molecular formula C4H5N3O.
[0116] "Cytosine deaminase activity" means catalyzing the deamination of cytosine or cytidine. In one embodiment, a polypeptide having cytosine deaminase activity converts an amino group into a carbonyl group. In one embodiment, a cytosine deaminase converts cytosine into uracil (i.e., C to U) or converts 5-methylcytosine into thymine (i.e., 5mC to T). In some embodiments, a cytosine deaminase as provided herein has an increased cytosine deaminase activity relative to a reference cytosine deaminase (e.g., at least 10-fold, 20-fold, 30-fold, 40-fold, 50-fold, 60-fold, 70-fold, 80-fold, 90-fold, 100-fold, or more).
[0117] As used herein, the term "deaminase" or "deaminase domain" refers to a protein or fragment thereof that catalyzes a deamination reaction.
[0118] "Detection" refers to identifying the presence, absence, or amount of an analyte to be detected. In one embodiment, sequence changes in a polynucleotide or polypeptide are detected. In another embodiment, the presence of an indel is detected.
[0119] By "detectable label" is meant a composition that, when attached to a molecule of interest, renders the latter detectable by spectroscopic, photochemical, biochemical, immunochemical, or chemical means. For example, useful labels include radioisotopes, magnetic beads, metal beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (e.g., as commonly used in enzyme-linked immunosorbent assays (ELISAs)), biotin, digoxigenin, or haptens.
[0120] "Disease" means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ. Examples of diseases include HBV infection and related diseases and disorders, including cirrhosis, hepatocellular carcinoma (HCC), and any other disease associated with or caused by HBV infection.
[0121] "Effective amount" means the amount required to improve the symptoms of the disease relative to an untreated patient. The effective amount of the active compound used to practice the present invention to treat the disease varies according to the mode of administration, the age, weight and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. This amount is referred to as an "effective" amount. In one embodiment, the effective amount is the amount of the base editor of the present invention sufficient to introduce changes in the HBV genome into a cell (e.g., in vitro or in vivo). In one embodiment, the effective amount is the amount of the base editor required to achieve a therapeutic effect (e.g., reducing or controlling HBV infection). This therapeutic effect does not need to be sufficient to change the HBV genome in all cells of the subject, tissue or organ, but only needs to change the HBV genome in about 1%, 5%, 10%, 25%, 50%, 75% or more of the cells in the subject, tissue or organ. In one embodiment, the effective amount is sufficient to improve one or more symptoms of HBV.
[0122] "Entecavir" means having a structure The molecule corresponding to CAS No. 142217-69-4 and its pharmaceutically acceptable salts. Entecavir has antiretroviral activity.
[0123] By "fragment" is meant a portion of a polypeptide or nucleic acid molecule. This portion contains at least about 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the full length of a reference nucleic acid molecule or polypeptide. A fragment can contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
[0124] "Guiding polynucleotide" means a polynucleotide or polynucleotide complex that is specific for a target sequence and can form a complex with a polynucleotide programmable nucleotide binding domain protein (e.g., Cas9 or Cpf1). In one embodiment, the guiding polynucleotide is a guide RNA (gRNA). The gRNA can exist as a complex of two or more RNAs, or as a single RNA molecule.
[0125] "Hybridization" means hydrogen bonding between complementary nucleobases, which can be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding. For example, adenine and thymine are complementary nucleobases that pair by forming hydrogen bonds.
[0126] By "increase" is meant a positive change of at least 10%, 25%, 50%, 75% or 100%.
[0127] The terms "inhibitor of base repair," "base repair inhibitor," "IBR," or grammatical equivalents thereof refer to proteins that are capable of inhibiting the activity of nucleic acid repair enzymes, such as base excision repair enzymes.
[0128] An "intein" is a fragment of a protein that is able to cleave itself off in a process called protein splicing, and the remaining fragment (the extein) is joined by peptide bonds.
[0129] The terms "isolated," "purified," or "biologically pure" refer to a material that is free to varying degrees from components normally associated with its natural state. "Isolated" means a degree of separation from the original source or surrounding environment. "Purified" means a degree of separation greater than that of isolation. A "purified" or "biologically pure" protein is sufficiently free from other substances so that any impurities do not substantially affect the biological properties of the protein or cause other undesirable consequences. That is, a nucleic acid or peptide of the invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized. Purity and homogeneity are typically determined using analytical chemistry techniques, such as polyacrylamide gel electrophoresis or high performance liquid chromatography. The term "purified" can mean that a nucleic acid or protein produces essentially a single band in an electrophoretic gel. For proteins that can be modified (e.g., phosphorylated or glycosylated), different modifications may result in different isolated proteins that can be purified separately.
[0130] "Isolated polynucleotide" means a nucleic acid (e.g., DNA) that is free of the genes that flank the genes in the naturally occurring genome of the organism from which the nucleic acid molecule of the invention is derived. Thus, the term includes, for example, recombinant DNA that is incorporated into a vector; incorporated into an autonomously replicating plasmid or virus; or incorporated into the genomic DNA of a prokaryotic or eukaryotic organism; or exists as a separate molecule (e.g., cDNA or genomic or cDNA fragments generated by PCR or restriction endonuclease digestion) that is independent of other sequences. In addition, the term includes RNA molecules transcribed from a DNA molecule, as well as recombinant DNA that is part of a hybrid gene encoding another polypeptide sequence.
[0131] By "isolated polypeptide" is meant a polypeptide of the present invention that has been separated from components with which it is naturally associated. Generally, a polypeptide is isolated when it is at least 60% by weight free from proteins and naturally occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99% by weight of the polypeptide of the present invention. An isolated polypeptide of the present invention can be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any suitable method, such as column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
[0132] "Lamivudine" or "3TC" means a compound with the structure The molecule corresponding to CAS number 134678-17-4 and having the IUPAC name 2',3'-dideoxy-3'-thiacytidyl-4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]-1,2-dihydropyrimidin-2-one and its pharmaceutically acceptable salts. Lamivudine has antiretroviral activity. Lamivudine is classified as a nucleoside / nucleotide reverse transcriptase inhibitor (NRTI).
[0133] As used herein, the term "linker" refers to a molecule that connects two moieties. In one embodiment, the term "linker" refers to a covalent linker (eg, a covalent bond) or a non-covalent linker.
[0134] "Marker" means any protein or polynucleotide with an expression level or activity that is associated with a disease or condition. Examples of diseases include HBV infection and related diseases and conditions (including cirrhosis, hepatocellular carcinoma (HCC)) and any other disease associated with or caused by HBV infection. The marker can be an HBV polynucleotide and / or polypeptide. Non-limiting examples of hepatitis B virus markers include HBsAg, HBeAg, core protein, 3.5kb viral RNA, and cccDNA (see, for example, Bai et al. "Quantification of Pregenomic RNA and Covalently Closed Circular DNA in Hepatitis B Virus-Related Hepatocellular Carcinoma," Int J Hepatol, 2013: 849290 (2013), DOI: 10.1155 / 2013 / 849290).
[0135] As used herein, the term "mutation" refers to the replacement of a residue within a sequence (e.g., a nucleic acid or amino acid sequence) by another residue, or the deletion or insertion of one or more residues within the sequence. Mutations are generally described herein by identifying the original residue, then identifying the position of the residue within the sequence, and then identifying the identity of the newly replaced residue. Various methods for performing amino acid substitutions (mutations) provided herein are well known in the art and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY (2012)).
[0136] As used herein, the terms "nucleic acid" and "nucleic acid molecule" refer to compounds comprising core bases and acidic moieties, such as polymers of nucleosides, nucleotides or nucleotides. Typically, polymeric nucleic acids (e.g., nucleic acid molecules comprising three or more nucleotides) are linear molecules in which adjacent nucleotides are connected to one another via phosphodiester bonds. In some embodiments, "nucleic acid" refers to independent nucleic acid residues (e.g., nucleotides and / or nucleosides). In some embodiments, "nucleic acid" refers to an oligonucleotide chain comprising three or more independent nucleotide residues. As used herein, the terms "oligonucleotide" and "polynucleotide" can be used interchangeably to refer to polymers (e.g., strings of at least three nucleotides) of nucleotides. In some embodiments, "nucleic acid" encompasses RNA and single-stranded and / or double-stranded DNA. Nucleic acid can be naturally occurring, for example, in the case of genomes, transcripts, mRNAs, tRNAs, rRNAs, siRNAs, snRNAs, plasmids, cosmids, chromosomes, chromatids or other naturally occurring nucleic acid molecules. On the other hand, nucleic acid molecules can be non-naturally occurring molecules, such as recombinant DNA or RNA, artificial chromosome, engineered genome or its fragment, or synthetic DNA, RNA, DNA / RNA hybrid, or comprise non-naturally occurring nucleotides or nucleosides. In addition, term " nucleic acid ", " DNA ", " RNA " and / or similar terms comprise nucleic acid analogs, such as analogs with the component except the phosphodiester backbone. Nucleic acid can be produced by natural source purification, using recombinant expression system, and optionally purified, chemically synthesized etc. When appropriate, such as in the case of chemically synthesized molecule, nucleic acid can comprise nucleoside analogs, such as analogs with chemically modified base or sugar and backbone modifications. Unless otherwise indicated, nucleotide sequence is presented with 5 ' to 3 ' direction. In some embodiments, the nucleic acid is or comprises natural nucleosides (e.g., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine); nucleoside analogs (e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyladenosine, 5-methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5-propynyl-uridine, C5-propynyl-cytidine, C5-methyl cytidine, 2-aminoadenosine, 7-deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine); chemically modified bases; biologically modified bases (e.g., methylated bases); inserted bases; modified sugars (e.g., 2′-fluororibose, ribose, 2′-deoxyribose, arabinose, and hexose); and / or modified phosphate groups (e.g., phosphorothioate and 5′-N-phosphoramidite linkages).
[0137] The term "nuclear localization sequence," "nuclear localization signal," or "NLS" refers to an amino acid sequence that facilitates the import of proteins into the cell nucleus. Nuclear localization sequences are known in the art and are described, for example, in International PCT Application No. PCT / EP2000 / 011690, filed November 23, 2000, by Plank et al. and published as WO / 2001 / 038547 on May 31, 2001, the contents of which are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS, such as described by Koblan et al., Nature Biotech. 2018 doi:10.1038 / nbt.4172. In some embodiments, the NLS comprises the amino acid sequence KRTADGSEFESPKKKRKV (SEQ ID NO: 190), KRPAATKKAGQAKKKK (SEQ ID NO: 191), KKTELQTTNAENKTKKL (SEQ ID NO: 192), KRGINDRNFWRGENGRKTR (SEQ ID NO: 193), RKSGKIAAIVVKRPRK (SEQ ID NO: 194), PKKKRKV (SEQ ID NO: 195), or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO: 196).
[0138] The terms "nucleobase," "nitrogenous base," or "base," used interchangeably herein, refer to nitrogenous biological compounds that form nucleosides, which are components of nucleotides. The ability of nucleobases to form base pairs and stack on each other directly leads to long helical structures, such as ribonucleic acid (RNA) and deoxyribonucleic acid (DNA). The five nucleobases, adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U), are referred to as primary or canonical. Adenine and guanine are derived from purines, and cytosine, uracil, and thymine are derived from pyrimidines. DNA and RNA may also contain other modified (non-basic) bases. Non-limiting examples of modified nucleobases may include hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5-methylcytosine (m5C), and 5-hydroxymethylcytosine. Hypoxanthine and xanthine can be produced by the presence of mutagens, and both are produced by deamination (replacing an amine group with a carbonyl group). Hypoxanthine can be modified from adenine. Xanthine can be modified from guanine. Uracil can be produced by deamination of cytosine. "Nucleoside" consists of a nucleobase and a five-carbon sugar (ribose or deoxyribose). Examples of nucleosides include adenosine, guanosine, uridine, cytidine, 5-methyluridine (m5U), deoxyadenosine, deoxyguanosine, thymidine, deoxyuridine, and deoxycytidine. Examples of nucleosides with modified nucleobases include inosine (I), xanthine (X), 7-methylguanosine (m7G), dihydrouridine (D), 5-methylcytidine (m5C), and pseudouridine (Ψ). "Nucleotide" consists of a nucleobase, a five-carbon sugar (ribose or deoxyribose), and at least one phosphate group.
[0139] The term "nucleic acid programmable DNA binding protein" or "napDNAbp" can be used interchangeably with "polynucleotide programmable nucleotide binding domain" to refer to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid or a guide polynucleotide (e.g., gRNA) that directs the napDNAbp to a specific nucleic acid sequence. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. The Cas9 protein can associate with a guide RNA that directs the Cas9 protein to a specific DNA sequence that is complementary to the guide RNA. In some embodiments, the napDNAbp is a Cas9 domain, such as a nuclease-active Cas9, a Cas9 nickase (nCas9), or a nuclease-inactive Cas9 (dCas9). Non-limiting examples of nucleic acid-programmable DNA-binding proteins include Cas9 (e.g., dCas9 and nCas9), Cas12a / Cpf1, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, and Cas12j / CasΦ (Cas12j / Casphi).Non-limiting examples of Cas enzymes include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also known as Csn1 or Csx12), Cas10, Cas10d, Cas12a / Cpf1, Cas12b / C2cl, Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i, Cas12j / CasΦ, Cpf1, Csy1, Csy2, Csy3, Csy4 , Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx 17. Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csx11, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, type II C Cas effector protein, type V Cas effector protein, type VI Cas effector protein, CARF, Din G, homologs thereof, or modified or engineered versions thereof. Other nucleic acid programmable DNA binding proteins are also within the scope of the present disclosure, although they may not be specifically listed in the present disclosure. See, for example, Makarova et al. "Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?" CRISPR J. 2018 Oct; 1: 325-336. doi: 10.1089 / crispr.2018.0033; Yan et al., "Functionally diverse type V CRISPR-Cas systems" Science. 2019 Jan 4; 363(6422): 88-91. doi: 10.1126 / science.aav7271, the entire contents of each of which are hereby incorporated by reference. Exemplary nucleic acid programmable DNA binding proteins and nucleic acid sequences encoding nucleic acid programmable DNA binding proteins are provided in the Sequence Listing as SEQ ID NOs: 197-230.
[0140] As used herein, the term "nucleobase editing domain" or "nucleobase editing protein" refers to a protein or enzyme that can catalyze nucleobase modifications in RNA or DNA, such as deamination of cytosine (or cytidine) to uracil (or uridine) or thymine (or thymidine) and adenine (or adenosine) to hypoxanthine (or inosine), as well as non-templated nucleotide additions and insertions. In some embodiments, the nucleobase editing domain is a deaminase domain (e.g., adenine deaminase or adenosine deaminase; or cytidine deaminase or cytosine deaminase).
[0141] As used herein, "obtaining" in "obtaining an agent" includes synthesizing, purchasing, or otherwise acquiring the agent.
[0142] "Subject" means a mammal, including but not limited to humans or non-human mammals, such as cattle, horses, dogs, sheep, rodents or felines. In one embodiment, a "patient" refers to a mammalian subject having a higher average probability of developing a disease or illness than a subject having a disease or illness. Exemplary patients can be humans, non-human primates, cats, dogs, pigs, cattle, cats, horses, camels, llamas, goats, sheep, rodents (e.g., mice, rabbits, rats or guinea pigs) and other mammals that can benefit from treatment disclosed herein. Exemplary human patients can be male and / or female. The example of disease includes HBV infection and related diseases and illness (including cirrhosis, hepatocellular carcinoma (HCC)) and any other disease associated with HBV infection or caused by HBV infection.
[0143] A "patient in need thereof" or "subject in need thereof" as used herein refers to a patient diagnosed with, at risk of or having, predetermined to have, or suspected of having a disease or condition.
[0144] The terms "pathogenic mutation," "pathogenic variant," "disease casing mutation," "disease causing variant," "deleterious mutation," or "susceptibility mutation" refer to a genetic alteration or mutation that increases an individual's susceptibility or predisposition to a disease or condition. In some embodiments, the pathogenic mutation comprises at least one wild-type amino acid substituted for at least one pathogenic amino acid in a protein encoded by a gene.
[0145] The terms "protein", "peptide" and "polypeptide" and their grammatical equivalents are used interchangeably herein and refer to a polymer of amino acid residues linked by peptide (amide) bonds. A protein, peptide or polypeptide may be naturally occurring, recombinant or synthetic, or any combination thereof.
[0146] As used herein, the term "fusion protein" refers to a hybrid polypeptide comprising protein domains from at least two different proteins.
[0147] As used herein, the term "recombinant" in the context of a protein or nucleic acid refers to a protein or nucleic acid that does not occur in nature but is a product of human engineering. For example, in some embodiments, a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations compared to any naturally occurring sequence.
[0148] By "reduction" is meant a negative change of at least 10%, 25%, 50%, 75% or 100%.
[0149] By "reference" is meant a standard or control condition. In one embodiment, the reference is a wild-type or healthy cell. In other embodiments and without limitation, the reference is an untreated cell that has not been subjected to the test condition, or has been subjected to a placebo or saline, culture medium, buffer, and / or a control vector that does not contain the polynucleotide of interest. The reference can be a cell or subject that is not infected with HBV. The reference can also be a subject before receiving treatment or before a change in treatment.
[0150] A "reference sequence" is a defined sequence used as a basis for sequence comparison. A reference sequence can be a subset or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence or a complete cDNA or gene sequence. For polypeptides, the length of the reference polypeptide sequence will typically be at least about 16 amino acids, at least about 20 amino acids, at least about 25 amino acids, about 35 amino acids, about 50 amino acids, or about 100 amino acids. For nucleic acids, the length of the reference nucleic acid sequence will typically be at least about 50 nucleotides, at least about 60 nucleotides, at least about 75 nucleotides, about 100 nucleotides, or about 300 nucleotides, or any integer therebetween. In some embodiments, the reference sequence is the wild-type sequence of the protein of interest. In other embodiments, the reference sequence is a polynucleotide sequence encoding the wild-type protein.
[0151] The terms "RNA programmable nuclease" and "RNA-guided nuclease" are used (e.g., bound to or associated with) one or more RNAs that are not cleavage targets. In some embodiments, when a complex is formed with RNA, the RNA programmable nuclease may be referred to as a nuclease: RNA complex. Typically, the bound RNA is referred to as a guide RNA (gRNA). In some embodiments, the RNA programmable nuclease is a (CRISPR-associated system) Cas9 endonuclease, e.g., Cas9 (Csnl) from Streptococcus pyogenes.
[0152] The term "single nucleotide polymorphism (SNP)" is a variation of a single nucleotide occurring at a specific position in the genome, where each variation is present to some extent in a population (eg, >1%).
[0153] By "specifically binds" is meant a nucleic acid molecule, polypeptide, polypeptide / polynucleotide complex, compound or molecule that recognizes and binds to a polypeptide and / or nucleic acid molecule of the present invention, but does not substantially recognize and bind to other molecules in a sample (e.g., a biological sample).
[0154] By "substantially identical" is meant a polypeptide or nucleic acid molecule that exhibits at least 50% identity to a reference amino acid sequence. In one embodiment, the reference sequence is a wild-type amino acid or nucleic acid sequence. In another embodiment, the reference sequence is any of the amino acid or nucleic acid sequences described herein. In one embodiment, such a sequence is at least 60%, 80%, 85%, 90%, 95%, or even 99% identical at the amino acid level or nucleic acid level to the sequence being compared.
[0155] Sequence identity is typically measured using sequence analysis software (e.g., the Sequence Analysis Software Package of Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis. 53705, BLAST, BESTFIT, GAP, or PILEUP / PRETTYBOX programs). Such software works by assigning degrees of homology to various substitutions, deletions, and / or other modifications. Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and phenylalanine, tyrosine. In an exemplary method for determining the degree of identity, the BLAST program can be used, where e -3 With e -100 Probability scores between and indicate closely related sequences.
[0156] COBALT is used for example with the following parameters:
[0157] a) Alignment parameters: gap penalty -11, -1 and end gap penalty -5, -1,
[0158] b) CDD parameters: use RPS BLAST (on); BlastE value 0.003; find conserved columns and recalculate (on), and
[0159] c) Query clustering parameters: use query clustering (on); word size (Word Size) 4; maximum cluster distance 0.8; regular characters (Alphabet Regular).
[0160] EMBOSS Needle is used for example with the following parameters:
[0161] a) Matrix: BLOSUM62;
[0162] b) Open spaces: 10;
[0163] c) Vacancy extension: 0.5;
[0164] d) Output format: Yes;
[0165] e) End Gap Penalty: False;
[0166] f) End gap open: 10; and
[0167] g) End vacancy extension: 0.5.
[0168] Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecule encoding a polypeptide of the present invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical to an endogenous nucleic acid sequence, but will generally exhibit substantial identity. A polynucleotide that is "substantially identical" to an endogenous sequence is generally capable of hybridizing to at least one strand of a double-stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the present invention include any nucleic acid molecule encoding a polypeptide of the present invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical to an endogenous nucleic acid sequence, but will generally exhibit substantial identity. A polynucleotide that is "substantially identical" to an endogenous sequence is generally capable of hybridizing to at least one strand of a double-stranded nucleic acid molecule. By "hybridization" is meant the pairing of complementary polynucleotide sequences (e.g., genes described herein) or portions thereof to form a double-stranded molecule under various stringent conditions. (See, e.g., Wahl, G.M. and S.L. Berger (1987) Methods Enzymol. 152:399; Kimmel, A.R. (1987) Methods Enzymol. 152:507).
[0169] For example, stringent salt concentrations will typically be less than about 750mM NaCl and 75mM trisodium citrate, preferably less than about 500mM NaCl and 50mM trisodium citrate, and more preferably less than about 250mM NaCl and 25mM trisodium citrate. Low stringency hybridization can be obtained in the absence of an organic solvent (e.g., formamide), while high stringency hybridization can be obtained in the presence of at least about 35% formamide, more preferably at least about 50% formamide. Stringent temperature conditions will typically include a temperature of at least about 30°C, more preferably at least about 37°C, and most preferably at least about 42°C. Changing other parameters, such as the inclusion or exclusion of hybridization time, detergent (e.g., sodium dodecyl sulfate (SDS)) concentration, and carrier DNA, is well known to those skilled in the art. Different stringency levels are achieved by combining these different conditions as needed. In a preferred embodiment, hybridization is carried out at 30°C in 750mM NaCl, 75mM trisodium citrate, and 1% SDS. In a more preferred embodiment, hybridization will be conducted in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 μg / ml denatured salmon sperm DNA (ssDNA) at 37° C. In a most preferred embodiment, hybridization will be conducted in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 μg / ml ssDNA at 42° C. Useful variations on these conditions will be apparent to those skilled in the art.
[0170] For most applications, the wash step following hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and temperature. As described above, wash stringency can be increased by lowering the salt concentration or by increasing the temperature. For example, the stringent salt concentration for the wash step will preferably be less than about 30 mM NaCl and 3 mM trisodium citrate, and most preferably less than about 15 mM NaCl and 1.5 mM trisodium citrate. Stringent temperature conditions for the wash step will typically include a temperature of at least about 25°C, more preferably at least about 42°C, and even more preferably at least about 68°C. In one embodiment, the wash step will be performed at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS. In another embodiment, the wash step will be performed at 42°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, the wash step will be performed at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al. (Current Protocols in Molecular Biology, Wiley Interscience, New York, 2001); Berger and Kimmel (Guide to Molecular Cloning Techniques, 1987, Academic Press, New York); and Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, New York.
[0171] By "split" is meant dividing into two or more fragments.
[0172] "Split Cas9 protein" or "split Cas9" refers to a Cas9 protein provided as an N-terminal fragment and a C-terminal fragment encoded by two separate nucleotide sequences. Polypeptides corresponding to the N-terminal and C-terminal portions of the Cas9 protein can be spliced to form a "reconstituted" Cas9 protein.
[0173] The term "target site" refers to a sequence within a nucleic acid molecule that is deaminated by a deaminase (e.g., cytidine or adenine deaminase) or a fusion protein comprising a deaminase (e.g., a dCas9-adenosine deaminase fusion protein or a base editor disclosed herein).
[0174] "Tenofovir" means having the structure The molecule corresponding to CAS No. 147127-20-6 and its pharmaceutically acceptable salt. Tenofovir has antiretroviral activity. Tenofovir is classified as a nucleoside / nucleotide reverse transcriptase inhibitor (NRTI).
[0175] As used herein, the term "treat / treating / treatment, etc." refers to reducing or improving a condition and / or symptoms associated therewith or obtaining a desired pharmacological and / or physiological effect. It will be understood that treating a condition or illness does not require the complete elimination of the condition, illness, or symptoms associated therewith, although this is not excluded. In some embodiments, the effect is therapeutic, i.e., but not limited to, the effect partially or completely reduces, weakens, eliminates, alleviates, relieves, reduces the intensity of the disease and / or adverse symptoms attributable to the disease, or cures the disease and / or adverse symptoms attributable to the disease. In some embodiments, the effect is preventive, i.e., the effect protects or prevents the occurrence or recurrence of a disease or illness. To this end, the currently disclosed method comprises administering a therapeutically effective amount of a composition as described herein. In one embodiment, the invention provides treatment for HBV infection.
[0176] "Uracil glycosylase inhibitor" or "UGI" means an agent that inhibits the uracil excision repair system. Base editors comprising cytidine deaminase convert cytosine to uracil, which is then converted to thymine by DNA replication or repair. Including an inhibitor of uracil DNA glycosylase (UGI) in a base editor prevents base excision repair that converts U back to C. An exemplary UGI comprises the following amino acid sequence:
[0177] >splP 14739IUNGI_BPPB2 uracil-DNA glycosylase inhibitor
[0178] MTNLSDIIEKETGKQLVIQESILMLPEEVEEVIGNKPESDILVHTAYDESTDENVMLLTSDAPEYKPWALVIQDSNGENKIKML (SEQ ID NO: 231).
[0179] 47,48,49,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94,100,101,102,103,104,105,106,107,108,1109,111
[0180] In any definition of a variable herein, the recitation of a list of chemical groups includes definitions of that variable as any single group or combination of listed groups. Reference herein to an embodiment of a variable or aspect includes that embodiment as any single embodiment or in combination with any other embodiment or portion thereof.
[0181] All terms are intended to be understood as understood by those skilled in the art. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.
[0182] In this application, the use of the singular includes the plural, unless specifically stated otherwise. It should be noted that, as used in this specification, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. In this application, the use of "or" means "and / or" unless otherwise stated. Furthermore, the use of various forms of "including" is not limiting.
[0183] As used in this specification and claims, the words "comprising" (and any form of comprising, such as "comprise" and "comprises"), "having" (and any form of having, such as "have" and "has"), "including" (and any form of including, such as "includes" and "include"), or "containing" (and any form of containing, such as "contains" and "contain") are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the present disclosure, and vice versa. In addition, the compositions of the present disclosure can be used to implement the methods of the present disclosure.
[0184] The term "about" or "approximately" means that a particular value is determined by one of ordinary skill in the art to be within an acceptable error range, which depends in part on how the value is measured or determined, i.e., the limitations of the measurement system. For example, according to practice in the art, "about" can mean within 1 or more standard deviations. Alternatively, "about" can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value. Alternatively, particularly with respect to biological systems or processes, the term can mean within a certain order of magnitude, e.g., within 5 times, within 2 times, of a value. Where specific values are described in the application and claims, unless otherwise indicated, the term "about" means that an acceptable error range should be assumed for that specific value.
[0185] Reference in the specification to "some embodiments," "an embodiment," "one embodiment," or "other embodiments" means that a particular feature, structure, or characteristic described in connection with the embodiment is included in at least some of the embodiments, but not necessarily all embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0186] Figure 1 Schematic representation of partially double-stranded and overlapping open reading frames (ORFs) of the hepatitis B surface antigen (HBsAg) gene, polymerase gene, protein X gene, and core gene. The HBsAg gene contains ORF pre-S1, ORF pre-S2, and ORF S, which encode the large, medium, and small surface proteins, respectively. ORF core and pre-C encode the capsid protein.
[0187] Figure 2 This is a diagram depicting the HBV life cycle. The term "ER" stands for endoplasmic reticulum. The term "HBsAg" stands for hepatitis B surface antigen. "HBx transcriptional activator" is the HBV-specific transcriptional activator of polymerase II and III promoters.
[0188] Figure 3 Presentation slides were presented. Figure 3 An overview of base editing strategies for introducing stop codons in viral genes and for generating base sites for treating chronic HBV is provided.
[0189] Figure 4 A bar graph is provided showing the % A to G editing efficiency of the indicated guide RNA sequences used in combination with the indicated base editors. The HEK293lenti HBV system and RNA transfection format were used. Some guide RNA sequences were associated with editing efficiencies exceeding 50%. The guide RNAs targeted HBV transcriptional elements or introduced missense mutations in HBV genes. The guide RNA sequences used in combination with the indicated base editors are listed on the x-axis (see Table 1).
[0190] Figures 5A to 5C A bar graph is provided showing the antiviral efficacy of the indicated base editors used in combination with the indicated guide RNAs (listed on the x-axis) in the HBV primary human hepatocyte (HBV-PHH) system. Figures 5A to 5C In FIG5 , the term “HBsAG” means “hepatitis B surface antigen”, and the term “HBeAg” means “hepatitis B e antigen”. In FIG5 , the y-axis represents the fold change relative to the untreated sample.
[0191] Figure 6 A schematic outlining the experimental procedure for functional gRNA screening in HBV-infected HepG2-NTCP cells is provided.
[0192] Figure 7 A schematic diagram of the HBV genome is provided. The genome map is annotated to indicate the locations of base edits associated with gRNA37 and gRNA40 used in conjunction with BE4.
[0193] Figure 8 Provided is a bar graph collection showing the functional gRNA screening results in HepG2pNTCP cells infected with HBV. Identified two leading gRNAs (i.e., gRNA37 and gRNA40) targeting HBsAg and core genes. Guidance gRNA37 (Stop-S) is associated with the reduction of HBsAg, and gRNA40 (Stop-front core) is associated with the reduction of HBeAg. Guidance RNA gRNA37 and gRNA40 are both associated with the reduction of total HBV DNA and 3.5kb RNA levels. The gRNAs (i.e., gRNA12, gRNA37, gRNA19, gRNA190, and gRNA40) used in combination with BE4 are listed on the x-axis. Negative control (-) is untreated cells, and control (contr) is a gRNA targeting the PCSK9 gene.
[0194] Figure 9 A set of bar graphs showing that multiple gRNAs simultaneously reduce respective HBV viral parameters in HepG2-NTCP is provided. The gRNAs used in combination with BE4 (i.e., gRNA37 and gRNA40) are listed on the x-axis. Both gRNAs target the same covalently closed circular DNA chain (cccDNA), and the target sequences are approximately 1 kb apart. Multiple gRNA37 and gRNA40 reduced HBsAg and HbBeAg, as well as total HBV DNA and 3.5 kb RNA. The base editor used is BE4. The negative control (-) is untreated cells, and the control (contr) is a gRNA targeting the PCSK9 gene.
[0195] Figure 10A bar graph is provided showing that a base editor system containing BE4 and guide RNA edits cccDNA without reducing cccDNA levels. The negative control (-) is untreated cells, and the control (contr) is a gRNA targeting the PCSK9 gene.
[0196] Figure 11 A schematic summarizing the experimental protocol used to evaluate the effects of lamivudine pretreatment on editing is provided.
[0197] Figure 12 A bar graph is provided showing that pretreatment with lamivudine is associated with increased editing efficiency. Pretreatment with lamivudine increased base editing efficiency in HepG2-NTCP cells by approximately 20%. High cccDNA editing in lamivudine-pretreated cells indicates that CBEs directly target cccDNA.
[0198] Figure 13 A set of bar graphs are provided showing that base editing using a combination of gRNA37 and gRNA40 (i.e., combination / multiple gRNA therapy) combined with lamivudine pretreatment is associated with a significant reduction in hepatitis B virus (HBV) markers. The negative control (-) is untreated cells, and the control (contr) is a gRNA targeting the PCSK9 gene.
[0199] Figure 14 A schematic summarizing the experimental protocol used to evaluate the antiviral activity of base editors relative to lamivudine is provided. Figure 14 The measured HBV parameters are listed.
[0200] Figure 15 A set of bar graphs are provided demonstrating that base editing using a combination of gRNA37 and gRNA40 (i.e., combinatorial / multiple gRNA therapy) resulted in a reduction of all HBV viral markers by approximately 70% to approximately 80% on day 25 after treatment, whereas treatment with lamivudine (LAM) for 8 days resulted in no reduction. The negative control (-) was untreated cells, and the control (contr) was a gRNA targeting the PCSK9 gene.
[0201] Figure 16 Provided are graphs showing the time course of extracellular HBV DNA levels for the indicated treatments. Base editing prevents rebound in primary hepatocyte co-cultures. HBV rebound occurs after discontinuation of lamivudine-only treatment. Control gRNA targets the PCSK9 gene. The "HBV" sample is an untreated sample. No HBV rebound was observed 2 weeks after the second transfection with the base editing reagent. HBV replication was assessed by HBV DNA qPCR, s / n.
[0202] Figure 17A bar graph is provided showing the individual base editing efficiencies at the sites targeted by gRNAs 37 and 40 when used in combination with BE4 to edit HBV cccDNA. An editing efficiency of approximately 30% was observed at the S antigen site, and an editing efficiency of approximately 60% was observed at the pre-core gene. These editing efficiencies are sufficient to achieve high antiviral efficacy and prevent rebound in primary human hepatocytes (PHHs).
[0203] Figure 18 A schematic diagram providing an overview of experiments evaluating combined treatment with lamivudine and a base editing system comprising BE4 and gRNAs 37 and 40 is provided.
[0204] Figure 19 Provided are graphs showing the time course of extracellular HBV DNA levels for the indicated treatments. The "HBV" sample is an untreated sample. Pretreatment with lamivudine improves editing in primary hepatocytes. Treatment with the base editor system and lamivudine combination prevents HBV rebound. HBV replication was assessed by HBV DNA qPCR, s / n.
[0205] Figure 20 A bar graph showing the base editing efficiency of sites targeted by gRNA37 and gRNA40 is provided. Cells were exposed to a combination of BE4 and gRNA37 and gRNA40 and also treated with lamivudine (LAM). Pretreatment with lamivudine improved editing of primary hepatocytes. Control cells (-) were not treated with lamivudine.
[0206] Figure 21 Provided is a bar graph showing that base editing combined with lamivudine treatment in primary hepatocytes resulted in a reduction of all HBV markers by about 70% to about 80%. The designation "HBV" indicates an untreated control.
[0207] Figure 22 A bar graph showing base editing of sites targeted by gRNA37 and gRNA40 is provided. Cells were exposed to a combination of BE4, ppApo, or rrA3F with gRNA37 and gRNA40. Using ppApo and rrA3F base editors (which reduced off-target activity and lowered nonspecific effects) instead of BE4 did not negatively alter base editing efficiency relative to BE4. All base editors were associated with comparable editing efficiencies.
[0208] Figure 23A bar graph is provided showing that contacting cells with base editors BE4, ppApo, or rrA3F in combination with gRNA37 and gRNA40 resulted in a reduction in HBsAg levels in HBV-infected cells. Thus, all three base editor systems have antiviral activity. The negative control (HBV) is untreated cells, and the control (contr) is a gRNA targeting the PCSK9 gene.
[0209] Figures 24A to 24C Graphs are provided showing somatic hepatitis B virus (HBV) antigen levels measured in the replication-competent HBVcircle mouse model (n=5) following injection on day 1 and, in some cases, reinjection on day 14 of lipid nanoparticles containing a polynucleotide encoding BE4 and guide RNAs gRNA37 and gRNA40 as indicated. Figure 24A The mean % HBsAg in IU / ml is plotted over time. Figure 24B HBeAg in PEI (Paul Elrich Institut International Standard Serum) U / ml is plotted over time. Figure 24C HBV DNA in copies / ml is plotted over time. Figures 24A to 24C In the present invention, the term "HM" refers to gRNA37-HM and gRNA40-HM containing scaffolds with "highly modified" (i.e., highly modified guide RNAs), the term "SOC" means "standard of care", and "SEM" means "standard error of the mean". Figures 24A to 24C In the table, “1x” means injection only on day 1 (“LNP-1 st inj.), and “2x” means on day 1 (“LNP-1 st inj.") and day 14 ("LNP 2 nd inj.”) injection.
[0210] Figures 25A to 25C Graphs are provided showing somatic hepatitis B virus (HBV) antigen levels measured in the replication-competent HBVcircle mouse model (n=5) following injection on day 1 and, in some cases, reinjection on day 14 of lipid nanoparticles containing a polynucleotide encoding BE4 and guide RNAs gRNA37 and gRNA40 as indicated. Figure 25A The mean % HBsAg in IU / ml is plotted over time. Figure 25B HBeAg in PEI (Paul Elrich Institut International Standard Serum) U / ml is plotted over time. Figure 25CHBV DNA in copies / ml is plotted over time. Figures 25A to 25C In the present invention, the term "HM" refers to gRNA37-HM and gRNA40-HM containing a scaffold with "highly modified" (i.e., highly modified guide RNA), the term "ETV" means "entecavir", and "SD" means "standard deviation". Figures 25A to 25C In the table, “1x” means injection only on day 1 (“LNP-1 st inj.), and “2x” means on day 1 (“LNP-1 st inj.") and day 14 ("LNP 2 nd inj.”) injection.
[0211] Figure 26A and Figure 26B A schematic diagram describing the strategy for gRNA selection and screening is provided. This strategy involves targeting conserved HBV regions, focusing on genotype D, which is the most prevalent worldwide and for which cell and animal models exist. In silico gRNA selection was based on the gRNA's potential to silence HBV genes. 100 gRNAs that introduce stop codons in viral genes (NGG, NGA, NNNRRT PAM) were designed. 24 conserved gRNAs were predicted to introduce missense mutations into the HBV genome. The final step involved testing editing in the Hek293-Lenti-HBV cell line.
[0212] Figures 27A to 27D show that base editing can prevent HBV rebound in primary human hepatocytes (PHH). Figure 27A provides a schematic diagram showing the experimental timeline for PHH. Figure 27B is a chart showing HBV replication assessed by HBV DNA qPCR in PHH supernatants on different days after transfection. Interruption of 3TC will cause HBV rebound, and base editing will prevent this rebound. Figure 27C is a chart showing that base editing leads to an effective reduction in HBsAg, HBeAg, 3.5kbRNA and HBV DNA, and further improves HBV replication inhibition in PHH. Figure 27D is a chart showing that approximately 30% editing of the S antigen and approximately 60% editing of the pre-core gene are sufficient to achieve high antiviral efficacy and prevent PHH rebound.
[0213] Figures 28A to 28D show that multiplexing two lead gRNAs reduces HBV parameters in a liver cancer cell line (HepG2-NTCP). Figure 28A shows the experimental timeline. Figure 28BIncludes a number of graphs showing that base editing results in an effective reduction in viral extracellular (HBsAg, HBeAg) and intracellular (3.5kbRNA and HBV DNA) parameters Figure 28C provides a series of graphs showing the results of HBsAg, HBeAg and 3.5kbRNA observed after 3TC treatment. Figure 28D shows that gRNA B + gRNAH combination also inhibited all HBs subtypes observed in Western blots.
[0214] Figures 29A to 29C show that base editing reduces HBs from naturally integrated HBV. Figure 29A provides an experimental scheme for PLC / PRF5 cells. Figure 29B is a graph showing extracellular HBs Ag levels measured by ELISA on day 6 after BE4 mRNA and gRNA B* transfection. Figure 29C is a graph showing that approximately 50% editing of the S antigen site is sufficient to achieve a significant reduction in HBs Ag.
[0215] Figure 30 A and Figure 30 B shows that the base editor functions through cccDNA editing without reducing cccDNA levels. Figure 30 Figure A is a graph showing cccDNA levels assessed by qPCR on DNA samples pretreated with ExoI / III to eliminate viral replication intermediates. No reduction in cccDNA was observed upon base editing with gRNA B + gRNA H in the absence or presence of 3TC. Figure 30 B is a graph showing functional editing assessed by NGS on cccDNA-enriched samples. Higher editing efficiency was detected in the presence of 3TC.
[0216] Figure 31A to Figure 31E It is shown that the multiplexing of two gRNAs with the BE4 base editor simultaneously reduced HBV viral parameters in HepG2-NTCP. Figure 31A provides a series of graphs showing that base editing resulted in an effective reduction in viral extracellular (HBsAg, HBeAg) and intracellular (3.5kbRNA and HBV DNA) parameters relative to control samples treated with base editing reagents targeting an unrelated PCSK9 gene. BE4 / gRNA (S1+C2) treatment inhibited all HBs subtypes, as observed in Western blots. Figure 31B provides an experimental timeline with lamivudine pretreatment. Figure 31C shows that treatment with a lamivudine combination can result in a significant reduction in HBV viral markers, similar to the results shown in sub-figure A. Figure 31D is a graph showing that base editing does not reduce cccDNA levels in HepG2-NTCP. Figure 31EIt was shown that pretreatment with lamivudine increased the base editing rate in HepG2-NTCP by 20%. Without being bound by theory, the high cccDNA editing under lamivudine pretreatment conditions suggests that CBE may directly target cccDNA.
[0217] Figure 32A to Figure 32C Figure 32A is a graph showing HBV replication assessed by HBV DNA qPCR in PHH supernatants. Interruption of lamivudine leads to HBV rebound, while base editing prevents viral rebound. Figure 32B Included are four graphs showing that base editing results in effective reduction of HBsAg, HBeAg, 3.5kb RNA, and HBV DNA. Figure 32C is a graph showing that approximately 55% edited S antigen and approximately 80% edited pre-core gene are sufficient to achieve high antiviral efficacy and prevent PHH rebound.
[0218] Figure 33A to Figure 33C LNP-mediated delivery of BE4 mRNA and gRNA S1 / C2 resulted in sustained reductions in viral markers in the HBV microcirculatory model. Figure 33A is a graph showing mean HBsAg reductions > 2 log. Importantly, HBsAg reductions were below the limit of detection in 5 / 9 mice. Figure 33B Figure 2 is a graph showing HBV rebound in the entecavir-treated group (positive control). In the base-edited group, serum HBV DNA continued to decrease by >3 log. No HBV rebound was observed in the base-edited group. Figure 33C Shown is the loss of HBeAg expression in all mice below the limit of detection two weeks after the first LNP injection. Data are presented as mean + / - SEM, n = 4 or 5 per group.
[0219] Figure 34 A and Figure 34 B is a graph showing that the combination of BE4, gRNA EMSbeam12 with a spacer sequence of SEQ ID NO.578, and MSPbeam37-PLC with a spacer sequence of SEQ ID NO.10834 edited the naturally integrated HBV genome present in the Alexander hepatoma cell line PLC / PRF / 5 ( Figure 34 A) and reduce HBsAg secretion ( Figure 34 B) Also included are protospacer sequences: the MSPbeam37 protospacer corresponds to SEQ ID NO. 508; the MSPbeam37-PLC protospacer (SEQ ID NO. 10833) includes a single nucleobase change relative to SEQ ID NO. 508.
[0220] Figure 35 A schematic diagram showing the experimental design for the in vitro evaluation of base editing in HepG2.2.15 cells with and without lamivudine (LAM) pretreatment is provided. Figure 35 In the figures, "D0", "D1", etc., indicate day 0, 1, etc. after the start of the experiment, "SN" indicates "supernatant", and "6 dpt" indicates "six (6) days after transduction".
[0221] Figure 36A and Figure 36B Provided are bar graphs showing HBsAg and HBeAg polypeptide levels in HepG2.2.15 cells after base editing using the BE4 base editor in combination with guide gRNA37 (g37) or gRNA12 (g12) (for base editing to reduce HBsAg expression) and / or with guide gRNA40 (g40) (for base editing to reduce HBeAg expression). As a control, cells were exposed to a combination of BE4 base editors and guides targeting the PCSK9 gene. Cells were base edited with and without lamivudine (LAM) pretreatment. Figure 36A Shown are HBsAg expression levels in HepG2.2.15 cells edited using the BE4 base editor in combination with the indicated guides, with and without LAM pretreatment. Figure 36B Shown are HBeAg expression levels in HepG2.2.15 cells base-edited using the BE4 base editor in combination with the indicated guides with and without LAM pretreatment. Expression levels were compared using ANOVA / nonparametric test / unpaired / multiple comparisons with PCSK9. DETAILED DESCRIPTION
[0222] The invention of the present disclosure features compositions and methods for editing the HBV genome. For example, in some embodiments, the compositions contemplated herein may include base editors or guide nucleic acids targeting specific nucleotides in the HBV gene. In some embodiments, the editor introduces an early termination codon in the coding sequence of one of the viral proteins. In another embodiment, the editor introduces one or more substitutions (e.g., missense mutations) in the coding sequence of one or more HBV proteins. In one embodiment, the editor changes the nucleobases in the transcription element (e.g., polyA site, enhancer, or promoter).
[0223] Recent studies have shown that newer-generation ABEs (e.g., ABE8) are able to induce higher editing rates. Furthermore, compared to earlier-generation cytidine base editors (CBEs), they have lower gRNA-independent off-target editing and are therefore attracting attention as potential therapeutic approaches. ABEs cannot generate stop codons, but they allow targeting of AT-rich regions in the HBV genome.
[0224] By safely introducing permanent mutations in cccDNA, base editing for HBV therapy could advantageously prevent HBV rebound and irreversibly silence HBsAg expression from integrated HBV DNA in the absence of DSBs.
[0225] As described in more detail below, the present disclosure provides the use of cytosine base editors (CBE, C to T conversion) to target an established HBV covalently closed circular DNA (cccDNA) pool. Infected HepG2-NTCP cells and long-term primary human hepatocyte cultures (PHH) were co-transfected with selected HBV targeting gRNA and mRNA encoding CBE. The base editing efficiency was evaluated by DNA amplicon sequencing, and the effect of base editing on viral replication was determined by analyzing different viral parameters. Without affecting the integrity of cccDNA, base editing introduced nonsense mutations in the HBs or HBe / HBc open reading frames (ORFs) and effectively inhibited the release of total HBV DNA and HBs / HBe antigens. In addition, the base editing rate remained high in the case of pretreatment with nucleoside analogs (NAs), which reduced the level of HBV DNA replication intermediates, indicating that CBE can directly target cccDNA. Multiplexing two gRNAs with CBE resulted in substantial reductions in HBsAg, HBeAg, total HBV DNA, and 3.5 kb of viral pregenomic RNA. Importantly, dual gRNA / CBE treatment prevented HBV rebound. Together, these results demonstrate that CBE can directly target cccDNA and generate nonsense mutations in the HBs and HBe / HBc ORFs that interfere with HBV replication. Furthermore, these effects persisted after CBE degradation, suggesting permanent functional changes in HBV cccDNA.
[0226] Targeting cccDNA transcriptional activity using base editing
[0227] The regions involved in cccDNA transcriptional activity are AT-rich regions, and an alternative to cccDNA degradation for HBV cure is permanent destruction of cccDNA transcriptional activity, which is currently unattainable.
[0228] An example of a region involved in cccDNA transcriptional activity is the polyadenylation signal (PAS), which is unique to all HBV viral RNAs and also serves as a regulatory element (TATA box). Targeting this region in cccDNA can destabilize all viral RNA species, including its genomic component pgRNA, and lead to cccDNA silencing.
[0229] As described in the Examples provided herein, sgRNAs targeting regulatory regions in cccDNA (e.g., enhancer I, enhancer II, basal core promoter, cryptic and canonical polyadenylation signals (PAS), S and X gene promoters) were identified by in silico analysis. More than 250 sgRNAs were identified, and these candidates were screened, and several with high in silico predicted efficiency were tested in the Hek293-lentiHBV system.
[0230] As further described in the Examples, certain aspects of the present disclosure include selecting highly conserved ABE gRNAs that are predicted to introduce missense mutations in the HBV gene. For example, gRNAs were selected based on their high conservation between HBV genotypes, with a focus on genotypes D and A. High sequence conservation allows for targeting a wider range of patient populations and is also necessary to avoid viral mutations that enable the HBV virus to escape base editing therapy. Another example of a selection criterion is the ability of the gRNA to generate edits in the HBV genome, which can result in missense mutations. A computer simulation analysis of the amino acid changes produced by base editing reagents was performed, and gRNAs that produce missense amino acid changes were selected, whose sequences are rarely detected in naturally occurring HBV genotypes (<0.05% frequency aa changes). In this way, the likelihood of gRNA introducing mutations that lead to HBV protein / genome damage is increased.
[0231] HBV genome
[0232] The HBV genome consists of approximately 3.2 kb of partially double-stranded DNA and an open reading frame (ORF) encoding seven proteins. Figure 1 The open reading frame (ORF) P encodes the viral polymerase. ORF C / pre-C encodes the capsid protein. ORF pre-S1, ORF pre-S2, and ORFs encode the large (L), middle (M), and small (S) surface proteins, respectively. ORF X encodes the secretory X protein.
[0233] The partially double-stranded HBV genome is converted into covalently closed circular DNA (cccDNA) by host factors. The cccDNA is transcribed by the host RNA polymerase to produce viral mRNA, including pregenomic RNA (pgRNA). The pgRNA is reverse transcribed by the HBV polymerase into genomic HBV DNA, which can be converted into cccDNA, packaged into virions, or integrated into the genome of the host cell ( Figure 2 cccDNA is a key component of the HBV life cycle and a stable molecule that leads to chronic HBV infection. Editing the HBV genome can disrupt the formation of cccDNA, thereby reducing the pathogenicity of the virus.
[0234] As shown in the geographical distribution map of hepatitis B virus genotypes worldwide in the World Gastroenterology Organization Global Guidelines 2015, there are ten different HBV genotypes (AJ). A "genotype" is characterized by a sequence identity of <92% with any other genome, and a subgenotype is characterized by a sequence identity of <96% to 92%. According to the map, HBV genotype D is the most prevalent in the United States. Research models for HBV genotype D are available, including viral libraries (e.g., genotype D, subgenotype ayw (Imquest)) and mouse models (e.g., humanized mouse models (Phoenixbio)).
[0235] Target gene editing
[0236] The invention disclosed herein provides methods and compositions for targeting HBV ORF for editing. These compositions may comprise a nuclear base editor having a Cas9 or other nucleic acid programmable DNA binding protein domain and an adenosine or cytosine deaminase domain. In some embodiments, the base editor introduces one or more changes into the HBV ORF. In some embodiments, the changes result in mutations in the conserved portion of the HBV protein. In a specific embodiment, the changes introduce one or more stop codons. Throughout the specification, the introduction of stop codons that result in premature termination of the protein is represented by the amino acid symbol, amino acid position, and the term STOP (e.g., R87STOP indicates that the codon encoding arginine at amino acid position 87 is replaced by a stop codon). Advantageously, the methods of the present invention do not introduce double-strand breaks in the HBV genome. The present invention provides a strategy for treating chronic HBV using base editing ( Figure 3). The introduction of stop codons into viral genes using the methods and compositions described herein can be achieved without generating double-strand breaks, thereby eliminating or reducing the risk of HBV severing host genetic material after integration into the host genome. In addition, the composition can employ deaminases, which are natural HBV antiviral restriction factors. For example, induction of APOBEC cytidine deaminases with interferon α or lymphotoxin beta receptor (LTBR) can promote the formation of abasic sites and cccDNA degradation ( Figure 3 ). In addition, the use of base editors without a uracil glycosylase inhibitor domain can target cellular uracil glycosylase to cccDNA and promote its degradation.
[0237] In the embodiments, a base editor comprising an adenosine deaminase (i.e., an adenosine base editor (ABE)) is used to edit the HBV ORF. Compared to the first generation of rAPOBEC1-based CBEs, ABEs have multiple advantages, including robust on-target editing and low gRNA-independent off-target editing. ABEs do not induce uracil N-glycosylase (UNG) reactions. There has been no description of A>I cccDNA deamination of HBV. ABEs can be used to edit polymerase active sites and / or cccDNA transcription sites, including the RNA polyadenylation site TATAAA, which is common in HBV transcripts. Important regions involved in cccDNA transcriptional activity are AT-rich regions and are alternatives to cccDNA degradation.
[0238] In some aspects, methods and compositions are provided for editing HBV cccDNA using base editors comprising a cytidine deaminase or adenosine deaminase domain.
[0239] Table 1 below provides exemplary guide RNAs. Other exemplary guide RNAs include those containing spacer sequences provided in any one of Table 1, Table 2A, Table 2B, and / or Table 2C or listed in the sequence table (e.g., SEQ ID NOs: 3105-5485 and 8220-10830). In various embodiments, a plurality of guide RNAs, optionally in combination with one or more nucleobase editor polypeptides, can be administered to a subject or cell simultaneously. In an embodiment, the multiple guide RNAs include 2, 3, 4, 5, 6, 7, 8, 9, 10 or more guides, optionally wherein the guide RNAs are selected from two or more of the following: cas12b-4, cas12b-5, cas12b-11, cas12b-17, cas12b-30, cas12b-42, cas12b-100, cas12b-147, cas12b-154, cas12b-35, cas12b-124, cas12b-127, and cas12b-122b (see Table 1). In an embodiment, the multiple guide RNAs administered to a subject or cell contain two guide RNAs (e.g., gRNA37 and gRNA40, see Table 1). The guides may optionally be administered simultaneously or sequentially with one or more base editor polypeptides (e.g., base editors encoded by mRNA molecules). Non-limiting examples of spacer sequences suitable for guide RNA molecules of the present disclosure include any spacer sequence targeting any part of the hepatitis B virus genome. Such spacer sequences can be designed and selected using methods available to skilled practitioners (for example, the design of gRNA targeting a specific sequence can be obtained from Invitrogen as a commercial service). Various strategies can be used to select gRNA, including as non-limiting examples: 1) targeting HBV transcription elements, and 2) selecting highly conserved ABE gRNAs that are predicted to introduce missense mutations into HBV genes. In embodiments, guide RNA can be used to target base editors to introduce missense mutations into HBV genes (for example, cas12b-4, cas12b-5, cas12b-11, cas12b-17, cas12b-30, cas12b-42, cas12b-100, cas12b-147, or cas12b-154). The guide RNAs listed in Table 1 or any guide RNA comprising a spacer sequence listed in Table 2A, Table 2B, Table 2C, or SEQ ID NOs: 3105-5485 and 8220-10830, or anywhere else in the sequence listing can also be used to target base editors to change the nucleobase at the transcription site (e.g., cas12b-35, cas12b-124, cas12b-127, or cas12b-122b).The transcription sites targeted for base editing by the guide RNA of Table 1 or any guide RNA comprising a spacer sequence listed in Table 2A, Table 2B, Table 2C, or anywhere in the sequence table (e.g., in SEQ ID NO3105-5485 and 8220-10830) include enhancer II box A (e.g., cas12b-35), enhancer I (e.g., cas12b-124 or cas12b-127), and HBX promoter (e.g., cas12b-122b). Non-limiting examples of transcription sites include basic core promoter (BCP), enhancer I, enhancer II, HBV polyA site, HBX promoter, and S promoter-CCAATC-region II. The guide RNA of the present invention can be used in combination with any base editor (e.g., Cas12b-ABE (ABE-bhCas12b); SEQ ID NO: 418). The base editor can target the PAM sequences listed in Table 2A or Table 2B below (e.g., RTTN sequences).
[0240] In embodiments, two or more guide RNAs are introduced into a subject, optionally simultaneously. In embodiments, the two or more guide RNAs include cas12b-5 and cas12b-4; cas12b-11 and cas12b-4; cas12b-17 and cas12b-4; cas12b-30 and cas12b-4; cas12b-42 and cas12b-4; cas12b-100 and cas12b-4; cas12b-147 and cas12b-4; cas12b-154 and cas12b-4; cas12b-35 and cas12b-4; cas12b-124 and cas12b-4; cas12b-127 ... s12b-122b and cas12b-4; cas12b-11 and cas12b-5; cas12b-17 and cas12b-5; cas12b-30 and cas12b-5; cas12b-42 and cas12b-5; cas12b-100 and cas12b-5; cas12b-147 and cas12b-5; cas12b-154 and cas12b-5; cas12b-35 and cas12b-5; cas12b-124 and cas12b-5; cas12b-127 and cas12b-5; cas12b-122b and cas12b-5; ca s12b-17 and cas12b-11; cas12b-30 and cas12b-11; cas12b-42 and cas12b-11; cas12b-100 and cas12b-11; cas12b-147 and cas12b-11; cas12b-154 and cas12b-11; cas12b-35 and cas12b-11; cas12b-124 and cas12b-11; cas12b-127 and cas12b-11; cas12b-122b and cas12b-11; cas12b-30 and cas12b-17; cas12b-42 and cas12b-11 s12b-17; cas12b-100 and cas12b-17; cas12b-147 and cas12b-17; cas12b-154 and cas12b-17; cas12b-35 and cas12b-17; cas12b-124 and cas12b-17; cas12b-127 and cas12b-17; cas12b-122b and cas12b-17; cas12b-42 and cas12b-30; cas12b-100 and cas12b-30; cas12b-147 and cas12b-30; cas12b-154 and cas12b-30;cas12b-35 and cas12b-30; cas12b-124 and cas12b-30; cas12b-127 and cas12b-30; cas12b-122b and cas12b-30; cas12b-100 and cas12b-42; cas12b-147 and cas12b-42; cas12b-154 and cas12b-42; cas12b-35 and cas12b-42; cas12b-1 24 and cas12b-42; cas12b-127 and cas12b-42; cas12b-122b and cas12b-42; cas12b-147 and cas12b-100; cas12b-154 and cas12b-100; cas12b-35 and cas12b-100; cas12b-124 and cas12b-100; cas12b-127 and cas12b-100; cas12b-122 b and cas12b-100; cas12b-154 and cas12b-147; cas12b-35 and cas12b-147; cas12b-124 and cas12b-147; cas12b-127 and cas12b-147; cas12b-122b and cas12b-147; cas12b-35 and cas12b-154; cas12b-124 and cas12b-154; cas12b-12 7 and cas12b-154; cas12b-122b and cas12b-154; cas12b-124 and cas12b-35; cas12b-127 and cas12b-35; cas12b-122b and cas12b-35; cas12b-127 and cas12b-124; cas12b-122b and cas12b-124; or cas12b-122b and cas12b-127 (see Table 1). ;
[0241] Table 1 Guide RNA
[0242]
[0243]
[0244]
[0245]
[0246]
[0247]
[0248] For all guides except gRNA37-HM and gRNA40-HM, mA*, mC*, mG*, and mU* indicate bases with 2′-O-methyl 3′-phosphorothioate modifications. For gRNA37-HM and gRNA-40HM, a, c, u, or g indicates bases with 2′-O-methyl (M) modifications, and as, cs, us, or gs indicates bases with 2′-O-methyl 3′-phosphorothioate (MS) modifications.
[0249] In order to produce the above-mentioned gene editing, cells (e.g., hepatocytes) are contacted with two or more guide RNAs and a base editor polypeptide comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a cytidine deaminase or adenosine deaminase. In some embodiments, the cell to be edited is contacted with at least one nucleic acid, wherein the at least one nucleic acid encodes two or more guide RNAs and a base editor polypeptide comprising a nucleic acid programmable DNA binding protein (napDNAbp) and a cytidine deaminase. In some embodiments, gRNA comprises nucleotide analogs (e.g., mA*, mC*, mG* and / or mU*). These nucleotide analogs can inhibit the degradation of gRNA in cellular processes. Tables 2A-2C provide exemplary target sequences and spacer sequences to be used for gRNA. Other exemplary target sequences and spacer sequences are provided in the sequence table as SEQ ID NOs: 724-3104 and 5609-8219 and SEQ ID NOs: 3105-5485 and 8220-10830, respectively. The gRNA can target all or a portion of all HBV genotypes (e.g., A, B, C, D, E, F, G, and / or H). The gRNA can target greater than 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 85%, or all hepatitis B viruses of a particular genotype or a group of genotypes.
[0250] In various embodiments, the gRNAs of the present disclosure (e.g., gRNA37-HM or gRNA40-HM) contain the following "highly modified" (HM) scaffold: gUUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcusususu (SEQ ID NO: 317), wherein "a", "c", "u", or "g" represent A, C, U, or G nucleotides containing a 2'O-methyl (M) modification, respectively; and as, cs, us, or gs represent A, C, U, or G nucleotides containing a 2'-O-methyl 3'-phosphorothioate (MS) modification, respectively. In embodiments, the guide RNAs of the present disclosure contain the HM scaffold and spacer sequences listed in any one of Tables 2A-2C.
[0251] Table 2A: Exemplary target sequences
[0252]
[0253]
[0254] "Core" refers to HBV core protein; "Pol" refers to HBV polymerase gene; "S" refers to HBV surface protein; and "X" refers to HBV protein X gene.
[0255]
[0256]
[0257] Table 2C: Exemplary target sequences
[0258]
[0259]
[0260]
[0261]
[0262]
[0263]
[0264]
[0265] gRNA can target HBV core protein, HBV polymerase gene, HBV surface protein or HBV X protein. In embodiments, the PAM sequence related to the sequence targeted by gRNA is not restrictive. Other targets may include polyadenylation signals (PAS) involved in cccDNA transcriptional activity and are unique to all important RNAs. PAS also acts as a regulatory element (TATA box). Targeting the PAS in cccDNA can make all viral RNA species, including pgRNA unstable, and lead to cccDNA silencing. sgRNA can target the main regulatory regions in cccDNA (such as enhancer I, enhancer II, basal core promoter, secret and typical polyadenylation signals (PAS), and S and X gene promoters). gRNA can be designed and evaluated by computer simulation before testing in cells (such as HEK293-lentiHBV system).
[0266] In an embodiment, any one of guides E1 to E24 is used in combination with a nucleobase editor polypeptide comprising SaCas9 and / or targeting a sequence associated with an NNRRT, NGG, or NGA PAM sequence. In an embodiment, a guide RNA comprising any of the spacer sequences provided herein (e.g., any one of Tables 2A-2C or those listed in the sequence table) or variants thereof is used in combination with any base editor and / or nucleic acid programmable DNA binding protein (e.g., BE4 or Cas12b) provided herein.
[0267] In certain embodiments, the fusion protein provided herein includes one or more features that improve the base editing activity of the fusion protein. For example, any fusion protein provided herein may include a Cas9 domain with reduced nuclease activity. In some embodiments, any fusion protein provided herein may have a Cas9 domain (dCas9) without nuclease activity, or a Cas9 domain that cuts a chain of a duplex DNA molecule, referred to as Cas9 nickase (nCas9). Without wishing to be bound by any particular theory, the presence of catalytic residues (e.g., H840) maintains the activity of Cas9 to cut the non-edited (e.g., non-methylated) chain relative to the targeted nuclear base. Mutations in catalytic residues (e.g., D10 becomes A10) prevent cutting the editing chain targeted to the A residue. Such Cas9 variants can produce single-stranded DNA breaks (nicks) at specific positions of the target sequence limited based on gRNA, resulting in repair of the non-edited chain, ultimately resulting in changes in the nuclear bases on the non-edited chain.
[0268] In some embodiments, precise modification of HBV genes reduces viral virulence and / or reduces the ability of the virus to propagate in vitro. Modifications can include premature stop codons or other mutations that damage or otherwise reduce HBV protein activity. In some embodiments, the HBV genes targeted for modification are the core, transcription site, or a combination of pol, X, S, pre-S1, pre-S2, or pre-core genes.
[0269] Nucleobase editors
[0270] The nuclear base editors that can be used for the methods and compositions described herein edit, modify or change the target nucleotide sequence of a polynucleotide. The nuclear base editors described herein generally include a polynucleotide programmable nucleotide binding domain and a nuclear base editing domain (e.g., adenosine deaminase or cytidine deaminase). When combined with a bound guidance polynucleotide (e.g., gRNA), the polynucleotide programmable nucleotide binding domain can specifically bind to the target polynucleotide sequence, thereby positioning the base editor to the target nucleic acid sequence that needs to be edited.
[0271] Polynucleotide programmable nucleotide binding domain
[0272] The polynucleotide programmable nucleotide binding domain binds to a polynucleotide (e.g., RNA, DNA). The polynucleotide programmable nucleotide binding domain of the base editor itself may comprise one or more domains (e.g., one or more nuclease domains). In some embodiments, the nuclease domain of the polynucleotide programmable nucleotide binding domain may comprise an endonuclease or an exonuclease. An endonuclease can cut a single strand of a double-stranded nucleic acid or two strands of a double-stranded nucleic acid molecule. In some embodiments, the nuclease domain of the polynucleotide programmable nucleotide binding domain can cut zero, one, or two chains of a target polynucleotide.
[0273] Non-limiting examples of polynucleotide programmable nucleotide binding domains that can be incorporated into base editors include domains derived from CRISPR proteins, restriction nucleases, large-range nucleases, TAL nucleases (TALENs), and zinc finger nucleases (ZFNs). In some embodiments, the base editor comprises a polynucleotide programmable nucleotide binding domain, which comprises a natural or modified protein or a portion thereof, which can bind to a nucleic acid sequence during CRISPR (i.e., clustered regularly interspaced short palindromic repeats)-mediated nucleic acid modification via a bound guide nucleic acid. This protein is referred to herein as “CRISPR protein”. Therefore, disclosed herein are base editors comprising polynucleotide programmable nucleotide binding domains, which comprise all or a portion of a CRISPR protein (i.e., a base editor comprises all or a portion of a CRISPR protein as a domain, also referred to as a “CRISPR protein-derived domain” of a base editor). The domain of the CRISPR protein-derived domain incorporated into the base editor can be modified compared to the wild type or natural version of the CRISPR protein. For example, as described below, a CRISPR protein-derived domain can comprise one or more mutations, insertions, deletions, rearrangements, and / or recombinations relative to a wild-type or native version of a CRISPR protein.
[0274] Cas proteins that can be used herein include Class 1 and Class 2. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 or Csx12), Cas10, Csy1, Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4 , Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, Csf1, Csf2, CsO, Csf4, Csd1, Csd2, Cst1, Cst2, Csh1, Csh2, Csa1, Csa2, Csa3, Csa4, Csa5, Cas12a / Cpf1, Cas12b / C2c1 (e.g., SEQ ID NO: 232), Cas12c / C2c3, Cas12d / CasY, Cas12e / CasX, Cas12g, Cas12h, Cas12i and Cas12j / CasΦ, CARF, DinG, homologs thereof, or modified versions thereof. The CRISPR enzyme can direct cleavage of one or both strands at a target sequence, such as within the target sequence and / or within the complement of the target sequence. For example, the CRISPR enzyme can direct cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of the target sequence.
[0275] Vectors encoding CRISPR enzymes that are mutated relative to the corresponding wild-type enzymes can be used, such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence. A Cas protein (e.g., Cas9, Cas12) or a Cas domain (e.g., Cas9, Cas12) can refer to a polypeptide or domain having at least or about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and / or sequence homology to a wild-type exemplary Cas polypeptide or Cas domain. Cas (e.g., Cas9, Cas12) can refer to a wild-type or modified form of a Cas protein, which can include amino acid changes such as deletions, insertions, substitutions, variants, mutations, fusions, chimeras, or any combination thereof.
[0276] In some embodiments, the CRISPR protein-derived domain of the base editor may include all or part of Cas9 from: Corynebacteri umulcerans (NCBI Reference Sequences: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Reference Sequences: NC_016782.1, NC_016786.1); Spiroplasma yrphidicola (NCBI Reference Sequence: NC_021284.1); Prevotella intermedia (NCBI Reference Sequence: NC_017861.1); Spiroplasma taiwanense (NCBI Reference Sequence: NC_021846.1); Streptococcus iniae (NC_021847.1); NCBI Reference Sequence: NC_021314.1); Belliella baltica (NCBI Reference Sequence: NC_018010.1); Psychroflexus torquis (NCBI Reference Sequence: NC_018721.1); Streptococcus thermophilus (NCBI Reference Sequence: YP_820832.1); Listeria innocua (NCBI Reference Sequence: NP_472073.1); Campylobacter jejuni (NCBI Reference Sequence: YP_002344900.1); Neisseria meningitidis (NCBI Reference Sequence: YP_002342100.1); Streptococcus pyogenes or Staphylococcus aureus.
[0277] The Cas9 nuclease sequence and structure are well known to those skilled in the art (see, for example, "Complete genome sequence of an M1 strain of Streptococcus pyogenes." Ferretti et al., Proc. Natl. Acad. Sci. USA 98: 4658-4663 (2001); "CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III." Deltcheva E. et al., Nature 471: 602-607 (2011); and "A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity." Jinek M. et al., Science 337: 816-821 (2012), each of which is incorporated herein by reference in its entirety). Cas9 orthologs have been described in a variety of species, including, but not limited to, Streptococcus pyogenes and Streptococcus thermophilus. Additional suitable Cas9 nucleases and sequences will be apparent to those skilled in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from organisms and loci disclosed in Chylinski, Rhun, and Charpentier, “The tracrRNA and Cas9 families of type II CRISPR-Cas immunitysystems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.
[0278] High-fidelity Cas9 domain
[0279] Some aspects of the present disclosure provide high-fidelity Cas9 domains. High-fidelity Cas9 domains are known in the art and are described in, for example, Kleinstiver, BP et al. "High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects." Nature 529, 490-495 (2016); and Slaymaker, IM et al. "Rationally engineered Cas9 nucleases with improved specificity." Science 351, 84-88 (2015); the entire contents of each of the above documents are incorporated herein by reference. An exemplary high-fidelity Cas9 domain is provided as SEQ ID NO: 233 in the sequence listing. In some embodiments, the high-fidelity Cas9 domain is an engineered Cas9 domain comprising one or more mutations that reduce the electrostatic interaction between the Cas9 domain and the sugar-phosphate backbone of DNA relative to the corresponding wild-type Cas9 domain. High-fidelity Cas9 domains with reduced electrostatic interactions with the sugar-phosphate backbone of DNA have fewer off-target effects. In some embodiments, the Cas9 domain (e.g., a wild-type Cas9 domain (SEQ ID NOs: 197 and 200)) comprises one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of DNA. In some embodiments, the Cas9 domain comprises one or more mutations that reduce the association between the Cas9 domain and the sugar-phosphate backbone of DNA by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70%.
[0280] In some embodiments, any Cas9 fusion protein provided herein includes one or more of D10A, N497X, R661X, Q695X and / or Q926X mutations or the corresponding mutations in any amino acid sequence provided herein, wherein X is any amino acid. In some embodiments, the high-fidelity Cas9 enzyme is SpCas9 (K855A), eSpCas9 (1.1), SpCas9-HF1 or ultra-precise Cas9 variant (HypaCas9). In some embodiments, the modified Cas9eSpCas9 (1.1) contains an alanine substitution that weakens the interaction between the HNH / RuvC groove and the non-target DNA chain, thereby preventing chain separation and cutting at the off-target site. Similarly, SpCas9-HF1 reduces off-target editing by destroying the alanine substitution of the interaction between Cas9 and the DNA phosphate backbone. HypaCas9 contains mutations (SpCas9N692A / M694A / Q695A / H698A) that increase Cas9 proofreading and target discrimination in the REC3 domain. All three high-fidelity enzymes produced fewer off-target edits than wild-type Cas9.
[0281] Cas9 domains with reduced exclusivity
[0282] Typically, Cas9 proteins, such as Cas9 from Streptococcus pyogenes (spCas9), require a “protospacer adjacent motif (PAM)” or PAM-like motif, which is a 2-6 base pair DNA sequence immediately following the targeted DNA sequence of the Cas9 nuclease in the CRISPR bacterial adaptive immune system. The presence of the NGG PAM sequence is required for binding to specific nucleic acid regions, where the “N” in “NGG” is adenosine (A), thymidine (T), or cytosine (C), and G is guanosine. This may limit the ability to edit desired bases within the genome. In some embodiments, the base editing fusion proteins provided herein may need to be placed in a precise position, such as a region containing a target base upstream of the PAM. See, for example, Komor, AC et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage” Nature 533, 420-424 (2016), the entire contents of which are incorporated herein by reference. Exemplary polypeptide sequences of spCas9 proteins capable of binding to PAM sequences are provided in the sequence listing as SEQ ID NOs: 197, 201, and 234-237. Thus, in some embodiments, any fusion protein provided herein may contain a Cas9 domain capable of binding to a nucleotide sequence that is not in accordance with a canonical (e.g., NGG) PAM sequence. Cas9 domains that bind to non-canonical PAM sequences have been described in the art and are readily apparent to those skilled in the art. For example, Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, BP et al., “Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature 523, 481-485 (2015); and Kleinstiver, BP et al., “Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition” Nature Biotechnology 33, 1293-1298 (2015); the entire contents of each of which are hereby incorporated by reference.
[0283] nickase
[0284] In some embodiments, the polynucleotide programmable nucleotide binding domain may include a nickase domain. In this article, the term "nickase" refers to a polynucleotide programmable nucleotide binding domain comprising a nuclease domain, which is capable of cutting only one of the two chains of a duplex nucleic acid molecule (e.g., DNA). In some embodiments, a nickase may be derived from a polynucleotide programmable nucleotide binding domain of complete catalytic activity (e.g., natural) form by introducing one or more mutations into an active polynucleotide programmable nucleotide binding domain. For example, in the case where a polynucleotide programmable nucleotide binding domain includes a nickase domain derived from Cas9, the nickase domain in Cas9 sources may include a D10A mutation and histidine at position 840. In such embodiments, residue H840 retains catalytic activity, and therefore can cut a single strand of a nucleic acid duplex. In another example, the nickase domain in Cas9 sources may include an H840A mutation, and the amino acid residue at position 10 is still D. In some embodiments, the nickase can be obtained from a polynucleotide programmable nucleotide binding domain in a fully catalytically active (e.g., native) form by removing all or part of the nuclease domain that is not required for nickase activity. For example, in the case where the polynucleotide programmable nucleotide binding domain comprises a nickase domain derived from Cas9, the nickase domain from Cas9 may comprise a deletion of all or part of a RuvC domain or a HNH domain.
[0285] In some embodiments, the wild-type Cas9 corresponds to or comprises the following amino acid sequence:
[0286]
[0287]
[0288] In some embodiments, the chain of the nucleic acid duplex target polynucleotide sequence cut by a base editor comprising a nickase domain (e.g., a nickase domain derived from Cas9, a nickase domain derived from Cas12) is a chain not edited by a base editor (i.e., the chain cut by the base editor is opposite to the chain comprising the base to be edited). In other embodiments, a base editor comprising a nickase domain (e.g., a nickase domain derived from Cas9, a nickase domain derived from Cas12) can cut a chain of a DNA molecule that is targeted for editing. In such embodiments, the non-targeting chain is not cut.
[0289] In some embodiments, the Cas9 nuclease has an inactive (e.g., inactivated) DNA cleavage domain, that is, Cas9 is a nickase, referred to as a "nCas9" protein (for "nickase" Cas9). The Cas9 nickase can be a Cas9 protein that can cut only one chain of a duplex nucleic acid molecule (e.g., a duplex DNA molecule). In some embodiments, the Cas9 nickase cuts the target chain of the duplex nucleic acid molecule, which means that the Cas9 nickase cuts the chain that is base-paired (complementary) with the gRNA (e.g., sgRNA) bound to Cas9. In some embodiments, the Cas9 nickase comprises a D10A mutation and has a histidine at position 840. In some embodiments, the Cas9 nickase cuts the non-target, non-base editing chain of the duplex nucleic acid molecule, which means that the Cas9 nickase cuts the chain that is not base-paired with the gRNA (e.g., sgRNA) bound to Cas9. In some embodiments, the Cas9 nickase comprises an H840A mutation and has an aspartic acid residue at position 10 or a corresponding mutation. In some embodiments, the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to those skilled in the art based on this disclosure and the knowledge in the art and are within the scope of this disclosure.
[0290] The amino acid sequence of an exemplary catalytic Cas9 nickase (nCas9) is as follows:
[0291]
[0292] The Cas9 nuclease has two functional endonuclease domains: RuvC and HNH. Cas9 undergoes a conformational change upon target binding, positioning the nuclease domain to cleave the opposite strand of the target DNA. The end result of Cas9-mediated DNA cleavage is a double-strand break (DSB) within the target DNA (approximately 3-4 nucleotides upstream of the PAM sequence). The resulting DSB is then repaired by one of two general repair pathways: (1) the highly efficient but error-prone nonhomologous end joining (NHEJ) pathway; or (2) the less efficient but high-fidelity homology-directed repair (HDR) pathway.
[0293] The "efficiency" of non-homologous end joining (NHEJ) and / or homology-directed repair (HDR) can be calculated by any convenient method. For example, in some embodiments, efficiency can be expressed as a percentage of successful HDR. For example, a surveyor nuclease assay can be used to produce cleavage products, and the ratio of product to substrate can be used to calculate the percentage. For example, a surveyor nuclease can be used that directly cuts DNA containing newly integrated restriction sequences as a result of successful HDR. More cleavage substrates represent a greater HDR percentage (higher HDR efficiency). As an illustrative example, the following equation can be used to calculate the score (percentage) of HDR: [(cleavage product) / (substrate plus cleavage product)] (e.g., (b+c) / (a+b+c), where "a" is the band intensity of the DNA substrate, and "b" and "c" are cleavage products).
[0294] In some embodiments, efficiency can be expressed as a percentage of successful NHEJ. For example, the T7 endonuclease I assay can be used to produce cleavage products, and the ratio of product to substrate can be used to calculate the NHEJ percentage. T7 endonuclease I cuts the mismatched heteroduplex DNA produced by hybridization of wild-type and mutant DNA chains (NHEJ produces small random insertions or deletions (indels) at the original break site). More cutting represents a higher percentage of NHEJ (higher NHEJ efficiency). As an illustrative example, the score (percentage) of NHEJ can be calculated using the following equation: (1-(1-(b+c) / (a+b+c)) 1 / 2 )×100, where “a” is the band intensity of the DNA substrate, and “b” and “c” are the cleavage products (Ran et al. Cell. 2013 Sep 12;154(6):1380-9; and Ran et al. Nat Protoc. 2013 Nov;8(11):2281-2308).
[0295] The NHEJ repair pathway is the most active repair mechanism, and it often results in small nucleotide insertions or deletions (indels) at the DSB site. The randomness of NHEJ-mediated DSB repair has important practical significance because cell populations expressing Cas9 and gRNA or guiding polynucleotides can result in a variety of mutations. In most embodiments, NHEJ produces small indels in the target DNA, resulting in amino acid deletions, insertions, or frameshift mutations, leading to premature stop codons within the open reading frame (ORF) of the target gene. The ideal end result is a loss-of-function mutation within the targeted gene.
[0296] While NHEJ-mediated DSB repair typically disrupts the open reading frame of a gene, homology-directed repair (HDR) can be used to generate specific nucleotide changes, ranging from single nucleotide changes to large insertions such as the addition of a fluorophore or tag.
[0297] To utilize HDR for gene editing, a DNA repair template containing the desired sequence can be delivered to the cell type of interest along with gRNA and Cas9 or Cas9 nickase. The repair template may contain the desired edits as well as additional homologous sequences immediately upstream and downstream of the target (referred to as left and right homologous arms). The length of each homology arm may depend on the size of the changes introduced, with larger insertions requiring longer homology arms. The repair template can be a single-stranded oligonucleotide, a double-stranded oligonucleotide, or a double-stranded DNA plasmid. The efficiency of HDR is typically low (<10% of modified alleles), even in cells expressing Cas9, gRNA, and an exogenous repair template. The efficiency of HDR can be improved by synchronizing cells because HDR occurs in the S and G2 phases of the cell cycle. Chemically or genetically inhibiting genes involved in NHEJ can also increase the frequency of HDR.
[0298] In some embodiments, Cas9 is a modified Cas9. A given gRNA targeting sequence may have additional sites in the entire genome where there is partial homology. These sites are called off-target targets and need to be taken into account when designing gRNA. In addition to optimizing gRNA design, CRISPR specificity can also be increased by modifying Cas9. Cas9 produces double-strand breaks (DSBs) through the combined activity of two nuclease domains, RuvC and HNH. Cas9 nickase is a D10A mutant of SpCas9 that retains one nuclease domain and produces DNA nicks instead of DSBs. The nickase system can also be combined with HDR-mediated gene editing for specific gene editing.
[0299] Catalytically Dead Nucleases
[0300] Also provided herein are base editors comprising catalytically dead (i.e., unable to cut the target polynucleotide sequence) polynucleotide programmable nucleotide binding domains.Herein, the terms "catalytically dead" and "nuclease dead" are used interchangeably and refer to polynucleotide programmable nucleotide binding domains having one or more mutations and / or deletions, which result in them being unable to cut the chain of nucleic acid. In some embodiments, the catalytically dead polynucleotide programmable nucleotide binding domain base editor may lack nuclease activity due to specific point mutations in one or more nuclease domains. For example, in the case of a base editor comprising a Cas9 domain, Cas9 may comprise both a D10A mutation and an H840A mutation. Such mutations inactivate two nuclease domains, resulting in loss of nuclease activity. In other embodiments, the catalytically dead polynucleotide programmable nucleotide binding domain may comprise one or more deletions of all or part of a catalytic domain (e.g., RuvC1 and / or HNH domain). In a further embodiment, the catalytically dead polynucleotide programmable nucleotide binding domain comprises a point mutation (e.g., D10A or H840A) and all or part of a nuclease domain. dCas9 domains are known in the art and are described, for example, in Qi et al., “Repurposing CRISPR as an RNA-guided platform for sequence-specific control of gene expression.” Cell. 2013; 152(5): 1173-83, the entire contents of which are incorporated herein by reference.
[0301] Based on the present disclosure and the knowledge in the art, additional suitable nuclease-inactive dCas9 domains will be apparent to those skilled in the art and are within the scope of the present disclosure. Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A / H840A, D10A / D839A / H840A, and D10A / D839A / H840A / N863A mutant domains (see, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology. 2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference).
[0302] In some embodiments, dCas9 corresponds to or partially or entirely comprises a Cas9 amino acid sequence having one or more mutations that inactivate Cas9 nuclease activity. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10X mutation and an H840X mutation of the amino acid sequence shown herein, or a corresponding mutation in any amino acid sequence provided herein, wherein X is any amino acid change. In some embodiments, the nuclease-inactive dCas9 domain comprises a D10A mutation and an H840A mutation of the amino acid sequence shown herein, or a corresponding mutation in any amino acid sequence provided herein. In some embodiments, the nuclease-inactive Cas9 domain comprises the amino acid sequence shown in the cloning vector pPlatTET-gRNA2 (accession number BAV54124).
[0303] In some embodiments, variant Cas9 protein can cut the complementary chain of the guide target sequence, but the ability of cutting the non-complementary chain of the double-stranded guide target sequence is reduced. For example, the variant Cas9 protein may have a mutation (amino acid substitution) that reduces the function of the RuvC domain. As a non-limiting example, in some embodiments, the variant Cas9 protein has D10A (aspartic acid at amino acid position 10 is changed to alanine), and thus can cut the complementary chain of the double-stranded guide target sequence, but the ability of cutting the non-complementary chain of the double-stranded guide target sequence is reduced (therefore when the variant Cas9 protein cuts the double-stranded target nucleic acid, it causes a single-strand break (SSB) instead of a double-strand break (DSB)) (see, for example, Jinek et al., Science. 2012 August 17; 337 (6096): 816-21).
[0304] In some embodiments, the variant Cas9 protein can cut the non-complementary chain of the double-stranded guide target sequence, but the ability to cut the complementary chain of the guide target sequence is reduced. For example, the variant Cas9 protein may have a mutation (amino acid substitution) that reduces the function of the HNH domain (RuvC / HNH / RuvC domain motif). As a non-limiting example, in some embodiments, the variant Cas9 protein has an H840A (histidine at amino acid position 840 becomes alanine) mutation, and can therefore cut the non-complementary chain of the guide target sequence, but the ability to cut the complementary chain of the guide target sequence is reduced (thus when the variant Cas9 protein cuts the double-stranded guide target sequence, it causes SSB instead of DSB). The ability of this Cas9 protein to cut the guide target sequence (e.g., single-stranded guide target sequence) is reduced, but the ability to bind to the guide target sequence (e.g., single-stranded guide target sequence) is retained.
[0305] As another non-limiting example, in some embodiments, the variant Cas9 protein carries W476A and W1126A mutations, such that the ability of the polypeptide to cleave target DNA is reduced. Such Cas9 proteins have a reduced ability to cleave target DNA (e.g., single-stranded target DNA) but retain the ability to bind to target DNA (e.g., single-stranded target DNA).
[0306] As another non-limiting example, in some embodiments, the variant Cas9 protein carries P475A, W476A, N477A, D1125A, W1126A and D1127A mutations, such that the ability of the polypeptide to cut the target DNA is reduced. Such Cas9 protein has a reduced ability to cut the target DNA (e.g., single-stranded target DNA), but retains the ability to bind to the target DNA (e.g., single-stranded target DNA).
[0307] As another non-limiting example, in some embodiments, variant Cas9 protein carries H840A, W476A and W1126A mutations, so that the ability of polypeptide cutting target DNA is reduced. The ability of this Cas9 protein to cut target DNA (e.g., single-stranded target DNA) is reduced, but the ability to bind target DNA (e.g., single-stranded target DNA) is retained. As another non-limiting example, in some embodiments, variant Cas9 protein carries H840A, D10A, W476A and W1126A mutations, so that the ability of polypeptide cutting target DNA is reduced. The ability of this Cas9 protein to cut target DNA (e.g., single-stranded target DNA) is reduced, but the ability to bind target DNA (e.g., single-stranded target DNA) is retained. In some embodiments, variant Cas9 has a catalytic His residue (A840H) recovered at position 840 in the Cas9HNH domain.
[0308] As another non-limiting example, in some embodiments, the variant Cas9 protein carries H840A, P475A, W476A, N477A, D1125A, W1126A and D1127A mutations, so that the ability of the polypeptide to cut the target DNA is reduced. The ability of this Cas9 protein to cut the target DNA (e.g., single-stranded target DNA) is reduced, but the ability to bind to the target DNA (e.g., single-stranded target DNA) is retained. As another non-limiting example, in some embodiments, the variant Cas9 protein carries D10A, H840A, P475A, W476A, N477A, D1125A, W1126A and D1127A mutations, so that the ability of the polypeptide to cut the target DNA is reduced. The ability of this Cas9 protein to cut the target DNA (e.g., single-stranded target DNA) is reduced, but the ability to bind to the target DNA (e.g., single-stranded target DNA) is retained. In some embodiments, when the variant Cas9 protein carries W476A and W1126A mutations or when the variant Cas9 protein carries P475A, W476A, N477A, D1125A, W1126A and D1127A mutations, the variant Cas9 protein does not effectively bind to the PAM sequence. Therefore, in some such embodiments, when this variant Cas9 protein is used in a method of binding, the method does not require a PAM sequence. In other words, in some embodiments, when this variant Cas9 protein is used in a method of binding, the method may include a guide RNA, but the method can be performed in the absence of a PAM sequence (and the specificity of binding is therefore provided by the targeting segment of the guide RNA). Other residues can be mutated to achieve the above effects (i.e., to inactivate one or another nuclease portion). As non-limiting examples, residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986 and / or A987 may be altered (i.e., substituted). Furthermore, mutations other than alanine substitutions are also suitable.
[0309] In some embodiments, the variant Cas9 protein has reduced catalytic activity (for example, when the Cas9 protein has D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986 and / or A987 mutations, such as D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A and / or D986A), the variant Cas9 protein can still bind to the target DNA in a site-specific manner (because it is still guided to the target DNA sequence by the guide RNA) as long as it retains the ability to interact with the guide RNA.
[0310] In some embodiments, the variant Cas protein can be spCas9, spCas9-VRQR, spCas9-VRER, xCas9(sp), saCas9, saCas9-KKH, spCas9-MQKSER, spCas9-LRKIQK, or spCas9-LRVSQL.
[0311] In some embodiments, the Cas9 domain is a Cas9 domain from Staphylococcus aureus (SaCas9). In some embodiments, the SaCas9 domain is a nuclease-active SaCas9, a nuclease-inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n). In some embodiments, SaCas9 comprises an N579A mutation or a corresponding mutation in any of the amino acid sequences provided in the sequence listing submitted herein.
[0312] In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM. In some embodiments, the SaCas9 domain, SaCas9d domain, or SaCas9n domain can bind to a nucleic acid sequence having a NNGRRT or NNGRRV PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of E781X, N967X, and R1014X mutations, or corresponding mutations in any amino acid sequence provided herein, wherein X is any amino acid. In some embodiments, the SaCas9 domain comprises one or more of E781K, N967K, and R1014H mutations, or one or more corresponding mutations in any amino acid sequence provided herein. In some embodiments, the SaCas9 domain comprises E781K, N967K, or R1014H mutations, or corresponding mutations in any amino acid sequence provided herein.
[0313] In some embodiments, one of the Cas9 domains present in the fusion protein can be replaced with a guide nucleotide sequence programmable DNA binding protein domain that does not require a PAM sequence. In some embodiments, the Cas9 is SaCas9. Residue A579 of SaCas9 can be mutated from N579 to generate a SaCas9 nickase. Residues K781, K967, and H1014 can be mutated from E781, N967, and R1014 to generate SaKKH Cas9.
[0314] In some embodiments, a modified SpCas9 comprising amino acid substitutions D1135M, S1136Q, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337R (SpCas9-MQKFRAER) and having specificity for an altered PAM 5′-NGC-3′ is used.
[0315] Alternatives to Streptococcus pyogenes Cas9 could include RNA-guided endonucleases from the Cpf1 family that display cleavage activity in mammalian cells. CRISPR from Prevotella and Francisella 1 (CRISPR / Cpf1) is a DNA editing technology similar to the CRISPR / Cas9 system. Cpf1 is an RNA-guided endonuclease of the class II CRISPR / Cas system. This acquired immunity mechanism is present in bacteria of the genera Prevotella and Francisella. The Cpf1 gene is associated with the CRISPR locus and encodes an endonuclease that uses a guide RNA to find and cut viral DNA. Cpf1 is a smaller and simpler endonuclease than Cas9, which overcomes some of the limitations of the CRISPR / Cas9 system. Unlike the Cas9 nuclease, Cpf1-mediated DNA cleavage results in a double-strand break with a short 3′ overhang. The staggered cleavage pattern of Cpf1 can open up the possibility of directed gene transfer similar to traditional restriction enzyme cloning, which can improve the efficiency of gene editing. Like the aforementioned Cas9 variants and orthologs, Cpf1 can also expand the number of sites that can be targeted by CRISPR to AT-rich regions or AT-rich genomes that lack the NGG PAM sites preferred by SpCas9. The Cpf1 locus contains a mixed α / β domain, RuvC-I, followed by a helical region, RuvC-II, and a zinc finger-like domain. The Cpf1 protein has a RuvC-like endonuclease domain similar to the RuvC domain of Cas9.
[0316] Furthermore, unlike Cas9, Cpf1 lacks the HNH endonuclease domain, and the N-terminus of Cpf1 lacks the α-helical recognition lobe of Cas9. The Cpf1 CRISPR-Cas domain architecture reveals that Cpf1 is functionally unique and is classified as a Class 2, Type V CRISPR system. The Cpf1 locus encodes the Cas1, Cas2, and Cas4 proteins, which are more similar to Type I and Type III than Type II systems. Functional Cpf1 does not require a transactivating CRISPR RNA (tracrRNA); therefore, only the CRISPR (crRNA) is required. This facilitates genome editing because Cpf1 is not only smaller than Cas9, but also has a smaller sgRNA molecule (approximately half the nucleotide length of Cas9). In contrast to the G-rich PAM targeted by Cas9, the Cpf1-crRNA complex cleaves target DNA or RNA by recognizing the protospacer-adjacent motifs 5′-YTN-3′ or 5′-TTN-3′. After identifying the PAM, Cpf1 introduces sticky-end-like DNA double-strand breaks with 4 or 5 nucleotide overhangs.
[0317] In some embodiments, Cas9 is a Cas9 variant that is specific for an altered PAM sequence. In some embodiments, additional Cas9 variants and PAM sequences are described in Miller, SM et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs, Nat. Biotechnol. (2020), the entire contents of which are incorporated herein by reference. In some embodiments, Cas9 variants (e.g., SpCas9 variants) are specific for NRNHPAMs, wherein R is A or G, and H is A, C, or T. In some embodiments, SpCas9 variants are specific for the PAM sequences AAA, TAA, CAA, GAA, TAT, GAT, or CAC. In some embodiments, the SpCas9 variant comprises an amino acid substitution at position 1114, 1134, 1135, 1137, 1139, 1151, 1180, 1188, 1211, 1218, 1219, 1221, 1249, 1256, 1264, 1290, 1318, 1317, 1320, 1321, 1323, 1332, 1333, 1335, 1337, or 1339, or their corresponding positions. In some embodiments, the SpCas9 variant comprises an amino acid substitution at position 1114, 1135, 1218, 1219, 1221, 1249, 1320, 1321, 1323, 1332, 1333, 1335, or 1337, or their corresponding positions. In some embodiments, the SpCas9 variant comprises an amino acid substitution at position 1114, 1134, 1135, 1137, 1139, 1151, 1180, 1188, 1211, 1219, 1221, 1256, 1264, 1290, 1318, 1317, 1320, 1323, 1333, or their corresponding positions. In some embodiments, the SpCas9 variant comprises an amino acid substitution at position 1114, 1131, 1135, 1150, 1156, 1180, 1191, 1218, 1219, 1221, 1227, 1249, 1253, 1286, 1293, 1320, 1321, 1332, 1335, 1339, or their corresponding positions. In some embodiments, the SpCas9 variant comprises an amino acid substitution at position 1114, 1127, 1135, 1180, 1207, 1219, 1234, 1286, 1301, 1332, 1335, 1337, 1338, 1349, or a corresponding position thereof. Exemplary amino acid substitutions and PAM specificities of SpCas9 variants are shown in Tables 3A-3D.
[0318] Table 3A SpCas9 variants
[0319]
[0320]
[0321]
[0322]
[0323]
[0324] In some embodiments, nucleic acid programmable DNA binding protein (napDNAbp) is a single effector of a microbial CRISPR-Cas system. Single effectors of microbial CRISPR-Cas systems include, but are not limited to, Cas9, Cpf1, Cas12b / C2c1, and Cas12c / C2c3. Typically, microbial CRISPR-Cas systems are divided into Class 1 and Class 2 systems. Class 1 systems have multi-subunit effector complexes, while Class 2 systems have single protein effectors. For example, Cas9 and Cpf1 are Class 2 effectors. In addition to Cas9 and Cpf1, Shmakov et al., "Discovery and Functional Characterization of DiverseClass 2 CRISPR Cas Systems", Mol.Cell, November 5, 2015; 60(3): 385-397 describe three different Class 2 CRISPR-Cas systems (Cas12b / C2c1 and Cas12c / C2c3), the entire contents of which are hereby incorporated by reference. The effectors of two of these systems, Cas12b / C2c1 and Cas12c / C2c3, contain a RuvC-like endonuclease domain associated with Cpf1. The third system contains an effector with two predicted HEPN RNase domains. Unlike CRISPR RNA production by Cas12b / C2c1, production of mature CRISPR RNA is tracrRNA-independent. Cas12b / C2c1 relies on both CRISPR RNA and tracrRNA for DNA cleavage.
[0325] In some embodiments, the napDNAbp is a circular permutant (eg, SEQ ID NO: 238).
[0326] The crystal structure of Alicyclobaccillus acidoterrastris Cas12b / C2c1 (AacC2c1) was reported to be complexed with a chimeric single-molecule guide RNA (sgRNA). See, for example, Liu et al., "C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism", Mol. Cell, January 19, 2017; 65(2): 310-322, the entire contents of which are hereby incorporated by reference. The crystal structure of Alicyclobaccillus acidoterrastris C2c1 bound to target DNA as a ternary complex was also reported. See, for example, Yang et al., "PAM-dependent Target DNA Recognition and Cleavage by C2C1 CRISPR-Cas endonuclease", Cell, December 15, 2016; 167(7): 1814-1828, the entire contents of which are hereby incorporated by reference. The catalytically competent conformations of AacC2c1 (with both target and non-target DNA strands) have been independently captured, positioned within a single RuvC catalytic pocket, with Cas12b / C2c1-mediated cleavage resulting in staggered seven-nucleotide breaks in the target DNA. Structural comparisons between the Cas12b / C2c1 ternary complex and previously identified Cas9 and Cpf1 counterparts demonstrate the diversity of mechanisms employed by the CRISPR-Cas9 system.
[0327] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) of any fusion protein provided herein can be Cas12b / C2c1 or Cas12c / C2c3 protein. In some embodiments, napDNAbp is Cas12b / C2c1 protein. In some embodiments, napDNAbp is Cas12c / C2c3 protein. In some embodiments, napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity with naturally occurring Cas12b / C2c1 or Cas12c / C2c3 protein. In some embodiments, napDNAbp is a naturally occurring Cas12b / C2c1 or Cas12c / C2c3 protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any of the napDNAbp sequences provided herein. It should be understood that Cas12b / C2c1 or Cas12c / C2c3 from other bacterial species can also be used according to the present disclosure.
[0328] In some embodiments, napDNAbp refers to Cas12c. In some embodiments, the Cas12c protein is Cas12c1 (SEQ ID NO: 239) or a variant of Cas12c1. In some embodiments, the Cas12 protein is Cas12c2 (SEQ ID NO: 240) or a variant of Cas12c2. In some embodiments, the Cas12 protein is a Cas12c protein (i.e., OspCas12c; SEQ ID NO: 241) or a variant of OspCas12c from a certain HI0009 of the genus Oleiphilus. These Cas12c molecules have been described in Yan et al., “Functionally Diverse Type VCRISPR-Cas Systems,” Science, January 4, 2019; 363: 88-91, the entire contents of which are hereby incorporated by reference. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identical to a naturally occurring Cas12c1, Cas12c2 or OspCas12c protein. In some embodiments, the napDNAbp is a naturally occurring Cas12c1, Cas12c2 or OspCas12c protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identical to any Cas12c1, Cas12c2 or OspCas12c protein described herein. It should be understood that Cas12c1, Cas12c2 or OspCas12c from other bacterial species may also be used according to the present disclosure.
[0329] In some embodiments, napDNAbp refers to Cas12g, Cas12h, or Cas12i, which have been described in, for example, Yan et al., "Functionally Diverse Type V CRISPR-Cas Systems," Science, Jan 4, 2019; 363:88-91, the entire contents of each of which are hereby incorporated by reference. Exemplary Cas12g, Cas12h, and Cas12i polypeptide sequences are provided in the sequence listing as SEQ ID NOs: 242-245. By aggregating over 10 terabytes of sequence data, a new classification of type V Cas proteins was identified that showed weak similarity to previously characterized class V proteins, including Cas12g, Cas12h, and Cas12i. In some embodiments, the Cas12 protein is Cas12g or a variant of Cas12g. In some embodiments, the Cas12 protein is Cas12h or a variant of Cas12h. In some embodiments, the Cas12 protein is Cas12i or a variant of Cas12i. It should be understood that other RNA-guided DNA binding proteins can be used as napDNAbp and are within the scope of the present disclosure. In some embodiments, the napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to a naturally occurring Cas12g, Cas12h or Cas12i protein. In some embodiments, the napDNAbp is a naturally occurring Cas12g, Cas12h or Cas12i protein. In some embodiments, the napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to any Cas12g, Cas12h or Cas12i protein described herein. It should be understood that Cas12g, Cas12h or Cas12i from other strains can also be used according to the present disclosure. In some embodiments, Cas12i is Cas12i1 or Cas12i2.
[0330] In some embodiments, the nucleic acid programmable DNA binding protein (napDNAbp) of any fusion protein provided herein can be a Cas12j / CasΦ protein. Cas12j / CasΦ is described in Pausch et al., "CRISPR-CasΦfrom huge phages is a hypercompact genome editor", Science, July 17, 2020, Vol. 369, No. 6501, pp. 333-337, which is incorporated herein by reference in its entirety. In some embodiments, napDNAbp comprises an amino acid sequence having at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to a naturally occurring Cas12j / CasΦ protein. In some embodiments, napDNAbp is a naturally occurring Cas 12j / CasΦ protein. In some embodiments, the napDNAbp is a nuclease-inactive ("dead") Cas 12j / CasΦ protein. It should be understood that Cas 12j / CasΦ from other species can also be used according to the present disclosure.
[0331] Fusion proteins with internal insertions
[0332] Provided herein is a fusion protein comprising a heterologous polypeptide fused to a nucleic acid programmable nucleic acid binding protein (e.g., napDNAbp). A heterologous polypeptide can be a polypeptide that is not present in a natural or wild-type napDNAbp polypeptide sequence. A heterologous polypeptide can be fused to napDNAbp at the C-terminus of napDNAbp, the N-terminus of napDNAbp, or inserted into an internal position of napDNAbp. In some embodiments, the heterologous polypeptide is a deaminase (e.g., a cytidine adenosine deaminase) or a functional fragment thereof. For example, the fusion protein can include a deaminase of an N-terminal fragment and a C-terminal fragment of a flanking Cas9 or Cas12 (e.g., Cas12b / C2c1) polypeptide. In some embodiments, the cytidine deaminase is an APOBEC deaminase (e.g., APOBEC 1). In some embodiments, the adenosine deaminase is TadA (e.g., TadA*7.10 or TadA*8). In some embodiments, TadA is TadA*8 or TadA*9. The TadA sequences described herein (eg, TadA7.10 or TadA*8) are suitable deaminases for the above-described fusion proteins.
[0333] In some embodiments, the fusion protein comprises the following structure:
[0334] NH2-[N-terminal fragment of napDNAbp]-[deaminase]-[C-terminal fragment of napDNAbp]-COOH;
[0335] NH2-[N-terminal fragment of Cas9]-[adenosine deaminase]-[C-terminal fragment of Cas9]-COOH;
[0336] NH2-[N-terminal fragment of Cas 12]-[adenosine deaminase]-[C-terminal fragment of Cas 12]-COOH;
[0337] NH2-[N-terminal fragment of Cas9]-[cytidine deaminase]-[C-terminal fragment of Cas9]-COOH;
[0338] NH2-[N-terminal fragment of Cas 12]-[cytidine deaminase]-[C-terminal fragment of Cas 12]-COOH;
[0339] wherein each instance of "]-[" is an optional linker.
[0340] The deaminase can be a circular permutation mutant deaminase. For example, the deaminase can be a circular permutation mutant adenosine deaminase. In some embodiments, the deaminase is a circular permutation mutant TadA, which has a circular permutation mutation at amino acid residue 116, 136, or 65, as numbered in the TadA reference sequence.
[0341] The fusion protein may comprise more than one deaminase. For example, the fusion protein may comprise one, two, three, four, five, or more deaminases. In some embodiments, the fusion protein comprises one or two deaminases. The two or more deaminases in the fusion protein may be adenosine deaminases, cytidine deaminases, or a combination thereof. The two or more deaminases may be homodimers or heterodimers. The two or more deaminases may be inserted in series within the napDNAbp. In some embodiments, the two or more deaminases may not be inserted in series within the napDNAbp.
[0342] In some embodiments, the napDNAbp in the fusion protein is a Cas9 polypeptide or a fragment thereof. The Cas9 polypeptide may be a variant Cas9 polypeptide. In some embodiments, the Cas9 polypeptide is a Cas9 nickase (nCas9) polypeptide or a fragment thereof. In some embodiments, the Cas9 polypeptide is a nuclease-dead Cas9 (dCas9) polypeptide or a fragment thereof. The Cas9 polypeptide in the fusion protein may be a full-length Cas9 polypeptide. In some cases, the Cas9 polypeptide in the fusion protein may not be a full-length Cas9 polypeptide. The Cas9 polypeptide may be truncated at, for example, the N-terminus or C-terminus relative to the naturally occurring Cas9 protein. The Cas9 polypeptide may be a circularly arranged mutant Cas9 protein. The Cas9 polypeptide may be a fragment, portion, or domain of the Cas9 polypeptide that is still capable of binding to the target polynucleotide and the guide nucleic acid sequence.
[0343] In some embodiments, the Cas9 polypeptide is a fragment or variant of Streptococcus pyogenes Cas9 (SpCas9), Staphylococcus aureus Cas9 (SaCas9), Streptococcus thermophilus 1 Cas9 (St1Cas9), or any Cas9 polypeptide described herein.
[0344] In some embodiments, the fusion protein comprises an adenosine deaminase domain and a cytidine deaminase domain inserted into Cas9. In some embodiments, the adenosine deaminase is fused into Cas9, and the cytidine deaminase is fused to the C-terminus. In some embodiments, the adenosine deaminase is fused into Cas9, and the cytidine deaminase is fused to the N-terminus. In some embodiments, the cytidine deaminase is fused into Cas9, and the adenosine deaminase is fused to the C-terminus. In some embodiments, the cytidine deaminase is fused into Cas9, and the adenosine deaminase is fused to the N-terminus.
[0345] An exemplary structure of a fusion protein with adenosine deaminase, cytidine deaminase, and Cas9 is provided below:
[0346] NH2-[Cas9(adenosine deaminase)]-[cytidine deaminase]-COOH;
[0347] NH2-[cytidine deaminase]-[Cas9(adenosine deaminase)]-COOH;
[0348] NH2-[Cas9(cytidine deaminase)]-[adenosine deaminase]-COOH; or
[0349] NH2-[Adenosine deaminase]-[Cas9(cytidine deaminase)]-COOH.
[0350] In some embodiments, the use of "-" in the above general scheme indicates the presence of an optional linker.
[0351] In various embodiments, the catalytic domain has DNA modification activity (e.g., deaminase activity), such as adenosine deaminase activity. In some embodiments, the adenosine deaminase is TadA (e.g., TadA*7.10). In some embodiments, TadA is TadA*8. In some embodiments, TadA*8 is fused within Cas9, and the cytidine deaminase is fused to the C-terminus. In some embodiments, TadA*8 is fused within Cas9, and the cytidine deaminase is fused to the N-terminus. In some embodiments, the cytidine deaminase is fused within Cas9, and TadA*8 is fused to the C-terminus. In some embodiments, the cytidine deaminase is fused within Cas9, and TadA*8 is fused to the N-terminus. Exemplary structures of fusion proteins with TadA*8, cytidine deaminase, and Cas9 are provided below:
[0352] NH2-[Cas9(TadA*8)]-[cytidine deaminase]-COOH;
[0353] NH2-[Cytidine deaminase]-[Cas9(TadA*8)]-COOH;
[0354] NH2-[Cas9(cytidine deaminase)]-[TadA*8]-COOH; or
[0355] NH2-[TadA*8]-[Cas9(cytidine deaminase)]-COOH.
[0356] In some embodiments, the use of "-" in the above general scheme indicates the presence of an optional linker.
[0357] Heterologous polypeptides (e.g., deaminases) can be inserted into napDNAbp (e.g., Cas9 or Cas12 (e.g., Cas12b / C2c1)) at appropriate positions, such as so that napDNAbp retains its ability to bind to target polynucleotides and guide nucleic acids. Deaminases (e.g., adenosine deaminases, cytidine deaminases, or adenosine deaminases and cytidine deaminases) can be inserted into napDNAbp without impairing the function of the deaminases (e.g., base editing activity) or the function of napDNAbp (e.g., the ability to bind to target nucleic acids and guide nucleic acids). Deaminases (e.g., adenosine deaminases, cytidine deaminases, or adenosine deaminases and cytidine deaminases) can be inserted into napDNAbp in, for example, disordered regions or regions comprising high temperature factors or B factors, as shown in crystallographic studies. Regions with lower order, disordered, or unstructured in proteins, such as solvent-exposed regions and loops, can be used for insertion without compromising structure or function. The deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) can be inserted into the flexible loop region or solvent-exposed region of napDNAbp. In some embodiments, the deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) is inserted into the flexible loop of the Cas9 or Cas12b / C2c1 polypeptide.
[0358] In some embodiments, the insertion position of the deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) is determined by B-factor analysis of the crystal structure of the Cas9 polypeptide. In some embodiments, the deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) is inserted into a region of the Cas9 polypeptide comprising a higher-than-average B-factor (e.g., a higher B-factor than the total protein or protein domain comprising a disordered region). The B-factor or temperature factor can indicate the fluctuation of an atom relative to its average position (e.g., due to temperature-dependent atomic vibrations or static disorder in the lattice). The high B-factor of the backbone atoms (e.g., higher-than-average B-factor) can indicate a region with a relatively high local mobility. Such a region can be used to insert a deaminase without compromising structure or function. A deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) can be inserted at a position having a residue having a B-factor for a Cα atom that is 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, or more than 200% greater than the average B-factor of the total protein. A deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) can be inserted at a position having a residue having a B-factor for a Cα atom that is 50%, 60%, 70%, 80%, 90%, 100%, 110%, 120%, 130%, 140%, 150%, 160%, 170%, 180%, 190%, 200%, or more than 200% greater than the average B-factor of the Cas9 protein domain comprising the residue. Cas9 polypeptide positions comprising higher-than-average B-factors may include, for example, residues 768, 792, 1052, 1015, 1022, 1026, 1029, 1067, 1040, 1054, 1068, 1246, 1247, and 1248 as numbered in the Cas9 reference sequence above. Regions of the Cas9 polypeptide comprising an above-average B-factor can include, for example, residues 792-872, 792-906, and 2-791 as numbered in the above-mentioned Cas9 reference sequence.
[0359] A heterologous polypeptide (e.g., a deaminase) can be inserted into the napDNAbp at an amino acid residue selected from the group consisting of 768, 791, 792, 1015, 1016, 1022, 1023, 1026, 1029, 1040, 1052, 1054, 1067, 1068, 1069, 1246, 1247, and 1248, as numbered in the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, the heterologous polypeptide is inserted between amino acid positions 768-769, 791-792, 792-793, 1015-1016, 1022-1023, 1026-1027, 1029-1030, 1040-1041, 1052-1053, 1054-1055, 1067-1068, 1068-1069, 1247-1248, or 1248-1249, or at their corresponding amino acid positions, as numbered by the above-mentioned Cas9 reference sequence. In some embodiments, the heterologous polypeptide is inserted between amino acid positions 769-770, 792-793, 793-794, 1016-1017, 1023-1024, 1027-1028, 1030-1031, 1041-1042, 1053-1054, 1055-1056, 1068-1069, 1069-1070, 1248-1249, or 1249-1250, or at amino acid positions corresponding thereto, as numbered by the above-mentioned Cas9 reference sequence. In some embodiments, the heterologous polypeptide replaces an amino acid residue selected from the group consisting of 768, 791, 792, 1015, 1016, 1022, 1023, 1026, 1029, 1040, 1052, 1054, 1067, 1068, 1069, 1246, 1247, and 1248 of the Cas9 reference sequence numbered above, or a corresponding amino acid residue in another Cas9 polypeptide. It should be understood that the reference sequence for insertion is for illustrative purposes only. Insertions as discussed herein are not limited to the Cas9 polypeptide sequences of the Cas9 reference sequences described above, but include insertions at corresponding positions in variant Cas9 polypeptides, such as Cas9 nickases (nCas9), nuclease-dead Cas9 (dCas9), Cas9 variants lacking a nuclease domain, truncated Cas9, or Cas9 domains lacking a partial or complete HNH domain.
[0360] A heterologous polypeptide (e.g., a deaminase) can be inserted into the napDNAbp at an amino acid residue selected from the group consisting of 768, 792, 1022, 1026, 1040, 1068, and 1247, or a corresponding amino acid residue in another Cas9 polypeptide, as numbered in the Cas9 reference sequence. In some embodiments, the heterologous polypeptide is inserted between amino acid positions 768-769, 792-793, 1022-1023, 1026-1027, 1029-1030, 1040-1041, 1068-1069, or 1247-1248, as numbered in the Cas9 reference sequence, or at amino acid positions corresponding thereto. In some embodiments, the heterologous polypeptide is inserted between amino acid positions 769-770, 793-794, 1023-1024, 1027-1028, 1030-1031, 1041-1042, 1069-1070, or 1248-1249, as numbered in the above-mentioned Cas9 reference sequence, or at amino acid positions corresponding thereto. In some embodiments, the heterologous polypeptide replaces an amino acid residue selected from the group consisting of 768, 792, 1022, 1026, 1040, 1068, and 1247, as numbered in the above-mentioned Cas9 reference sequence, or a corresponding amino acid residue in another Cas9 polypeptide.
[0361] A heterologous polypeptide (e.g., a deaminase) can be inserted into napDNAbp at an amino acid residue as described herein or a corresponding amino acid residue in another Cas9 polypeptide. In one embodiment, a heterologous polypeptide (e.g., a deaminase) can be inserted into napDNAbp at an amino acid residue selected from the group consisting of 1002, 1003, 1025, 1052-1056, 1242-1247, 1061-1077, 943-947, 686-691, 569-578, 530-539, and 1060-1077, or a corresponding amino acid residue in another Cas9 polypeptide, as numbered by the above-mentioned Cas9 reference sequence. A deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) can be inserted into or replace the residue at the N-terminus or C-terminus of the residue. In some embodiments, a deaminase (eg, an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted C-terminally to the residue.
[0362] In some embodiments, an adenosine deaminase (e.g., TadA) is inserted at an amino acid residue selected from the group consisting of 1015, 1022, 1029, 1040, 1068, 1247, 1054, 1026, 768, 1067, 1248, 1052, and 1246, as numbered in the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, an adenosine deaminase (e.g., TadA) is inserted to replace residues 792-872, 792-906, or 2-791, as numbered in the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, the adenosine deaminase is inserted at the N-terminus of an amino acid selected from the group consisting of 1015, 1022, 1029, 1040, 1068, 1247, 1054, 1026, 768, 1067, 1248, 1052, and 1246 as numbered in the Cas9 reference sequence above, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, the adenosine deaminase is inserted at the C-terminus of an amino acid selected from the group consisting of 1015, 1022, 1029, 1040, 1068, 1247, 1054, 1026, 768, 1067, 1248, 1052, and 1246 as numbered in the Cas9 reference sequence above, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, an adenosine deaminase is inserted to replace an amino acid selected from the group consisting of 1015, 1022, 1029, 1040, 1068, 1247, 1054, 1026, 768, 1067, 1248, 1052, and 1246, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide.
[0363] In some embodiments, a cytidine deaminase (e.g., APOBEC1) is inserted at an amino acid residue selected from the group consisting of 1016, 1023, 1029, 1040, 1069, and 1247, as numbered in the Cas9 reference sequence above, or a corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a cytidine deaminase is inserted at the N-terminus of an amino acid selected from the group consisting of 1016, 1023, 1029, 1040, 1069, and 1247, as numbered in the Cas9 reference sequence above, or a corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a cytidine deaminase is inserted at the C-terminus of an amino acid selected from the group consisting of 1016, 1023, 1029, 1040, 1069, and 1247, as numbered in the Cas9 reference sequence above, or a corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a cytidine deaminase is inserted to replace an amino acid selected from the group consisting of 1016, 1023, 1029, 1040, 1069, and 1247, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide.
[0364] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 768 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 768 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 768 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 768, as numbered by the above Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0365] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 791 as numbered by the above-mentioned Cas9 reference sequence or at amino acid residue 792 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 791 as numbered by the above-mentioned Cas9 reference sequence or at the N-terminus of amino acid 792 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid 791 as numbered by the above-mentioned Cas9 reference sequence or at the N-terminus of amino acid 792 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid 791, as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid 792, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide.
[0366] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1016 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1016 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1016 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1016, as numbered by the above Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0367] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1022 as numbered by the above-mentioned Cas9 reference sequence or at amino acid residue 1023 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1022 as numbered by the above-mentioned Cas9 reference sequence or at the N-terminus of amino acid residue 1023 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1022 as numbered by the above-mentioned Cas9 reference sequence or at the C-terminus of amino acid residue 1023 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1022, as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1023, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0368] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1026 as numbered by the above-mentioned Cas9 reference sequence or at amino acid residue 1029 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1026 as numbered by the above-mentioned Cas9 reference sequence or at the N-terminus of amino acid residue 1029 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1026 as numbered by the above-mentioned Cas9 reference sequence or at the C-terminus of amino acid residue 1029 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1026, as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1029, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0369] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1040 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1040 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1040 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1040, as numbered by the above Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0370] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1052 as numbered by the above-mentioned Cas9 reference sequence or at amino acid residue 1054 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1052 as numbered by the above-mentioned Cas9 reference sequence or at the N-terminus of amino acid residue 1054 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1052 as numbered by the above-mentioned Cas9 reference sequence or at the C-terminus of amino acid residue 1054 as numbered by the above-mentioned Cas9 reference sequence or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or both an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1052, as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1054, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0371] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1067 as numbered by the above-mentioned Cas9 reference sequence, or at amino acid residue 1068 as numbered by the above-mentioned Cas9 reference sequence, or at amino acid residue 1069 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1067 as numbered by the above-mentioned Cas9 reference sequence, or at the N-terminus of amino acid residue 1068 as numbered by the above-mentioned Cas9 reference sequence, or at the N-terminus of amino acid residue 1069 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1067 as numbered by the above-mentioned Cas9 reference sequence, or at the C-terminus of amino acid residue 1068 as numbered by the above-mentioned Cas9 reference sequence, or at the C-terminus of amino acid residue 1069 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1067 as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1068 as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1069 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residues in another Cas9 polypeptide.
[0372] In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at amino acid residue 1246 as numbered by the above-mentioned Cas9 reference sequence, or at amino acid residue 1247 as numbered by the above-mentioned Cas9 reference sequence, or at amino acid residue 1248 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the N-terminus of amino acid residue 1246 as numbered by the above-mentioned Cas9 reference sequence, or at the N-terminus of amino acid residue 1247 as numbered by the above-mentioned Cas9 reference sequence, or at the N-terminus of amino acid residue 1248 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residue in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted at the C-terminus of amino acid residue 1246 as numbered by the above-mentioned Cas9 reference sequence, or at the C-terminus of amino acid residue 1247 as numbered by the above-mentioned Cas9 reference sequence, or at the C-terminus of amino acid residue 1248 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, a deaminase (e.g., an adenosine deaminase, a cytidine deaminase, or an adenosine deaminase and a cytidine deaminase) is inserted to replace amino acid residue 1246 as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1247 as numbered by the above-mentioned Cas9 reference sequence, or to replace amino acid residue 1248 as numbered by the above-mentioned Cas9 reference sequence, or at the corresponding amino acid residues in another Cas9 polypeptide.
[0373] In some embodiments, a heterologous polypeptide (e.g., a deaminase) is inserted into a flexible loop of a Cas9 polypeptide. The flexible loop portion can be selected from 530-537, 569-570, 686-691, 943-947, 1002-1025, 1052-1077, 1232-1247, or 1298-1300 of the Cas9 reference sequence numbering, or the corresponding amino acid residues in another Cas9 polypeptide. The flexible loop portion can be selected from 1-529, 538-568, 580-685, 692-942, 948-1001, 1026-1051, 1078-1231, or 1248-1297 of the Cas9 reference sequence numbering, or the corresponding amino acid residues in another Cas9 polypeptide.
[0374] A heterologous polypeptide (e.g., an adenine deaminase) can be inserted into the region of the Cas9 polypeptide corresponding to amino acid residues 1017-1069, 1242-1247, 1052-1056, 1060-1077, 1002-1003, 943-947, 530-537, 568-579, 686-691, 1242-1247, 1298-1300, 1066-1077, 1052-1056, or 1060-1077, as numbered in the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide.
[0375] A heterologous polypeptide (e.g., adenine deaminase) can be inserted to replace the missing region of the Cas9 polypeptide. The missing region may correspond to the N-terminal or C-terminal portion of the Cas9 polypeptide. In some embodiments, the missing region corresponds to residues 792-872 numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, the missing region corresponds to residues 792-906 numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, the missing region corresponds to residues 2-791 numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. In some embodiments, the missing region corresponds to residues 1017-1069 numbered by the above-mentioned Cas9 reference sequence, or their corresponding amino acid residues.
[0376] Exemplary internal fusion base editors are provided in Table 4 below:
[0377] Table 4: Insertion loci in Cas9 protein
[0378]
[0379]
[0380] A heterologous polypeptide (e.g., a deaminase) can be inserted into the structure or functional domain of a Cas9 polypeptide. A heterologous polypeptide (e.g., a deaminase) can be inserted between two structure or functional domains of a Cas9 polypeptide. A heterologous polypeptide (e.g., a deaminase) can be inserted in place of the structure or functional domain of a Cas9 polypeptide, for example, after the domain is deleted from the Cas9 polypeptide. The structure or functional domain of a Cas9 polypeptide can include, for example, RuvC I, RuvC II, RuvC III, Rec 1, Rec2, PI, or HNH.
[0381] In some embodiments, the Cas9 polypeptide lacks one or more domains selected from the group consisting of RuvC I, RuvC II, RuvC III, Rec1, Rec2, PI, or HNH domains. In some embodiments, the Cas9 polypeptide lacks a nuclease domain. In some embodiments, the Cas9 polypeptide lacks an HNH domain. In some embodiments, the Cas9 polypeptide lacks a portion of an HNH domain, such that the Cas9 polypeptide has reduced or eliminated HNH activity. In some embodiments, the Cas9 polypeptide comprises a deletion of the nuclease domain, and a deaminase is inserted to replace the nuclease domain. In some embodiments, the HNH domain is deleted, and a deaminase is inserted in its place. In some embodiments, one or more RuvC domains are deleted, and a deaminase is inserted in its place.
[0382] The fusion protein comprising a heterologous polypeptide may be flanked by the N-terminal and C-terminal segments of napDNAbp. In some embodiments, the fusion protein comprises a deaminase flanked by the N-terminal segment and the C-terminal segment of the Cas9 polypeptide. The N-terminal segment or the C-terminal segment may bind to the target polynucleotide sequence. The C-terminus of the N-terminal segment or the N-terminus of the C-terminal segment may comprise a portion of the flexible loop of the Cas9 polypeptide. The C-terminus of the N-terminal segment or the N-terminus of the C-terminal segment may comprise a portion of the α-helical structure of the Cas9 polypeptide. The N-terminal segment or the C-terminal segment may comprise a DNA binding domain. The N-terminal segment or the C-terminal segment may comprise a RuvC domain. The N-terminal segment or the C-terminal segment may comprise an HNH domain. In some embodiments, neither the N-terminal segment nor the C-terminal segment comprises an HNH domain.
[0383] In some embodiments, when the fusion protein deaminates the target nucleobase, the C-terminus of the N-terminal Cas9 fragment comprises an amino acid close to the target nucleobase. In some embodiments, when the fusion protein deaminates the target nucleobase, the N-terminus of the C-terminal Cas9 fragment comprises an amino acid close to the target nucleobase. The insertion position of different deaminases can be different so that the target nucleobase is close to the amino acid in the C-terminus of the N-terminal Cas9 fragment or the N-terminus of the C-terminal Cas9 fragment. For example, the insertion position of the deaminase can be at an amino acid residue selected from the following: 1015, 1022, 1029, 1040, 1068, 1247, 1054, 1026, 768, 1067, 1248, 1052 and 1246 as numbered in the above-mentioned Cas9 reference sequence, or the corresponding amino acid residue in another Cas9 polypeptide.
[0384] The N-terminal Cas9 fragment of the fusion protein (i.e., the N-terminal Cas9 fragment flanking the deaminase in the fusion protein) may comprise the N-terminus of the Cas9 polypeptide. The N-terminal Cas9 fragment of the fusion protein may comprise a length of at least about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. The N-terminal Cas9 fragment of the fusion protein may comprise a sequence corresponding to the following amino acid residues: 1-56, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-718, 1-765, 1-780, 1-906, 1-918, or 1-1100, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. The N-terminal Cas9 fragment may comprise a sequence comprising at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% sequence identity to amino acid residues 1-56, 1-95, 1-200, 1-300, 1-400, 1-500, 1-600, 1-700, 1-718, 1-765, 1-780, 1-906, 1-918, or 1-1100, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide.
[0385] The C-terminal Cas9 fragment of the fusion protein (i.e., the C-terminal Cas9 fragment flanking the deaminase in the fusion protein) may comprise the C-terminus of the Cas9 polypeptide. The C-terminal Cas9 fragment of the fusion protein may comprise a length of at least about 100, 200, 300, 400, 500, 600, 700, 800, 900, 1000, 1100, 1200, or 1300 amino acids. The C-terminal Cas9 fragment of the fusion protein may comprise a sequence corresponding to the following amino acid residues: 1099-1368, 918-1368, 906-1368, 780-1368, 765-1368, 718-1368, 94-1368, or 56-1368, as numbered by the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide. The N-terminal Cas9 fragment may comprise a sequence comprising at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% sequence identity to amino acid residues 1099-1368, 918-1368, 906-1368, 780-1368, 765-1368, 718-1368, 94-1368 or 56-1368 as numbered in the above-mentioned Cas9 reference sequence, or the corresponding amino acid residues in another Cas9 polypeptide.
[0386] The N-terminal Cas9 fragment and the C-terminal Cas9 fragment of the fusion protein taken together may not correspond to the full-length naturally occurring Cas9 polypeptide sequence, e.g., as set forth in the Cas9 reference sequence above.
[0387] Fusion protein as described herein can achieve targeted deamination, wherein the deamination at non-target sites (for example, off-target sites) is reduced, such as genome-wide false deamination is reduced. Fusion protein as described herein can achieve targeted deamination, wherein the bystander deamination at non-target sites is reduced. Compared with the terminal fusion protein of the deaminase fused to the N-terminus or C-terminus of the Cas9 polypeptide, for example, non-desired deamination or off-target deamination can be reduced by at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% or at least 99%. Compared with the terminal fusion protein of the deaminase fused to the N-terminus or C-terminus of the Cas9 polypeptide, for example, non-desired deamination or off-target deamination can be reduced by at least one time, at least two times, at least three times, at least four times, at least five times, at least ten times, at least fifteen times, at least twenty times, at least thirty times, at least forty times, at least fifty times, at least 60 times, at least 70 times, at least 80 times, at least 90 times or at least one hundred times.
[0388] In some embodiments, the deaminase (e.g., adenosine deaminase, cytidine deaminase, or adenosine deaminase and cytidine deaminase) of the fusion protein deaminates no more than two nucleobases within the R- loop. In some embodiments, the deaminase of the fusion protein deaminates no more than three nucleobases within the R- loop. In some embodiments, the deaminase of the fusion protein deaminates no more than 2, 3, 4, 5, 6, 7, 8, 9, or 10 nucleobases within the R- loop. The R- loop is a three-stranded nucleic acid structure including a DNA: RNA hybrid, a DNA: DNA or RNA: RNA complementary structure, and associates with a single-stranded DNA. As used herein, when a target polynucleotide contacts a CRISPR complex or a base editing complex, an R- loop may be formed, wherein a portion of a guide polynucleotide (e.g., a guide RNA) hybridizes with a portion of a target polynucleotide (e.g., a target DNA) and replaces it. In some embodiments, the R loop comprises a hybridization region of a spacer sequence and a target DNA complementary sequence. The length of the R-loop region can be about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50 base pairs. In some embodiments, the length of the R-loop region is about 20 base pairs. It should be understood that, as used herein, the R-loop region is not limited to the target DNA strand that hybridizes with the guide polynucleotide. For example, the editing of the target nucleobase in the R-loop region can be for the DNA strand that comprises the complementary strand of the guide RNA, or it can be for the DNA strand that is the opposite strand of the strand that is complementary to the guide RNA. In some embodiments, editing in a region of the R-loop comprises editing nucleobases on the non-complementary strand (the protospacer strand) of the guide RNA in the target DNA sequence.
[0389] The fusion proteins described herein can achieve target deamination in an editing window that is different from canonical base editing. In some embodiments, the target nucleobase is about 1 to about 20 bases upstream of the PAM sequence in the target polynucleotide sequence. In some embodiments, the target nucleobase is about 2 to about 12 bases upstream of the PAM sequence in the target polynucleotide sequence. In some embodiments, the target nucleobase is about 1 to 9 base pairs away from the PAM sequence or is about 3 to 11 base pairs upstream of the PAM sequence: about 4 to 12 base pairs, about 5 to 13 base pairs, about 6 to 14 base pairs, about 7 to 15 base pairs, about 8 to 16 base pairs, about 9 to 17 base pairs, about 10 to 18 base pairs, about 11 to 19 base pairs, about 12 to 20 base pairs. base pairs, about 1 to 7 base pairs, about 2 to 8 base pairs, about 3 to 9 base pairs, about 4 to 10 base pairs, about 5 to 11 base pairs, about 6 to 12 base pairs, about 7 to 13 base pairs, about 8 to 14 base pairs, about 9 to 15 base pairs, about 10 to 16 base pairs, about 11 to 17 base pairs, about 12 to 18 base pairs, about 13 to 19 base pairs, about 14 to 20 base pairs, about 1 to 5 base pairs, about 2 to 6 base pairs , about 3 to 7 base pairs, about 4 to 8 base pairs, about 5 to 9 base pairs, about 6 to 10 base pairs, about 7 to 11 base pairs, about 8 to 12 base pairs, about 9 to 13 base pairs, about 10 to 14 base pairs, about 11 to 15 base pairs, about 12 to 16 base pairs, about 13 to 17 base pairs, about 14 to 18 base pairs, about 15 to 19 base pairs, about 16 to 20 base pairs, about 1 to 3 base pairs, about 2 to 4 base pairs, about 3 to 5 base pairs, about 4 to 6 base pairs, about 5 to 7 base pairs, about 6 to 8 base pairs, about 7 to 9 base pairs, about 8 to 10 base pairs, about 9 to 11 base pairs, about 10 to 12 base pairs, about 11 to 13 base pairs, about 12 to 14 base pairs, about 13 to 15 base pairs, about 14 to 16 base pairs, about 15 to 17 base pairs, about 16 to 18 base pairs, about 17 to 19 base pairs, about 18 to 20 base pairs. In some embodiments, the target nucleobase is about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or more base pairs from or upstream of a PAM sequence. In some embodiments, the target nucleobase is about 1, 2, 3, 4, 5, 6, 7, 8, or 9 base pairs upstream of a PAM sequence. In some embodiments, the target nucleobase is about 2, 3, 4, or 6 base pairs upstream of a PAM sequence.
[0390] The fusion protein may comprise more than one heterologous polypeptide. For example, the fusion protein may further comprise one or more UGI domains and / or one or more nuclear localization signals. Two or more heterologous domains may be inserted in series. Two or more heterologous domains may be inserted in a position such that they are not in series in NapDNAbp.
[0391] The fusion protein may include a linker between the deaminase and the napDNAbp polypeptide. The linker may be a peptide or non-peptide linker. For example, the linker may be XTEN, (GGGS)n (SEQ ID NO: 246), (GGGGS)n (SEQ ID NO: 247), (G)n, (EAAAK)n (SEQ ID NO: 248), (GGS)n, SGSETPGTSESATPES (SEQ ID NO: 249). In some embodiments, the fusion protein includes a linker between the N-terminal Cas9 fragment and the deaminase. In some embodiments, the fusion protein includes a linker between the C-terminal Cas9 fragment and the deaminase. In some embodiments, the N-terminal and C-terminal fragments of napDNAbp are connected to the deaminase with a linker. In some embodiments, the N-terminal and C-terminal fragments are connected to the deaminase domain without a linker. In some embodiments, the fusion protein includes a linker between the N-terminal Cas9 fragment and the deaminase, but does not include a linker between the C-terminal Cas9 fragment and the deaminase. In some embodiments, the fusion protein comprises a linker between the C-terminal Cas9 fragment and the deaminase, but does not comprise a linker between the N-terminal Cas9 fragment and the deaminase.
[0392] In some embodiments, the napDNAbp in the fusion protein is a Cas12 polypeptide, such as Cas12b / C2c1, or a fragment thereof. The Cas12 polypeptide can be a variant Cas12 polypeptide. In other embodiments, the N-terminal or C-terminal fragment of the Cas12 polypeptide comprises a nucleic acid programmable DNA binding domain or a RuvC domain. In other embodiments, the fusion protein contains a linker between the Cas12 polypeptide and the catalytic domain. In other embodiments, the amino acid sequence of the linker is GGSGGS (SEQ ID NO: 250) or GSSGSETPGTSESATPESSG (SEQ ID NO: 251). In other embodiments, the linker is a rigid linker. In other embodiments of the above aspects, the linker is encoded by GGAGGCTCTGGAGGAAGC (SEQ ID NO: 252) or GGCTCTTCTGGATCTGAAACACCTGGCACAAGCGAGAGCGCCACCCCTGAGAGCTCTGGC (SEQ ID NO: 253).
[0393] The fusion protein of the heterologous catalytic domain comprising the N and C-terminal fragments of the flanking Cas12 polypeptide can also be used for base editing in the method as described herein. The fusion protein comprising Cas12 and one or more deaminase domains (e.g., adenosine deaminase) or the adenosine deaminase domain comprising the flanking Cas12 sequence can also be used for the highly specific and effective base editing of the target sequence. In one embodiment, the chimeric Cas12 fusion protein contains a heterologous catalytic domain (e.g., adenosine deaminase, cytidine deaminase or adenosine deaminase and cytidine deaminase) inserted in the Cas12 polypeptide. In some embodiments, the fusion protein comprises an adenosine deaminase domain and a cytidine deaminase domain inserted in Cas12. In some embodiments, adenosine deaminase is fused in Cas12, and cytidine deaminase is fused to the C-terminus. In some embodiments, adenosine deaminase is fused in Cas12, and cytidine deaminase is fused to the N-terminus. In some embodiments, cytidine deaminase is fused in Cas12, and adenosine deaminase is fused to the C-terminus. In some embodiments, cytidine deaminase is fused within Cas12, and adenosine deaminase is fused to the N-terminus. An exemplary structure of a fusion protein with adenosine deaminase, cytidine deaminase, and Cas12 is provided below:
[0394] NH2-[Cas12(adenosine deaminase)]-[cytidine deaminase]-COOH;
[0395] NH2-[cytidine deaminase]-[Cas12(adenosine deaminase)]-COOH;
[0396] NH2-[Cas12(cytidine deaminase)]-[adenosine deaminase]-COOH; or
[0397] NH2-[adenosine deaminase]-[Cas12(cytidine deaminase)]-COOH;
[0398] In some embodiments, the use of "-" in the above general scheme indicates the presence of an optional linker.
[0399] In various embodiments, the catalytic domain has DNA modification activity (e.g., deaminase activity), such as adenosine deaminase activity. In some embodiments, the adenosine deaminase is TadA (e.g., TadA*7.10). In some embodiments, TadA is TadA*8. In some embodiments, TadA*8 is fused within Cas12, and the cytidine deaminase is fused to the C-terminus. In some embodiments, TadA*8 is fused within Cas12, and the cytidine deaminase is fused to the N-terminus. In some embodiments, the cytidine deaminase is fused within Cas12, and TadA*8 is fused to the C-terminus. In some embodiments, the cytidine deaminase is fused within Cas12, and TadA*8 is fused to the N-terminus. Exemplary structures of fusion proteins with TadA*8, cytidine deaminase, and Cas12 are provided below:
[0400] N-[Cas12(TadA*8)]-[cytidine deaminase]-C;
[0401] N-[Cytidine deaminase]-[Cas12(TadA*8)]-C;
[0402] N-[Cas12(cytidine deaminase)]-[TadA*8]-C; or
[0403] N-[TadA*8]-[Cas12(cytidine deaminase)]-C.
[0404] In some embodiments, the use of "-" in the above general scheme indicates the presence of an optional linker.
[0405] In other embodiments, the fusion protein contains one or more catalytic domains. In other embodiments, at least one of the one or more catalytic domains is inserted into the Cas12 polypeptide or fused to the Cas12 N-terminus or C-terminus. In other embodiments, at least one of the one or more catalytic domains is inserted into a loop, an alpha helical region, an unstructured portion, or a solvent accessible portion of the Cas12 polypeptide. In other embodiments, the Cas12 polypeptide is Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i, or Cas12j / CasΦ. In other embodiments, the Cas12 polypeptide has at least about 85% amino acid sequence identity to Bacillus Cas12b, Bacillus thermomylovora Cas12b, Bacillus sp. V3-13 Cas12b, or Bacillus acidophilus Cas12b (SEQ ID NO: 254). In other embodiments, the Cas12 polypeptide has at least about 90% amino acid sequence identity to Bacillus exogenous Cas12b (SEQ ID NO: 255), Bacillus thermomylovora Cas12b, Bacillus sp. V3-13 Cas12b, or Bacillus acidophilic Cas12b. In other embodiments, the Cas12 polypeptide has at least about 95% amino acid sequence identity to Bacillus exogenous Cas12b, Bacillus thermomylovora Cas12b (SEQ ID NO: 256), Bacillus sp. V3-13 Cas12b (SEQ ID NO: 257), or Bacillus acidophilic Cas12b. In other embodiments, the Cas12 polypeptide contains a fragment of Bacillus exogenous Cas12b, Bacillus thermomylovora Cas12b, Bacillus sp. V3-13 Cas12b, or Bacillus acidophilic Cas12b, or consists essentially of a fragment thereof. In embodiments, the Cas12 polypeptide contains BvCas12b (V4), which in some embodiments is expressed as 5′ mRNA Cap---5′ UTR---bhCas12b---terminator sequence---3′ UTR---120 poly A tail (SEQ ID NOs: 258-260).
[0406] In other embodiments, the catalytic domain is inserted between amino acid positions 153-154, 255-256, 306-307, 980-981, 1019-1020, 534-535, 604-605 or 344-345 of BhCas12b or the corresponding amino acid residues of Cas12a, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i or Cas12j / CasΦ. In other embodiments, the catalytic domain is inserted between amino acids P153 and S154 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acids K255 and E256 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acids D980 and G981 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acids K1019 and L1020 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acids F534 and P535 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acids K604 and G605 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acids H344 and F345 of BhCas12b. In other embodiments, the catalytic domain is inserted between amino acid positions 147 and 148, 248 and 249, 299 and 300, 991 and 992 or 1031 and 1032 of BvCas12b or the corresponding amino acid residues of Cas12a, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i or Cas12j / CasΦ. In other embodiments, the catalytic domain is inserted between amino acids P147 and D148 of BvCas12b. In other embodiments, the catalytic domain is inserted between amino acids G248 and G249 of BvCas12b. In other embodiments, the catalytic domain is inserted between amino acids P299 and E300 of BvCas12b. In other embodiments, the catalytic domain is inserted between amino acids G991 and E992 of BvCas12b. In other embodiments, the catalytic domain is inserted between amino acids K1031 and M1032 of BvCas12b. In other embodiments, the catalytic domain is inserted between amino acid positions 157 and 158, 258 and 259, 310 and 311, 1008 and 1009 or 1044 and 1045 of AaCas12b or the corresponding amino acid residues of Cas12a, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h, Cas12i or Cas12j / CasΦ. In other embodiments, the catalytic domain is inserted between amino acids P157 and G158 of AaCas12b.In other embodiments, the catalytic domain is inserted between amino acids V258 and G259 of AaCas12b. In other embodiments, the catalytic domain is inserted between amino acids D310 and P311 of AaCas12b. In other embodiments, the catalytic domain is inserted between amino acids G1008 and E1009 of AaCas12b. In other embodiments, the catalytic domain is inserted between amino acids G1044 and K1045 of AaCas12b.
[0407] In other embodiments, the fusion protein contains a nuclear localization signal (e.g., a bipartite nuclear localization signal). In other embodiments, the amino acid sequence of the nuclear localization signal is MAPKKKRKVGIHGVPAA (SEQ ID NO: 261). In other embodiments of the above aspects, the nuclear localization signal is encoded by the following sequence:
[0408] ATGGCCCCAAAGAAGAAGCGGAAGGTCGGTATCCACGGAGTCCCAGCAGCC (SEQ ID NO: 262). In other embodiments, the Cas12b polypeptide contains a mutation that silences the catalytic activity of the RuvC domain. In other embodiments, the Cas12b polypeptide contains D574A, D829A and / or D952A mutations. In other embodiments, the fusion protein further contains a tag (e.g., an influenza hemagglutinin tag).
[0409] In some embodiments, the fusion protein comprises a napDNAbp domain (e.g., a Cas12-derived domain) having an internally fused nucleobase editing domain (e.g., a deaminase domain such as all or part of an adenosine deaminase domain). In some embodiments, the napDNAbp is Cas12b. In some embodiments, the base editor comprises a BhCas12b domain having an internally fused TadA*8 domain inserted at the locus provided in Table 5 below.
[0410] Table 5: Insertion loci in Cas12b proteins
[0411]
[0412]
[0413] As a non-limiting example, adenosine deaminase (e.g., TadA*8.13) can be inserted into BhCas12b to generate a fusion protein (e.g., TadA*8.13-BhCas12b) that effectively edits nucleic acid sequences.
[0414] In some embodiments, the base editing system described herein is an ABE with TadA inserted into Cas9. The polypeptide sequences of the relevant ABEs with TadA inserted into Cas9 are provided in the accompanying sequence listing as SEQ ID NOs: 263-308.
[0415] In some embodiments, an adenosine deaminase base editor is generated to insert TadA or a variant thereof into a Cas9 polypeptide at an identified position.
[0416] Exemplary, but non-limiting, fusion proteins are described in International PCT Application No. PCT / US2020 / 016285 and U.S. Provisional Application Nos. 62 / 852,228 and 62 / 852,224, the contents of which are incorporated herein by reference in their entireties.
[0417] A to GEdit
[0418] In some embodiments, the base editor described herein includes an adenosine deaminase domain. This adenosine deaminase domain of the base editor can facilitate the editing of adenine (A) core base to guanine (G) core base by deaminating A to form inosine (I) exhibiting the base pairing properties of G. Adenosine deaminase is capable of deaminating (i.e., removing amine groups) adenine of deoxyadenosine residues in deoxyribonucleic acid (DNA). In some embodiments, the A to G base editor further includes an inosine base excision repair inhibitor, for example, a uracil glycosylase inhibitor (UGI) domain or a catalytically inactive inosine-specific nuclease. Without wishing to be bound by any particular theory, the UGI domain or the catalytically inactive inosine-specific nuclease can inhibit or prevent base excision repair of deaminated adenosine residues (e.g., inosine), which can improve the activity or efficiency of the base editor.
[0419] The base editor comprising adenosine deaminase can act on any polynucleotide, including DNA, RNA and DNA-RNA hybrids. In certain embodiments, the base editor comprising adenosine deaminase can deaminate the target A of the polynucleotide comprising RNA. For example, the base editor may include an adenosine deaminase domain capable of deaminating the target A of an RNA polynucleotide and / or a DNA-RNA hybrid polynucleotide. In one embodiment, the adenosine deaminase incorporated into the base editor includes all or part of an adenosine deaminase acting on RNA (ADAR, such as ADAR1 or ADAR2) or tRNA (ADAT). The base editor comprising an adenosine deaminase domain can also deaminate the A core base of a DNA polynucleotide. In one embodiment, the adenosine deaminase domain of the base editor includes all or part of an ADAT, and the ADAT includes one or more mutations that allow ADAT to deaminate the target A in DNA. For example, a base editor can comprise all or a portion of ADAT (EcTadA) from Escherichia coli comprising one or more of the following mutations: D108N, A106V, D147Y, E155V, L84F, H123Y, I156F, or corresponding mutations in another adenosine deaminase. Exemplary ADAT homolog polypeptide sequences are provided in the sequence listing as SEQ ID NOs: 1 and 309-315.
[0420] Adenosine deaminase can be derived from any suitable organism (e.g., Escherichia coli). In some embodiments, adenosine deaminase is from a prokaryotic organism. In some embodiments, adenosine deaminase is from bacteria. In some embodiments, adenosine deaminase is from Escherichia coli, Staphylococcus aureus, Salmonella typhi, Shewanella putrefaciens, Haemophilus influenzae, Caulobacter crescentus, or Bacillus subtilis. In some embodiments, adenosine deaminase is from Escherichia coli. In some embodiments, adenine deaminase is a naturally occurring adenosine deaminase comprising one or more mutations corresponding to any mutation provided herein (e.g., mutations in ecTadA). Corresponding residues in any homologous proteins can be identified by, for example, sequence alignment and determination of homologous residues. Mutations in any naturally occurring adenosine deaminase (eg, having homology to ecTadA) corresponding to any mutation described herein (eg, any mutation identified in ecTadA) can be generated accordingly.
[0421] In some embodiments, the adenosine deaminase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any of the amino acid sequences shown in any of the adenosine deaminases provided herein. It should be understood that the adenosine deaminases provided herein can include one or more mutations (e.g., any mutation provided herein). The present disclosure provides any deaminase domain having a certain percentage of identity plus any mutation described herein, or a combination thereof. In some embodiments, the adenosine deaminase comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to a reference sequence or any adenosine deaminase provided herein. In some embodiments, the adenosine deaminase comprises an amino acid sequence having at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, or at least 170 identical consecutive amino acid residues compared to any amino acid sequence known in the art or described herein.
[0422] It will be appreciated that any mutation provided herein (e.g., based on a TadA reference sequence) can be introduced into other adenosine deaminases, such as Escherichia coli TadA (ecTadA), Staphylococcus aureus TadA (saTadA), or other adenosine deaminases (e.g., bacterial adenosine deaminases). It will be apparent to those skilled in the art that other deaminases can be similarly aligned to identify homologous amino acid residues that can be mutated as provided herein. Thus, any mutation identified in a TadA reference sequence can be generated in other adenosine deaminases (e.g., ecTadA) having homologous amino acid residues. It will also be appreciated that any mutation provided herein can be generated in a TadA reference sequence or another adenosine deaminase, alone or in any combination.
[0423] In some embodiments, the adenosine deaminase comprises a D108X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises a D108G, D108N, D108V, D108A, or D108Y mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase. However, it will be appreciated that other deaminases can be similarly aligned to identify homologous amino acid residues that can be mutated as provided herein.
[0424] In some embodiments, the adenosine deaminase comprises an A106X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an A106V mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0425] In some embodiments, the adenosine deaminase comprises an E155X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein the presence of X represents any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an E155D, E155G, or E155V mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0426] In some embodiments, the adenosine deaminase comprises a D147X mutation in the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, wherein the presence of X represents any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises a D147Y mutation in the TadA reference sequence, or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0427] In some embodiments, the adenosine deaminase comprises an A106X, E155X, or D147X mutation in the TadA reference sequence, or a corresponding mutation in another adenosine deaminase (e.g., ecTadA), wherein X represents any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an E155D, E155G, or E155V mutation. In some embodiments, the adenosine deaminase comprises D147Y.
[0428] It should also be understood that any mutation provided herein can be generated individually or in any combination in a TadA reference sequence or another adenosine deaminase. For example, an adenosine deaminase can contain a D108N, A106V, E155V, and / or D147Y mutation in a TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA). In some embodiments, the adenosine deaminase comprises the following groups of mutations in the TadA reference sequence (groups of mutations are separated by ";") or corresponding mutations in another adenosine deaminase: D108N and A106V; D108N and E155V; D108N and D147Y; A106V and E155V; A106V and D147Y; E155V and D147Y; D108N, A106V, and E155V; D108N, A106V, and D147Y; D108N, E155V, and D147Y; A106V, E155V, and D147Y; and D108N, A106V, E155V, and D147Y. However, it will be appreciated that any combination of the corresponding mutations provided herein can be generated in an adenosine deaminase (e.g., ecTadA).
[0429] In some embodiments, the adenosine deaminase comprises one or more of the H8X, T17X, L18X, W23X, L34X, W45X, R51X, A56X, E59X, E85X, M94X, I95X, V102X, F104X, A106X, R107X, D108X, K110X, M118X, N127X, A138X, F149X, M151X, R153X, Q154X, I156X, and / or K157X mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, wherein the presence of X represents any amino acid in addition to the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one or more of the H8Y, T17S, L18E, W23L, L34S, W45L, R51H, A56E or A56S, E59G, E85K or E85G, M94L, I95L, V102A, F104L, A106V, R107C or R107H or R107P, D108G or D108N or D108V or D108A or D108Y, K110I, M118K, N127S, A138V, F149Y, M151V, R153C, Q154L, I156D, and / or K157R mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
[0430] In some embodiments, the adenosine deaminase comprises one or more of the H8X, D108X, and / or N127X mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, wherein X represents the presence of any amino acid. In some embodiments, the adenosine deaminase comprises one or more of the H8Y, D108N, and / or N127S mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
[0431] In some embodiments, the adenosine deaminase comprises one or more of the H8X, R26X, M61X, L68X, M70X, A106X, D108X, A109X, N127X, D147X, R152X, Q154X, E155X, K161X, Q163X, and / or T166X mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X represents the presence of any amino acid in addition to the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one or more of the H8Y, R26W, M61I, L68Q, M70V, A106T, D108N, A109T, N127S, D147Y, R152C, Q154H or Q154R, E155G or E155V or E155D, K161Q, Q163H, and / or T166P mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
[0432] In some embodiments, the adenosine deaminase comprises one, two, three, four, five, or six mutations in the TadA reference sequence selected from H8X, D108X, N127X, D147X, R152X, and Q154X, or corresponding mutations or mutations in another adenosine deaminase (e.g., ecTadA), wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations in the TadA reference sequence selected from H8X, M61X, M70X, D108X, N127X, Q154X, E155X, and Q163X, or corresponding mutations or mutations in another adenosine deaminase (e.g., ecTadA), wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, or five mutations in a TadA reference sequence selected from H8X, D108X, N127X, E155X, and T166X, or a corresponding mutation or mutations in another adenosine deaminase (e.g., ecTadA), wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
[0433] In some embodiments, the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from H8X, A106X, and D108X, or corresponding mutations or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from H8X, R26X, L68X, D108X, N127X, D147X, and E155X, or corresponding mutations or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in wild-type adenosine deaminase.
[0434] In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, or seven mutations in the TadA reference sequence selected from H8X, R126X, L68X, D108X, N127X, D147X, and E155X, or a corresponding mutation or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, or five mutations in the TadA reference sequence selected from H8X, D108X, A109X, N127X, and E155X, or a corresponding mutation or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
[0435] In some embodiments, the adenosine deaminase comprises one, two, three, four, five, or six mutations in the TadA reference sequence selected from H8Y, D108N, N127S, D147Y, R152C, and Q154H, or corresponding mutations or mutations in another adenosine deaminase (e.g., ecTadA). In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations in the TadA reference sequence selected from H8Y, M61I, M70V, D108N, N127S, Q154R, E155G, and Q163H, or corresponding mutations or mutations in another adenosine deaminase (e.g., ecTadA). In some embodiments, the adenosine deaminase comprises one, two, three, four, or five mutations selected from the group consisting of H8Y, D108N, N127S, E155V, and T166P in the TadA reference sequence, or corresponding mutations or mutations in another adenosine deaminase (e.g., ecTadA). In some embodiments, the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8Y, A106T, D108N, N127S, E155D, and K161Q in the TadA reference sequence, or corresponding mutations or mutations in another adenosine deaminase (e.g., ecTadA). In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations in the TadA reference sequence selected from H8Y, R26W, L68Q, D108N, N127S, D147Y, and E155V, or a corresponding mutation or mutations in another adenosine deaminase (e.g., ecTadA). In some embodiments, the adenosine deaminase comprises one, two, three, four, or five mutations in the TadA reference sequence selected from H8Y, D108N, A109T, N127S, and E155G, or a corresponding mutation or mutations in another adenosine deaminase (e.g., ecTadA).
[0436] In some embodiments, the adenosine deaminase comprises one or more or one or more corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises a D108N, D108G, or D108V mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises an A106V and D108N mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises an R107C and D108N mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises an H8Y, D108N, N127S, D147Y, and Q154H mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises H8Y, D108N, N127S, D147Y, and E155V mutations in the TadA reference sequence or corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises D108N, D147Y, and E155V mutations in the TadA reference sequence or corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises H8Y, D108N, and N127S mutations in the TadA reference sequence or corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises A106V, D108N, D147Y, and E155V mutations in the TadA reference sequence or corresponding mutations in another adenosine deaminase (e.g., ecTadA).
[0437] In some embodiments, the adenosine deaminase comprises one or more of the S2X, H8X, I49X, L84X, H123X, N127X, I156X, and / or K160X mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, wherein the presence of X represents any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one or more of the S2A, H8Y, I49F, L84F, H123Y, N127S, I156F, and / or K160S mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase (e.g., ecTadA).
[0438] In some embodiments, the adenosine deaminase comprises an L84X mutant adenosine deaminase, wherein X represents any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an L84F mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0439] In some embodiments, the adenosine deaminase comprises an H123X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an H123Y mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0440] In some embodiments, the adenosine deaminase comprises an I156X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an I156F mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0441] In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, or seven mutations in the TadA reference sequence selected from L84X, A106X, D108X, H123X, D147X, E155X, and I156X, or a corresponding mutation or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, five, or six mutations in the TadA reference sequence selected from S2X, I49X, A106X, D108X, D147X, and E155X, or a corresponding mutation or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, or five mutations in the TadA reference sequence selected from H8X, A106X, D108X, N127X, and K160X, or a corresponding mutation or mutations in another adenosine deaminase, wherein X represents the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
[0442] In some embodiments, the adenosine deaminase comprises one, two, three, four, five, six, or seven mutations selected from the group consisting of L84F, A106V, D108N, H123Y, D147Y, E155V, and I156F in the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of S2A, I49F, A106V, D108N, D147Y, and E155V in the TadA reference sequence.
[0443] In some embodiments, the adenosine deaminase comprises one, two, three, four, or five mutations selected from H8Y, A106T, D108N, N127S, and K160S in the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
[0444] In some embodiments, the adenosine deaminase comprises one or more of E25X, R26X, R107X, A142X, and / or A143X mutations in a TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, wherein the presence of X represents any amino acid in addition to the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one or more of the E25M, E25D, E25A, E25R, E25V, E25S, E25Y, R26G, R26N, R26Q, R26C, R26L, R26K, R107P, R107K, R107A, R107N, R107W, R107H, R107S, A142N, A142D, A142G, A143D, A143G, A143E, A143L, A143W, A143M, A143S, A143Q, and / or A143R mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises one or more of the mutations described herein corresponding to a TadA reference sequence or one or more corresponding mutations in another adenosine deaminase.
[0445] In some embodiments, the adenosine deaminase comprises an E25X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an E25M, E25D, E25A, E25R, E25V, E25S, or E25Y mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0446] In some embodiments, the adenosine deaminase comprises an R26X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an R26G, R26N, R26Q, R26C, R26L, or R26K mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0447] In some embodiments, the adenosine deaminase comprises an R107X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an R107P, R107K, R107A, R107N, R107W, R107H, or R107S mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0448] In some embodiments, the adenosine deaminase comprises an A142X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an A142N, A142D, A142G mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0449] In some embodiments, the adenosine deaminase comprises an A143X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an A143D, A143G, A143E, A143L, A143W, A143M, A143S, A143Q, and / or A143R mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase (e.g., ecTadA).
[0450] In some embodiments, the adenosine deaminase comprises one or more of H36X, N37X, P48X, I49X, R51X, M70X, N72X, D77X, E134X, S 146X, Q154X, K157X, and / or K161X mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, wherein the presence of X represents any amino acid in addition to the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises one or more of the H36L, N37T, N37S, P48T, P48L, I49V, R51H, R51L, M70L, N72S, D77G, E134G, S146R, S146C, Q154H, K157N, and / or K161T mutations in the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase (e.g., ecTadA).
[0451] In some embodiments, the adenosine deaminase comprises an H36X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an H36L mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0452] In some embodiments, the adenosine deaminase comprises an N37X mutation in the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an N37T or N37S mutation in the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
[0453] In some embodiments, the adenosine deaminase comprises a P48X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises a P48T or P48L mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0454] In some embodiments, the adenosine deaminase comprises an R51X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an R51H or R51L mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0455] In some embodiments, the adenosine deaminase comprises an S146X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an S146R or S146C mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0456] In some embodiments, the adenosine deaminase comprises a K157X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises a K157N mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0457] In some embodiments, the adenosine deaminase comprises a P48X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises a P48S, P48T, or P48A mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0458] In some embodiments, the adenosine deaminase comprises an A142X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an A142N mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0459] In some embodiments, the adenosine deaminase comprises a W23X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises a W23R or W23L mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0460] In some embodiments, the adenosine deaminase comprises an R152X mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase, wherein X represents any amino acid except the corresponding amino acid in the wild-type adenosine deaminase. In some embodiments, the adenosine deaminase comprises an R152P or R52H mutation in the TadA reference sequence or a corresponding mutation in another adenosine deaminase.
[0461] In one embodiment, the adenosine deaminase may comprise mutations H36L, R51L, L84F, A106V, D108N, H123Y, S146C, D147Y, E155V, I156F, and K157N. In some embodiments, the adenosine deaminase comprises the following combinations of mutations relative to the TadA reference sequence, wherein each mutation in the combination is separated by a "_" and each combination of mutations is between brackets:
[0462] (A106V_D108N),
[0463] (R107C_D108N),
[0464] (H8Y_D108N_N127S_D147Y_Q154H),
[0465] (H8Y_D108N_N127S_D147Y_E155V),
[0466] (D108N_D147Y_E155V),
[0467] (H8Y_D108N_N127S),
[0468] (H8Y_D108N_N127S_D147Y_Q154H),
[0469] (A106V_D108N_D147Y_E155V),
[0470] (D108Q_D147Y_E155V),
[0471] (D108M_D147Y_E155V),
[0472] (D108L_D147Y_E155V),
[0473] (D108K_D147Y_E155V),
[0474] (D108I_D147Y_E155V),
[0475] (D108F_D147Y_E155V),
[0476] (A106V_D108N_D147Y),
[0477] (A106V_D108M_D147Y_E155V),
[0478] (E59A_A106V_D108N_D147Y_E155V),
[0479] (E59A catalytically dead_A106V_D108N_D147Y_E155V),
[0480] (L84F_A106V_D108N_H123Y_D147Y_E155V_I156Y),
[0481] (L84F_A106V_D108N_H123Y_D147Y_E155V_I156F),
[0482] (D103A_D104N),
[0483] (G22P_D103A_D104N),
[0484] (D103A_D104N_S138A),
[0485] (R26G_L84F_A106V_R107H_D108N_H123Y_A142N_A143D_D147Y_E155V_I156F)、
[0486] (E25G_R26G_L84F_A106V_R107H_D108N_H123Y_A142N_A143D_D147Y_E155V_I156F)、
[0487] (E25D_R26G_L84F_A106V_R107K_D108N_H123Y_A142N_A143G_D147Y_E155V_I156F)、
[0488] (R26Q_L84F_A106V_D108N_H123Y_A142N_D147Y_E155V_I156F)、
[0489] (E25M_R26G_L84F_A106V_R107P_D108N_H123Y_A142N_A143D_D147Y_E155V_I156F)、
[0490] (R26C_L84F_A106V_R107H_D108N_H123Y_A142N_D147Y_E155V_I156F)、
[0491] (L84F_A106V_D108N_H123Y_A142N_A143L_D147Y_E155V_I156F)、
[0492] (R26G_L84F_A106V_D108N_H123Y_A142N_D147Y_E155V_I156F)、
[0493] (E25A_R26G_L84F_A106V_R107N_D108N_H123Y_A142N_A143E_D147Y_E155V_I156F)、
[0494] (R26G_L84F_A106V_R107H_D108N_H123Y_A142N_A143D_D147Y_E155V_I156F)、
[0495] (A106V_D108N_A142N_D147Y_E155V)、
[0496] (R26G_A106V_D108N_A142N_D147Y_E155V)、
[0497] (E25D_R26G_A106V_R107K_D108N_A142N_A143G_D147Y_E155V)、
[0498] (R26G_A106V_D108N_R107H_A142N_A143D_D147Y_E155V)、
[0499] (E25D_R26G_A106V_D108N_A142N_D147Y_E155V)、
[0500] (A106V_R107K_D108N_A142N_D147Y_E155V)、
[0501] (A106V_D108N_A142N_A143G_D147Y_E155V)、
[0502] (A106V_D108N_A142N_A143L_D147Y_E155V)、
[0503] (H36L_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N)、
[0504] (N37T_P48T_M70L_L84F_A106V_D108N_H123Y_D147Y_I49V_E155V_I156F)、
[0505] (N37S_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F_K161T)、
[0506] (H36L_L84F_A106V_D108N_H123Y_D147Y_Q154H_E155V_I156F)、
[0507] (N72S_L84F_A106V_D108N_H123Y_S146R_D147Y_E155V_I156F)、
[0508] (H36L_P48L_L84F_A106V_D108N_H123Y_E134G_D147Y_E155V_I156F)、
[0509] (H36L_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F_K157N)
[0510] (H36L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F)、
[0511] (L84F_A106V_D108N_H123Y_S146R_D147Y_E155V_I156F_K161T)、
[0512] (N37S_R51H_D77G_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0513] (R51L_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F_K157N)、
[0514] (D24G_Q71R_L84F_H96L_A106V_D108N_H123Y_D147Y_E155V_I156F_K160E)、
[0515] (H36L_G67V_L84F_A106V_D108N_H123Y_S146T_D147Y_E155V_I156F)、
[0516] (Q71L_L84F_A106V_D108N_H123Y_L137M_A143E_D147Y_E155V_I156F)、
[0517] (E25G_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F_Q159L)、
[0518] (L84F_A91T_F104I_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0519] (N72D_L84F_A106V_D108N_H123Y_G125A_D147Y_E155V_I156F)、
[0520] (P48S_L84F_S97C_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0521] (W23G_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0522] (D24G_P48L_Q71R_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F_Q159L)、
[0523] (L84F_A106V_D108N_H123Y_A142N_D147Y_E155V_I156F)、
[0524] (H36L_R51L_L84F_A106V_D108N_H123Y_A142N_S146C_D147Y_E155V_I156F_K157N)、
[0525] (N37S_L84F_A106V_D108N_H123Y_A142N_D147Y_E155V_I156F_K161T)、
[0526] (L84F_A106V_D108N_D147Y_E155V_I156F)、
[0527] (R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N_K161T)、
[0528] (L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K161T)、
[0529] (L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N_K160E_K161T)、
[0530] (L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N_K160E)、
[0531] (R74Q_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0532] (R74A_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0533] (L84F_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0534] (R74Q_L84F_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0535] (L84F_R98Q_A106V_D108N_H123Y_D147Y_E155V_I156F)、
[0536] (L84F_A106V_D108N_H123Y_R129Q_D147Y_E155V_I156F)、
[0537] (P48S_L84F_A106V_D108N_H123Y_A142N_D147Y_E155V_I156F)、
[0538] (P48S_A142N)、
[0539] (P48T_I49V_L84F_A106V_D108N_H123Y_A142N_D147Y_E155V_I156F_L157N)、
[0540] (P48T_I49V_A142N)、
[0541] (H36L_P48S_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N)、
[0542] (H36L_P48S_R51L_L84F_A106V_D108N_H123Y_S146C_A142N_D147Y_E155V_I156F
[0543] (H36L_P48T_I49V_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N)、
[0544] (H36L_P48T_I49V_R51L_L84F_A106V_D108N_H123Y_A142N_S146C_D147Y_E155V_I156F_K157N)、
[0545] (H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N)、
[0546] (H36L_P48A_R51L_L84F_A106V_D108N_H123Y_A142N_S146C_D147Y_E155V_I156F_K157N)、
[0547] (H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_A142N_D147Y_E155V_I156F_K157N)、
[0548] (W23L_H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N)、
[0549] (W23R_H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_E155V_I156F_K157N)、
[0550] (W23L_H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146R_D147Y_E155V_I156F_K161T)、
[0551] (H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_R152H_E155V_I156F_K157N)、
[0552] (H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_R152P_E155V_I156F_K157N)、
[0553] (W23L_H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_R152P_E155V_I156F_K157N)、
[0554] (W23L_H36L_P48A_R51L_L84F_A106V_D108N_H123Y__A142A_S146C_D147Y_E155V_I156F_K157N)、
[0555] (W23L_H36L_P48A_R51L_L84F_A106V_D108N_H123Y__A142A_S146C_D147Y_R152P_E155V_I156F_K157N),
[0556] (W23L_H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146R_D147Y_E155V_I156F_K161T),
[0557] (W23R_H36L_P48A_R51L_L84F_A106V_D108N_H123Y_S146C_D147Y_R152P_E155V_I156F_K157N),
[0558] (H36L_P48A_R51L_L84F_A106V_D108N_H123Y_A142N_S146C_D147Y_R152P_E155V_I156F_K157N).
[0559] In some embodiments, the TadA deaminase is a TadA variant. In some embodiments, the TadA variant is TadA*7.10. In specific embodiments, the fusion protein comprises a single TadA*7.10 domain (e.g., provided as a monomer). In other embodiments, the fusion protein comprises TadA*7.10 and TadA(wt) capable of forming a heterodimer. In one embodiment, the fusion protein of the present invention comprises wild-type TadA connected to TadA*7.10, which is connected to the Cas9 nickase.
[0560] In some embodiments, TadA*7.10 comprises at least one alteration. In some embodiments, adenosine deaminase comprises an alteration in the following sequence:
[0561] TadA*7.10
[0562] MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCYFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 1).
[0563] In some embodiments, TadA*7.10 comprises an alteration at amino acid 82 and / or 166. In specific embodiments, TadA*7.10 comprises one or more of the following alterations: Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. In other embodiments, a variant of TadA*7.10 comprises a combination of alterations selected from the following groups: Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H +Y147R;V82S+Y123H+Q154R;Y147R+Q154R+Y123H;Y147R+Q154R+I76Y;Y147R+Q154R+T166R;Y123H+Y147R+Q154R+I76Y;V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0564] In some embodiments, the adenosine deaminase variant (e.g., TadA*8) comprises a deletion. In some embodiments, the adenosine deaminase variant comprises a C-terminal deletion. In specific embodiments, the adenosine deaminase variant comprises a C-terminal deletion starting at residues 149, 150, 151, 152, 153, 154, 155, 156, and 157 relative to the corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA.
[0565] In other embodiments, the adenosine deaminase variant (e.g., TadA*8) is a monomer comprising one or more of the following alterations relative to TadA*7.10, a TadA reference sequence, or the corresponding mutations in another TadA: Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R. In other embodiments, the adenosine deaminase variant (TadA*8) is a monomer comprising a combination of alterations selected from the group consisting of Y147T+Q154R; Y147T+Q154S; Y147R+Q154S; V82S+Q154S; V82S+Y147R; V82S+Q154R; V82S+Y123H; I76Y+V82S; V82S+Y 123H+Y147T;V82S+Y123H+Y147R;V82S+Y123H+Q154R;Y147R+Q154R+Y123H;Y147R+Q154R+I76Y;Y147R+Q154R+T166R;Y123H+Y147R+Q154R+I76Y;V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0566] In other embodiments, the adenosine deaminase variant is a homodimer comprising two adenosine deaminase domains (e.g., TadA*8), each adenosine deaminase domain having one or more of the following alterations Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R relative to TadA*7.10, a TadA reference sequence, or a corresponding mutation in another TadA. In other embodiments, the adenosine deaminase variant is a homodimer comprising two adenosine deaminase domains (e.g., TadA*8), each of which has a combination of alterations selected from the group consisting of Y147T+Q154R; Y147T+Q154S; Y147R+Q154S; V82S+Q154S; V82S+Y147R; V82S+Q154R; V82S+Y123H; I7 6Y+V82S;V82S+Y123H+Y147T;V82S+Y123H+Y147R;V82S+Y123H+Q154R;Y147R+Q154R+Y123H;Y147R+Q154R+I76Y;Y147R+Q154R+T166R;Y123H+Y147R+Q154R+I76Y;V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0567] In other embodiments, the adenosine deaminase variant is a heterodimer of a wild-type adenosine deaminase domain and an adenosine deaminase variant domain (e.g., TadA*8), comprising one or more of the following changes Y147T, Y147R, Q154S, Y123H, V82S, T166R, and / or Q154R relative to the corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA. In other embodiments, the adenosine deaminase variant is a heterodimer of a wild-type adenosine deaminase domain and an adenosine deaminase variant domain (e.g., TadA*8), the adenosine deaminase variant domain comprising a combination of alterations selected from the group consisting of: Y147T+Q154R; Y147T+Q154S; Y147R+Q154S; V82S+Q154S; V82S+Y147R; V82S+Q154R; V82S+Y1 23H;I76Y+V82S;V82S+Y123H+Y147T;V82S+Y123H+Y147R;V82S+Y123H+Q154R;Y147R+Q154R+Y123H;Y147R+Q154R+I76Y;Y147R+Q154R+T166R;Y123H+Y147R+Q154R+I76Y;V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0568] In other embodiments, the adenosine deaminase variant is a heterodimer of a TadA*7.10 domain and an adenosine deaminase variant domain (e.g., TadA*8) comprising one or more of the following changes Y147T, Y147R, Q154S, Y123H, V82S, T166R and / or Q154R relative to TadA*7.10, a TadA reference sequence, or the corresponding mutations in another TadA. In other embodiments, the adenosine deaminase variant is a heterodimer of a TadA*7.10 domain and an adenosine deaminase variant domain (e.g., TadA*8), wherein the adenosine deaminase variant domain comprises a combination of alterations selected from the group consisting of: Y147T+Q154R; Y147T+Q154S; Y147R+Q154S; V82S+Q154S; V82S+Y147R; V82S+Q154R; V82S+Y147R; V82S+Q154R; V82S+Y147R 123H;I76Y+V82S;V82S+Y123H+Y147T;V82S+Y123H+Y147R;V82S+Y123H+Q154R;Y147R+Q154R+Y123H;Y147R+Q154R+I76Y;Y147R+Q154R+T166R;Y123H+Y147R+Q154R+I76Y;V82S+Y123H+Y147R+Q154R; and I76Y+V82S+Y123H+Y147R+Q154R.
[0569] In a specific embodiment, the adenosine deaminase heterodimer comprises a TadA*8 domain and an adenosine deaminase domain, wherein the adenosine deaminase domain is selected from Staphylococcus aureus (S. aureus) TadA, Bacillus subtilis (B. subtilis) TadA, Salmonella typhimurium (S. typhimurium) TadA, Shewanella putrefaciens (S. putrefaciens) TadA, Haemophilus influenzae F3031 (H. influenzae) TadA, C. crescentus TadA, G. sulfurreducens TadA or TadA*7.10.
[0570] In some embodiments, the adenosine deaminase is TadA*8. In one embodiment, the adenosine deaminase is TadA*8 comprising or essentially consisting of the following sequence or a fragment thereof having adenosine deaminase activity:
[0571] MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHYPGMNHRVEITEGILADECAALLCTFFRMPRQVFNAQKKAQSSTD (SEQ ID NO: 316).
[0572] In some embodiments, TadA*8 is truncated. In some embodiments, the truncated TadA*8 lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal amino acid residues relative to full-length TadA*8. In some embodiments, the truncated TadA*8 lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 C-terminal amino acid residues relative to full-length TadA*8. In some embodiments, the adenosine deaminase variant is full-length TadA*8.
[0573] In some embodiments, TadA*8 is TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7, TadA*8.8, TadA*8.9, TadA*8.10, TadA*8.11, TadA*8 .12, TadA*8.13, TadA*8.14, TadA*8.15, TadA*8.16, TadA*8.17, TadA*8.18, TadA*8.19, TadA*8.20, TadA*8.21, TadA*8.22, TadA*8.23 or TadA*8.24.
[0574] In other embodiments, the base editor of the present disclosure comprises an adenosine deaminase variant (e.g., TadA*8) monomer comprising one or more of the following changes relative to TadA*7.10, a TadA reference sequence, or a corresponding mutation in another TadA: R26C, V88A, A109S, T111R, D119N, H122N, Y147D, F149Y, T166I, and / or D167N. In other embodiments, the adenosine deaminase variant (TadA*8) monomer comprises a combination of changes selected from the following groups relative to the corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA: R26C+A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167N; V88A+A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167N; 19N+H122N+F149Y+T166I+D167N; R26C+A109S+T111R+D119N+H122N+F149Y+T166I+D167N; V88A+T111R+D119N+F149Y; and A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167N.
[0575] In other embodiments, the base editor comprises a heterodimer of a wild-type adenosine deaminase domain and an adenosine deaminase variant domain (e.g., TadA*8), wherein the adenosine deaminase variant domain comprises one or more of the following changes R26C, V88A, A109S, T111R, D119N, H122N, Y147D, F149Y, T166I and / or D167N relative to the corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA. In other embodiments, the base editor comprises a heterodimer of a wild-type adenosine deaminase domain and an adenosine deaminase variant domain (e.g., TadA*8), wherein the adenosine deaminase variant domain comprises a combination of changes selected from the group consisting of R26C+A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167 relative to the corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA. N; V88A+A109S+T111R+D119N+H122N+F149Y+T166I+D167N; R26C+A109S+T111R+D119N+H122N+F149Y+ T166I+D167N; V88A+T111R+D119N+F149Y; and A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167N.
[0576] In other embodiments, the base editor comprises a heterodimer of a TadA*7.10 domain and an adenosine deaminase variant domain (e.g., TadA*8), wherein the adenosine deaminase variant domain comprises one or more of the following changes R26C, V88A, A109S, T111R, D119N, H122N, Y147D, F149Y, T166I and / or D167N relative to the corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA. In other embodiments, the base editor comprises a heterodimer of a TadA*7.10 domain and an adenosine deaminase variant domain (e.g., TadA*8), wherein the adenosine deaminase variant domain comprises a combination of changes selected from the group consisting of R26C+A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167 relative to corresponding mutations in TadA*7.10, a TadA reference sequence, or another TadA. N; V88A+A109S+T111R+D119N+H122N+F149Y+T166I+D167N; R26C+A109S+T111R+D119N+H122N+F149Y+ T166I+D167N; V88A+T111R+D119N+F149Y; and A109S+T111R+D119N+H122N+Y147D+F149Y+T166I+D167N.
[0577] In some embodiments, TadA*8 is a variant as shown in Table 6. Table 6 shows certain amino acid position numbers in the TadA amino acid sequence and the amino acids present at those positions in the TadA-7.10 adenosine deaminase. Table 6 also shows the amino acid changes of TadA variants relative to TadA-7.10 after phage-assisted discontinuous evolution (PANCE) and phage-assisted continuous evolution (PACE), as described in M. Richter et al., 2020, Nature Biotechnology, doi.org / 10.1038 / s41587-020-0453-z, the entire contents of which are incorporated herein by reference. In some embodiments, TadA*8 is TadA*8a, TadA*8b, TadA*8c, TadA*8d, or TadA*8e. In some embodiments, TadA*8 is TadA*8e.
[0578] Table 6. Selected TadA*8 variants
[0579] TadA amino acid numbering
[0580]
[0581] In one embodiment, the fusion protein of the invention comprises wild-type TadA linked to an adenosine deaminase variant described herein (e.g., TadA*8) linked to a Cas9 nickase. In a specific embodiment, the fusion protein comprises a single TadA*8 domain (e.g., provided as a monomer). In other embodiments, the fusion protein comprises TadA*8 and TadA(wt) that are capable of forming heterodimers.
[0582] In some embodiments, the adenosine deaminase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any of the amino acid sequences shown in any of the adenosine deaminases provided herein. It should be understood that the adenosine deaminases provided herein can include one or more mutations (e.g., any mutation provided herein). The present disclosure provides any deaminase domain having a certain percentage of identity plus any mutation described herein, or a combination thereof. In some embodiments, the adenosine deaminase comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to a reference sequence or any adenosine deaminase provided herein. In some embodiments, the adenosine deaminase comprises an amino acid sequence having at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, or at least 170 identical consecutive amino acid residues compared to any amino acid sequence known in the art or described herein.
[0583] In certain embodiments, TadA*8 comprises one or more mutations at any of the following positions shown in bold. In other embodiments, TadA*8 comprises one or more mutations at any of the positions shown underlined:
[0584]
[0585] For example, relative to the corresponding mutations in TadA*7.10, the TadA reference sequence, or another TadA, TadA*8 alone or in combination with any one or more of the following Y147T, Y147R, Q154S, Y123H, and / or Q154R contains alterations (e.g., V82S, T166R) at amino acid positions 82 and / or 166. In certain embodiments, relative to the corresponding mutations in TadA*7.10, the TadA reference sequence, or another TadA, the combinations of alterations are selected from: Y147T + Q154R; Y147T + Q154S; Y147R + Q154S; V82S + Q154S; V82S + Y147R; V82S + Q154R; V82S + Y123H; I76Y + V82S; V82S + Y123H + Y147T; V82S + Y123H + Y147R; V82S + Y123H + Q154R; Y147R + Q154R + Y123H; Y147R + Q154R + I76Y; Y147R + Q154R + T166R; Y123H + Y147R + Q154R + I76Y; V82S + Y123H + Y147R + Q154R; and I76Y + V82S + Y123H + Y147R + Q154R.
[0586] In some embodiments, TadA*8 is truncated. In some embodiments, the truncated TadA*8 lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal amino acid residues relative to the full-length TadA*8. In some embodiments, the truncated TadA*8 lacks 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or २० C-terminal amino acid residues relative to the full-length TadA*8. In some embodiments, the adenosine deaminase variant is full-length TadA*8.
[0587] In one embodiment, the fusion protein of the invention comprises wild-type TadA linked to an adenosine deaminase variant (e.g., TadA*8) described herein that is linked to Cas9 nickase. In certain embodiments, the fusion protein comprises a single TadA*8 domain (e.g., provided as a monomer). In other embodiments, the base editor comprises TadA*8 and TadA(wt) that are capable of forming a heterodimer.
[0588] In a specific embodiment, the fusion protein comprises a single (e.g., provided as a monomer) TadA*8. In some embodiments, TadA*8 is linked to a Cas9 nickase. In some embodiments, the fusion protein of the present invention comprises a heterodimer of wild-type TadA (TadA(wt)) linked to TadA*8. In other embodiments, the fusion protein of the present invention comprises a heterodimer of TadA*7.10 linked to TadA*8. In some embodiments, the base editor is ABE8 comprising a TadA*8 variant monomer. In some embodiments, the base editor is ABE8 comprising a heterodimer of TadA*8 and TadA(wt). In some embodiments, the base editor is ABE8 comprising a heterodimer of TadA*8 and TadA*7.10. In some embodiments, the base editor is ABE8 comprising a heterodimer of TadA*8. In some embodiments, TadA*8 is selected from Table 6, 12, or 13. In some embodiments, ABE8 is selected from Table 12, 13, or 15.
[0589] In some embodiments, the adenosine deaminase is a TadA*9 variant. In some embodiments, the adenosine deaminase is a TadA*9 variant selected from the following variants and with reference to the following sequence (referred to as TadA*7.10):
[0590]
[0591] In some embodiments, the adenosine deaminase comprises one or more of the following changes: R21N, R23H, E25F, N38G, L51W, P54C, M70V, Q71M, N72K, Y73S, V82T, M94V, P124W, T133K, D139L, D139M, C146R, and A158K. The one or more changes are underlined and in bold in the above sequence.
[0592] In some embodiments, the adenosine deaminase comprises one or more of the following combinations of alterations: V82S+Q154R+Y147R; V82S+Q154R+Y123H; V82S+Q154R+Y147R+Y123H; Q154R+Y147R+Y123H+I76Y+V82S; V82S+I76Y; V82S+Y147R; V82S+Y147R+Y123H; V82S+Q154R+Y123H; Q154R+Y147R+Y123H+I76Y 6Y;V82S+Y147R;V82S+Y147R+Y123H;V82S+Q154R+Y123H;V82S+Q154R+Y147R;V82S+Q154R+Y147R;Q154R+Y147R+Y123H+I76Y;Q154R+Y147R+Y123H+I76Y+V82S;I76Y_V82S_Y123H_Y147R_Q154R;Y147R+Q154R+H123H;and V82S+Q154R.
[0593] In some embodiments, the adenosine deaminase comprises one or more of the following combinations of alterations: E25F+V82S+Y123H, T133K+Y147R+Q154R; E25F+V82S+Y123H+Y147R+Q154R; L51W+V82S+Y123H+C146R+Y147R+Q154R; Y73S+V82S+Y123H+Y147R+Q154R; P54C+V82S+Y123H+Y147 R+Q154R; N38G+V82T+Y123H+Y147R+Q154R; N72K+V82S+Y123H+D139L+Y147R+Q154R; E25F+V82S+Y123H+D1 39M+Y147R+Q154R; Q71M+V82S+Y123H+Y147R+Q154R; E25F+V82S+Y123H+T133K+Y147R+Q154R; E25F+V82S+ Y123H+Y147R+Q154R; V82S+Y123H+P124W+Y147R+Q154R; L51W+V82S+Y123H+C146R+Y147R+Q154R; P54C+V 82S+Y123H+Y147R+Q154R; Y73S+V82S+Y123H+Y147R+Q154R; N38G+V82T+Y123H+Y147R+Q154R; R23H+V82S+ Y123H+Y147R+Q154R; R21N+V82S+Y123H+Y147R+Q154R; V82S+Y123H+Y147R+Q154R+A158K; N72K+V82S+Y123H+D139L+Y147R+Q154R; E25F+V82S+Y123H+D139M+Y147R+Q154R; and M70V+V82S+M94V+Y123H+Y147R+Q154R
[0594] In some embodiments, the adenosine deaminase comprises one or more of the following combinations of alterations: Q71M+V82S+Y123H+Y147R+Q154R; E25F+I76Y+V82S+Y123H+Y147R+Q154R; I76Y+V82T+Y123H+Y147R+Q154R; N38G+I76Y+V82S+Y123H+Y147R+Q154R; R23H+I76Y+V82S+Y123H+Y147R+Q154R; P54C+I76Y+V82S+Y123H+Y147R+Q154R; R21N+I76Y+V82S+Y 123H+Y147R+Q154R; I76Y+V82S+Y123H+D139M+Y147R+Q154R; Y73S+I7 6Y+V82S+Y123H+Y147R+Q154R; E25F+I76Y+V82S+Y123H+Y147R+Q154R; I76Y+V82T+Y123H+Y147R+Q154R; N38G+I76Y+V82S+Y123H+Y147R+Q154 R; R23H+I76Y+V82S+Y123H+Y147R+Q154R; P54C+I76Y+V82S+Y123H+Y14 7R+Q154R; R21N+I76Y+V82S+Y123H+Y147R+Q154R; I76Y+V82S+Y123H+ D139M+Y147R+Q154R; Y73S+I76Y+V82S+Y123H+Y147R+Q154R; and V82S+Q1 54R; N72K_V82S+Y123H+Y147R+Q154R; Q71M_V82S+Y123H+Y147R+Q154R ;V82S+Y123H+T133K+Y147R+Q154R; V82S+Y123H+T133K+Y147R+Q154R+ A158K;M70V+Q71M+N72K+V82S+Y123H+Y147R+Q154R;N72K_V82S+Y123H+Y147R+Q154R;Q71M_V82S+Y123H+Y147R+Q154R;M70V+V82S+M94V+Y123H+Y147R+Q154R;V82S+Y123H+T133K+Y147R+Q154R;V82S+Y123H+T133K+Y147R+Q154R+A158K;and M70V+Q71M+N72K+V82S+Y123H+Y147R+Q154R. In some embodiments, adenosine deaminase is expressed as a monomer. In other embodiments, adenosine deaminase is expressed as a heterodimer.In some embodiments, the deaminase or other polypeptide sequence lacks methionine, for example when included as a component of a fusion protein. This can change the numbering of positions. However, the skilled artisan will understand that such corresponding mutations refer to the same mutation, for example, Y73S and Y72S and D139M and D138M.
[0595] In some embodiments, the TadA*9 variant comprises an alteration as described in Table 16 as described herein. In some embodiments, the TadA*9 variant is a monomer. In some embodiments, the TadA*9 variant is a heterodimer with wild-type TadA adenosine deaminase. In some embodiments, the TadA*9 variant is a heterodimer with another TadA variant (e.g., TadA*8, TadA*9). International PCT application No. PCT / 2020 / 049975 describes additional details of TadA*9 adenosine deaminase, which is incorporated herein by reference in its entirety.
[0596] Any mutation provided herein and any additional mutation (e.g., based on the ecTadA amino acid sequence) can be introduced into any other adenosine deaminase. Any mutation provided herein can be generated alone or in any combination in a TadA reference sequence or another adenosine deaminase (e.g., ecTadA).
[0597] Details of the A to G nucleobase editing protein are described in International PCT Application No. PCT / 2017 / 045381 (WO2018 / 027078) and Gaudelli, NM et al., “Programmable base editing of A·T to G·C ingenomic DNA without DNA cleavage,” Nature, 551, 464-471 (2017), the entire contents of which are hereby incorporated by reference.
[0598] C to T Edit
[0599] In some embodiments, the base editor disclosed herein comprises a fusion protein comprising a cytidine deaminase capable of deaminating a target cytidine (C) base of a polynucleotide to produce uridine (U) having the base pairing properties of thymine. In some embodiments, for example, where the polynucleotide is double-stranded (e.g., DNA), the uridine base can then be replaced by a thymidine base (e.g., by a cell repair mechanism) to produce a C:G to T:A transition. In other embodiments, the deamination of C in a nucleic acid to U by a base editor is not accompanied by a substitution of U to T.
[0600] The target C deamination in the polynucleotide to produce U is a non-limiting example of a base editing type that can be performed by a base editor as described herein. In another example, a base editor comprising a cytidine deaminase domain can mediate the conversion of cytosine (C) bases into guanine (G) bases. For example, the U of the polynucleotide produced by the cytidine deamination domain of the base editor can be removed from the polynucleotide by a base excision repair mechanism (e.g., by uracil DNA glycosylase (UDG) domain), producing an abasic site. The core base opposite to the abasic site can then be replaced (e.g., by a base repair mechanism) by another base (such as C) by, for example, a trans-damage polymerase. Although the core base opposite the abasic site is typically replaced by C, other substitutions (e.g., A, G, or T) may also occur.
[0601] Thus, in some embodiments, the base editors described herein comprise a deamination domain (e.g., a cytidine deaminase domain) capable of deaminating a target C in a polynucleotide to U. Further, as described below, the base editor may comprise an additional domain that promotes the conversion of U produced by deamination into T or G in some embodiments. For example, a base editor comprising a cytidine deaminase domain may further comprise a uracil glycosylase inhibitor (UGI) domain to mediate the replacement of U by T, completing a C to T base editing event. In another example, a base editor may be incorporated into a trans-lesion polymerase to improve the efficiency of C to G base editing, because the trans-lesion polymerase can promote the incorporation of C relative to the abasic site (i.e., causing G to be incorporated at the abasic site, completing a C to G base editing event).
[0602] A base editor comprising a cytidine deaminase as a domain can deaminate the target C in any polynucleotide base (including DNA, RNA, and DNA-RNA hybrids). Typically, cytidine deaminase catalyzes the C core base positioned in the case of a single-stranded portion of a polynucleotide. In some embodiments, the complete polynucleotide comprising target C can be single-stranded. For example, the cytidine deaminase incorporated into the base editor can deaminate the target C in a single-stranded RNA polynucleotide. In other embodiments, the base editor comprising a cytidine deaminase domain can act on a double-stranded polynucleotide, but the target C can be located in a portion of a polynucleotide that is in a single-stranded state during the deamination reaction. For example, in an embodiment in which the NAGPB domain includes a Cas9 domain, during the formation of the Cas9-gRNA-target DNA complex, several nucleotides can remain unpaired, thereby leading to the formation of a cas9 "R-loop complex". These unpaired nucleotides can form a single-stranded DNA bubble, which can serve as a substrate for a single-stranded specific nucleotide deaminase (e.g., cytidine deaminase).
[0603] In some embodiments, the cytidine deaminase of the base editor may include all or part of an apolipoprotein B mRNA editing complex (APOBEC) family deaminase. APOBEC is an evolutionarily conserved family of cytidine deaminases. Members of this family are C to U editing enzymes. The N-terminal domain of the APOBEC-like protein is the catalytic domain, while the C-terminal domain is a pseudocatalytic domain. More specifically, the catalytic domain is a zinc-dependent cytidine deaminase domain and is important for cytidine deamination. APOBEC family members include APOBEC1, APOBEC2, APOBEC3A, APOBEC3B, APOBEC3C, APOBEC3D ("APOBEC3E" now refers to this), APOBEC3F, APOBEC3G, APOBEC3H, APOBEC4, and activation-induced (cytidine) deaminase. In some embodiments, the deaminase incorporated into the base editor includes all or part of the APOBEC1 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC2 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3A deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3B deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3C deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3D deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3E deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3F deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3G deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC3H deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC4 deaminase. In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an activation-induced deaminase (AID). In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of cytidine deaminase 1 (CDA1). It should be understood that the base editor may comprise a deaminase from any suitable organism (e.g., human or rat). In some embodiments, the deaminase domain of the base editor is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse.In some embodiments, the deaminase domain of the base editor is derived from rat (e.g., rat APOBEC1). In some embodiments, the deaminase domain of the base editor is human APOBEC1. In some embodiments, the deaminase domain of the base editor is pmCDA1.
[0604] Other exemplary deaminases that can be fused to Cas9 according to aspects of the present disclosure are provided below. In an embodiment, the deaminase is an activation-induced deaminase (AID). It should be understood that in some embodiments, an active domain of the corresponding sequence can be used, such as a domain without a localization signal (nuclear localization sequence, no nuclear export signal, cytoplasmic localization signal).
[0605] Some aspects of the present disclosure are based on the recognition that, for example, by modulating the catalytic activity of the deaminase domain of any fusion protein described herein, by generating point mutations in the deaminase domain, can affect the processivity of the fusion protein (e.g., base editor). For example, mutations that reduce but do not eliminate the catalytic activity of the deaminase domain within a base editing fusion protein can make the deaminase domain less likely to catalyze the deamination of residues adjacent to the target residue, thereby narrowing the deamination window. The ability to narrow the deamination window can prevent unwanted deamination of residues adjacent to a specific target residue, which can reduce or prevent off-target effects.
[0606] For example, in some embodiments, the APOBEC deaminase incorporated into the base editor may comprise one or more mutations selected from H121X, H122X, R126X, R126X, R118X, W90X, W90X, and R132X of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise one or more mutations selected from H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
[0607] In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise one or more mutations selected from D316X, D317X, R320X, R320X, R313X, W285X, W285X, R326X of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid. In some embodiments, any fusion protein provided herein comprises an APOBEC deaminase comprising one or more mutations selected from D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
[0608] In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise the H121R and H122R mutations of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the R126A mutation of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the R126E mutation of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the R118A mutation of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising a W90A mutation of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising a W90Y mutation of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising an R132E mutation of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising W90Y and R126E mutations of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising R126E and R132E mutations of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising W90Y and R132E mutations of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising W90Y, R126E, and R132E mutations of rAPOBEC1 or one or more corresponding mutations in another APOBEC deaminase.
[0609] In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the D316R and D317R mutations of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, any fusion protein provided herein comprises an APOBEC deaminase comprising the R320A mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the R320E mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the R313A mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising a W285A mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising a W285Y mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising an R326E mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising a W285Y and R320E mutation of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the R320E and R326E mutations of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the W285Y and R326E mutations of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase. In some embodiments, the APOBEC deaminase incorporated into the base editor may comprise an APOBEC deaminase comprising the W285Y, R320E, and R326E mutations of hAPOBEC3G or one or more corresponding mutations in another APOBEC deaminase.
[0610] Many modified cytidine deaminases are commercially available, including but not limited to SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, VRER-BE3, YE1-BE3, EE-BE3, YE2-BE3, and YEE-BE3, which can be purchased from Addgene (plasmids 85169, 85170, 85171, 85172, 85173, 85174, 85175, 85176, 85177). In some embodiments, the deaminase incorporated into the base editor comprises all or a portion of an APOBEC1 deaminase.
[0611] In some embodiments, the fusion protein of the present invention includes one or more cytidine deaminase domains. In some embodiments, the cytidine deaminase provided herein can deaminate cytosine or 5-methylcytosine to uracil or thymine. In some embodiments, the cytidine deaminase provided herein can deaminate the cytosine in DNA. The cytidine deaminase can be derived from any suitable organism. In some embodiments, the cytidine deaminase is a naturally occurring cytidine deaminase that includes one or more mutations corresponding to any mutation provided herein. Those skilled in the art will be able to identify the corresponding residues in any homologous protein, for example, by sequence alignment and determination of homologous residues. Therefore, those skilled in the art will be able to produce a mutation corresponding to any mutation described herein in any naturally occurring cytidine deaminase. In some embodiments, the cytidine deaminase is from a prokaryotic organism. In some embodiments, the cytidine deaminase is from a bacterium. In some embodiments, the cytidine deaminase is from a mammal (e.g., people).
[0612] In some embodiments, the cytidine deaminase comprises an amino acid sequence having at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, 95%, at least 96%, at least 97%, at least 98%, at least 99% or at least 99.5% identity to any cytidine deaminase amino acid sequence shown herein. It should be understood that the cytidine deaminase provided herein may include one or more mutations (e.g., any mutation provided herein). Some embodiments provide polynucleotide molecules encoding any of the aforementioned aspects or cytidine deaminase nucleobase editor polypeptides as described herein. In some embodiments, the polynucleotide is codon optimized.
[0613] The present disclosure provides any deaminase domain having a certain percentage identity plus any mutation described herein or a combination thereof. In some embodiments, the cytidine deaminase comprises an amino acid sequence having 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to a reference sequence or any cytidine deaminase provided herein. In some embodiments, the cytidine deaminase comprises an amino acid sequence having at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, or at least 170 identical consecutive amino acid residues compared to any amino acid sequence known in the art or described herein.
[0614] The fusion protein of the second protein of the present invention comprises two or more nucleic acid editing domains.
[0615] Details of C to T nucleobase editing proteins are described in International PCT Application No. PCT / US2016 / 058344 (WO2017 / 070632) and Komor, AC et al., “Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage,” Nature 533, 420-424 (2016), the entire contents of which are hereby incorporated by reference.
[0616] Guide polynucleotide
[0617] The polynucleotide programmable nucleotide binding domain can specifically bind to the target polynucleotide sequence when bound to the bound guide polynucleotide (e.g., gRNA) (i.e., via complementary base pairing between the bases of the bound guide nucleic acid and the bases of the target polynucleotide sequence), thereby positioning the base editor to the target nucleic acid sequence that needs to be edited. In some embodiments, the target polynucleotide sequence includes single-stranded DNA or double-stranded DNA. In some embodiments, the target polynucleotide sequence includes RNA. In some embodiments, the target polynucleotide sequence includes a DNA-RNA hybrid.
[0618] CRISPR is an adaptive immune system that provides protection for mobile genetic elements (viruses, transposable elements, and conjugated plasmids). The CRISPR cluster contains a spacer, a sequence complementary to the preceding mobile element, and a target invading nucleic acid. The CRISPR cluster is transcribed and processed into CRISPRRNA (crRNA). In the type II CRISPR system, the correct processing of pre-crRNA requires trans-encoded small RNA (tracrRNA), endogenous ribonuclease 3 (me), and Cas9 protein. TracrRNA acts as a guide for ribonuclease 3 to assist in the processing of pre-crRNA. Subsequently, Cas9 / crRNA / tracrRNA endonuclease cuts linear or circular dsDNA targets complementary to the spacer. The target chain that is not complementary to crRNA is first cut in an endonucleolytic manner and then trimmed in a 3′-5′ exonucleolytic manner. In nature, DNA binding and cutting generally require proteins and two types of RNA. However, single guide RNA ("sgRNA" or "gRNA" for short) can be engineered to incorporate aspects of both crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J.A., Charpentier E. Science 337:816-821 (2012), the entire contents of which are hereby incorporated by reference. Cas9 recognizes a short motif (PAM or protospacer adjacent motif) in the CRISPR repeat sequence to help distinguish self from non-self. See, e.g., “Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti, JJ et al., Natl. Acad. Sci. USA 98:4658-4663 (2001); “CRISPR RNAmaturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E. et al., Nature 471:602-607 (2011); and “Programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.” Jinek M. et al., Science 337:816-821 (2012), the entire contents of each of which are incorporated herein by reference).
[0619] The PAM sequence can be any PAM sequence known in the art. Suitable PAM sequences include, but are not limited to, NGG, NGA, NGC, NGN, NGT, NGCG, NGAG, NGAN, NGNG, NGCN, NGCG, NGTN, NNGRRT, NNNRRT, NNGRR(N), TTTV, TYCV, TYCV, TATV, NNNNGATT, NNAGAAW, or NAAAC. Y is a pyrimidine; N is any nucleotide base; and W is A or T.
[0620] In one embodiment, the guiding polynucleotide described herein can be RNA ...
Claims
1. A method of editing nucleobases of the hepatitis B virus (HBV) genome, the method comprising coordinating the HBV genome with one or more guide RNAs and a polynucleotide programmable DNA binding domain and an adenoid base editor contact of glycoside deaminase, wherein the guide RNA targets the base editor to achieve the Changes in the nucleobase of the HBV genome, and wherein the one or more guide RNAs comprise a nucleotide sequence from 5' to 3' selected from one or more of the following, or 1, 2 thereof , 5' and / or 3' truncated fragments of 3, 4 or 5 nucleotides: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CA CCUGUAUUCCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGU CUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACU GG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 405) NO:410),UUCUUCUAGGGGACCUGCCU(SEQ ID NO:411),GAGGACAAACGGGCAACAUA(SEQ ID NO:412),UUGUCAAC AAGAAAAACCCC(SEQ ID NO:413),CCCAAGGUCUUACAUA AGAG(SEQ ID NO:414),CCGGGCAACGGGGUAAAGGU(SEQID NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416), GAAAGCCCAAGAUGAUGGGA (SEQ ID NO.10834) and CACG CACGCGCUGAUGGCCC (SEQ ID NO:417).
2. A method for editing nucleobases of the hepatitis B virus (HBV) genome, the method include: (i) contacting a cell comprising an HBV genome with one or more guide RNAs and a base editor comprising a polynucleotide programmable DNA binding domain and an adenosine deaminase or cytidine deaminase, wherein said guide RNA targeting the base editor to effect changes in the nucleobases of the HBV genome, thereby editing the nucleobases in the HBV genome; and (ii) contacting the cell with an antiretroviral drug, wherein contacting the cell with the antiretroviral drug has a greater effect on base editing efficiency relative to a reference cell not contacted with the antiretroviral drug related to the improvement.
3. A method of reducing HBsAg produced by integrated HBV DNA, the method comprising contacting a cell comprising the HBV genome with one or more guide RNAs and a polynucleotide comprising a programmable DNA binding domain and adenosine deamination Enzyme or base editor contact of cytidine deaminase, wherein the guide RNA targets the base editor to achieve changes in the nucleobases of the HBV genome, thereby reducing production by integrated HBV DNA HBsAg.
4. The method of claim 2, wherein the antiretroviral drug is selected from the group consisting of lamivudine, entecavir, tenofovir, interferon, and peginterferon.
5. The method of any one of claims 2-4, wherein step (i) precedes step (ii), or step (ii) precedes step (i).
6. The method of any one of claims 2-5, wherein step (i) is first preceded by about or at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13 or 14 days before the cells are exposed to the antiretroviral drug.
7. The method of any one of claims 2-6, wherein the cells have not been previously contacted with the antiretroviral drug.
8. The method of any one of claims 2-7, wherein the cells are in a subject.
9. The method of any one of claims 1-8, wherein the HBV genome is contacted with two or more guide RNAs simultaneously.
10. The method of any one of claims 2-9, wherein the guide RNA is selected from one or more of the following: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUUCCCAUCCCAU (SEQ ID NO:407), GGGGCCAAGU CUGUACAGCA (SEQ ID NO: 408), GCUGACGCAACCCCCACU GG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO: 410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO: 411), GAGGACAAACGGGCAACAUA (SEQ ID NO: 412), UUGUCAAC AAGAAAAACCC (SEQ ID NO: 411) NO:413), CCCAAGGUCUUACAUA AGAG (SEQ ID NO:414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO:417).
11. The method of any one of claims 2-10, wherein the one or more guide RNAs comprise selected from Table 2A, Table 2B, Table 2C and / or SEQ ID NOs: 3105-5485 and 8220 Spacer sequences for sequences listed in -10830.
12. The method of any one of claims 2-11, wherein the one or more guide RNAs comprise a spacer comprising the nucleotide sequence GAAAGCC CAGGAUGAUGGGA (SEQ ID NO: 657) , 5'-GAAAGCCCAAGAT GATGGGA-3' and CCAUGCCCCAAAGCCACCCA (SEQ ID NO: 662).
13. The method of any one of claims 2-12, wherein the one or more guide RNAs comprise the nucleotide sequence mG*mA*mA*AGCCCAGGAUGAUGGG AGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGUC CGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUmU*mU*mU* (SEQ ID NO: 424) and mC*mC*mA*UGCCCCAAAGCCACC CAGUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAGGCUAGU CCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUmU*mU*mU* (SEQ ID NO: 422).
14. The method of any one of claims 1-13, wherein the one or more guide RNAs comprise the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaA uAaggcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcususu (SEQ ID NO:317), wherein a, c, u or g represents a base with 2'O-methyl (M) modification, and as, cs, us or gs represents a base with 2'-O-methyl 3'-sulfur Phosphate substituted (MS) modified bases.
15. The method of any one of claims 2-12, wherein the one or more guide RNAs comprise the following nucleotide sequence: gsasasAGCCCAGGAUGAUGGGAg UUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGUccGUUAucAAcuug aaaaagugGcaccgagucggugcususu (SEQ ID NO: 424) and cscsasUGCCCCAAAGCCACCCAgUUUUAGagcuagaaauagcaaGU UaAaAuAaggcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcusus usu(SEQ ID NO:422), wherein a, c, u or g respectively represent A, C, U or G nucleotides containing 2'O-methyl (M) modification; and as, cs, us or gs respectively represent containing 2 '-O-Methyl 3'-phosphorothioate (MS) modified A, C, U or G nucleotides.
16. The method of any one of claims 2-15, wherein the cell is contacted with the one or more guide RNAs and the base editor at a first time point and a second time point .
17. The method of claim 16, wherein the first and second contacting the cells are separated by at least one week.
18. The method of claim 16, wherein the first and second contacting the cells are separated by at least two weeks.
19. The method of any one of claims 2-18, wherein base editing efficiency is increased by at least about 5%, 10%, 15%, or 20%.
20. A method of editing nucleobases of the hepatitis B virus (HBV) genome, the method comprising contacting a cell containing the HBV genome with an mRNA encoding a base editor and one or more guide RNAs, said The base editor comprises a polynucleotide programmable DNA binding domain and an adenosine deaminase or cytidine deaminase, the one or more guide RNAs comprising the sequence GAAAGCCCAGGAUGAUGGGA (SEQ ID NO:657) and CCAUGCCCCAAAGCCACCCA (SEQ ID NO:662), wherein the one or more guide RNAs target the base editor to achieve changes in the nucleobases of the HBV genome, thereby editing the Describe the nucleobases in the HBV genome.
21. The method of claim 20, further comprising contacting the cells with lamivudine, wherein the cells are contacted with lamivudine relative to a reference cell not contacted with the antiretroviral drug. Targeted contacts are associated with increased base editing efficiency.
22. The method of claim 20 or claim 21, wherein the guide RNA comprises the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaAuAagg cuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcususu (SEQ ID NO:317), wherein a, c, u or g represents a base with 2'O-methyl (M) modification, and as, cs, us or gs represents a base with 2'-O-methyl 3'-sulfur Phosphate substituted (MS) modified bases.
23. The method of claim 20 or claim 21, wherein the guide RNA comprises the following scaffold sequence: GUUUUAGAGCUAGAAAUAGCAAGUUA AAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGGCUmU*mU*mU* (SEQ ID NO: 422), where mA*, mC*, mG* and mU* represent bases modified with 2'-O-methyl 3'-phosphorothioate.
24. The method of any one of claims 20-23, wherein the cell is contacted with the one or more guide RNAs and the base editor at a first time point and a second time point .
25. The method of claim 24, wherein the first and second contacting the cells are separated by at least one week.
26. The method of any one of claims 20-25, wherein the base editor is BE4.
27. The method of any one of claims 1-26, wherein the nucleobase is located in a polynucleotide encoding an HBV protein.
28. The method of any one of claims 1-26, wherein the contacting is performed in a eukaryotic cell, a mammalian cell, or a human cell.
29. The method of any one of claims 2 to 28, wherein the cells are in vivo or ex vivo.
30. The method of any one of claims 1 to 29, wherein the adenosine deaminase converts the target A·T in the hepatitis B virus (HBV) genome to G·C.
31. The method of any one of claims 1-29, wherein the nucleobase is located at an HBV encoding selected from the group consisting of HBV core protein (Core), HBV polymerase (Pol), HBV surface protein or HBV protein X in the polynucleotide sequence of the protein.
32. The method of any one of claims 1-31, wherein the change in the nucleobase in the polynucleotide encoding the HBV protein results in a missense mutation.
33. The method of any one of claims 1-32, wherein the nucleobase is associated with a site of transcription.
34. The method of claim 33, wherein the transcription site is selected from one or more of enhancer II box A, enhancer I and HBX promoter.
35. The method of any one of claims 1-34, wherein the change in nucleobases is associated with reduced transcription of a polynucleotide sequence encoding an HBV protein.
36. The method of claim 35, wherein the HBV protein is HBV polymerase (Pol) and / or HBV protein X.
37. The method of claim 32, wherein the missense mutation is located in the HBV pol gene.
38. The method of claim 37, wherein the missense mutation results in the HBV E24G, L25F, P26F, R27C, V48A, V48I, S382F, V378I, V378A, V379I, V379A, L377F, D380G, D38 in the HBV polymerase protein encoded by the pol gene 0N, F381P, R376G, A422T, F423P, A432V, M433V, P434S, D540G, A688V, D689G, A717T, E718K, P713S, P713L or L719P.
39. The method of claim 32, wherein the missense mutation is located in the HBV core gene.
40. The method of claim 39, wherein the missense mutation results in T160A, T160A, P161F, S162L, C183R or *184Q in the HBV core protein encoded by the HBV core gene.
41. The method of claim 32, wherein the missense mutation is located in the HBV X gene.
42. The method of claim 41, wherein the missense mutation results in H86R, W120R, E122K, E121K or L141P in the HBV X protein encoded by the HBV X gene.
43. The method of claim 32, wherein the missense mutation is located in the HBV S gene.
44. The method of claim 43, wherein the missense mutation results in S38F, L39F, W35R, W36R, T37I, T37A, R78Q, S34L, F80P or D33G in the HBV S protein encoded by the HBV S gene .
45. The method of any one of claims 1-44, wherein the polynucleotide programmable DNA binding domain comprises a Cas12 polypeptide.
46. The method of any one of claims 1-45, wherein the polynucleotide programmable DNA binding domain comprises Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h or Cas12i.
47. The method of any one of claims 1-46, wherein the polynucleotide programmable DNA binding domain comprises Bacillus ectomuranschen Cas12b, Bacillus thermomylophilus Cas12b, Bacillus spp. V3-13 Cas12b or Alicyclobacillus acidophilus Cas12b has a sequence of at least about 85% amino acid sequence identity.
48. The method of claim 47, wherein the polynucleotide programmable DNA binding domain comprises a sequence that has at least about 85% amino acid sequence identity to Bacillus exomuramura Cas12b (bhCas12b).
49. The method of any one of claims 1-48, wherein the polynucleotide programmable DNA binding domain comprises a nuclease inactive variant or a nickase variant.
50. The method of claim 49, wherein the nuclease-inactive variant or nickase variant comprises nuclease-activated bhCas12b comprising the amino acid substitutions D952A, S893R, K846R and E837G or their corresponding amino acid substitutions.
51. The method of any one of claims 1-50, wherein the adenosine deaminase domain is capable of deaminating adenine in deoxyribonucleic acid (DNA).
52. The method of any one of claims 1-51, wherein the adenosine deaminase is TadA deaminase.
53. The method of claim 52, wherein the TadA deaminase is TadA*7.10, TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7 , TadA*8.8, TadA*8.9, TadA*8.10, TadA* 8.11, TadA*8.12, TadA*8.13, TadA*8.14, TadA*8.15, TadA*8.16, TadA*8.17, Ta dA*8.18, TadA*8.19, TadA*8.20, TadA*8.21, TadA*8.22, TadA*8.23 or TadA*8.
24.
54. The method of claim 53, wherein the TadA deaminase is TadA*8.
13.
55. The method of any one of claims 1-54, wherein the one or more guide RNAs comprise CRISPRRNA (crRNA) and a trans-encoding small RNA (tracrRNA), wherein the crRNA comprises and A nucleic acid sequence complementary to the HBV nucleic acid sequence.
56. The method of any one of claims 1-55, wherein the base editor forms a complex with a single guide RNA (sgRNA) comprising a nucleic acid sequence complementary to an HBV nucleic acid sequence.
57. The method of any one of claims 1-56, comprising editing two or more nucleobases.
58. The method of any one of claims 1-57, comprising contacting the HBV genome with two or more guide RNAs targeting two or more HBV nucleic acid sequences.
59. A method of treating hepatitis B virus (HBV) infection in a subject, comprising administering to a subject in need thereof a fusion protein, a protein complex, or a polynucleotide encoding the fusion protein or protein complex and one or more guide RNAs, the fusion protein or protein complex comprising a polynucleotide programmable DNA binding domain and a base editor domain as an adenosine deaminase domain, the one or A plurality of guide RNAs target the base editor domain to achieve changing the A·T of the nucleobases of the HBV genome to G·C, wherein the one or more guide RNAs comprise selected from the following: One or more nucleotide sequences from 5' to 3', or 5' and / or 3' truncated fragments of 1, 2, 3, 4 or 5 nucleotides thereof: ACAAGAAUCCUCACAAUACC (SEQ ID NO:405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO:406), CACCUGUAU UCCCAUCCCAU (SEQ ID NO:407), GGGGCCAAGUCUGUACA GCA (SEQ ID NO:408), GCUGACGCAACCCCCACUGG (SEQ ID NO:409), GGAGCUACUGUGGAGUUACU (SEQ ID NO:408) NO:410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO:411), GAGGACAA ACGGGCAACAUA (SEQ ID NO:412), UUGUCAACAAGAAAAA CCCC (SEQ ID NO:413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO:414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO:410) NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO:417).
60. A method of treating hepatitis B virus (HBV) infection in a subject, comprising administering to a subject in need thereof one or more polynucleotides encoding programmable DNA binding domains and as an adenosine-depleted protein. A polynucleotide of a base editor domain of an ammonia enzyme domain, and one or more guide RNAs targeting the base editor Structural domain to achieve changing the A·T of the nucleobase of the HBV genome to G·C, wherein the one or more guide RNAs comprise from 5' to 3' selected from one or more of the following The nucleotide sequence, or 5' and / or 3' truncated fragments of 1, 2, 3, 4 or 5 nucleotides thereof: ACAAGAAUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO: 406), CACCUGUAUU CCCAUCCCAU (SEQ ID NO: 407), GGGGCCAAGUCUGUACAG CA (SEQ ID NO: 408), GCUGACGCAACCCCCACUGG (SEQ ID NO: 409), GGAGCUACUGUGGAGUUACU (SEQ ID NO:410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO:411), GAGGACAAA CGGGCAACAUA (SEQ ID NO:412), UUGUCAACAAGAAAAAC CCC (SEQ ID NO:413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO:414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO:410) NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO:417).
61. A method of treating hepatitis B virus (HBV) infection in a subject, comprising administering to a subject in need thereof one or more guide RNAs and a method comprising a polynucleotide programmable DNA binding domain and an adenoid A base editor for a glycoside deaminase or a cytidine deaminase, wherein the one or more guide RNAs comprise the sequences GAAAGCCCAGGAUGAUGGG A (SEQ ID NO: 657) and CCAUGCCCCAAAGCCACCCA (SEQ ID NO: 662), which targets the base editor to achieve changes in the nucleobases of the HBV genome, thereby editing the nucleobases in the HBV genome.
62. The method of any one of claims 59-61, wherein the subject is a mammal or a human.
63. The method of any one of claims 59-62, comprising converting said fusion protein, said polynucleotide encoding said fusion protein, or said polynucleotide encoding said polynucleotide into a programmable DNA binding domain and one or more polynucleotides of the base editor domain, and the one or more guide RNAs are delivered to cells of the subject.
64. The method of claim 63, wherein said cells are hepatocytes.
65. The method of any one of claims 59-64, wherein the nucleobase is located in a polynucleotide encoding an HBV protein.
66. The method of claim 65, wherein the HBV protein is HBV core protein (Core), HBV polymerase (Pol), HBV surface protein or HBV protein X.
67. The method of claim 65 or claim 66, wherein the change in the nucleobase in the polynucleotide encoding the HBV protein results in a missense mutation.
68. The method of any one of claims 59-67, wherein the nucleobase is associated with a site of transcription.
69. The method of claim 68, wherein the transcription site is selected from one or more of enhancer II box A, enhancer I and HBX promoter.
70. The method of any one of claims 59-69, wherein the change in nucleobases is associated with reduced transcription of a polynucleotide sequence encoding an HBV protein.
71. The method of claim 70, wherein the HBV protein is HBV polymerase (Pol) and / or HBV protein X.
72. The method of claim 67, wherein the missense mutation is located in the HBV pol gene.
73. The method of claim 72, wherein the missense mutation results in the HBV E24G, L25F, P26F, R27C, V48A, V48I, S382F, V378I, V378A, V379I, V379A, L377F, D380G, D38 in the HBV polymerase protein encoded by the pol gene 0N, F381P, R376G, A422T, F423P, A432V, M433V, P434S, D540G, A688V, D689G, A717T, E718K, P713S, P713L or L719P.
74. The method of claim 67, wherein the missense mutation is located in the HBV core gene.
75. The method of claim 74, wherein the missense mutation results in T160A, T160A, P161F, S162L, C183R or *184Q in the HBV core protein encoded by the HBV core gene.
76. The method of claim 67, wherein the missense mutation is located in the HBV X gene.
77. The method of claim 76, wherein the missense mutation results in H86R, W120R, E122K, E121K or L141P in the HBV X protein encoded by the HBV X gene.
78. The method of claim 67, wherein the missense mutation is located in the HBV S gene.
79. The method of claim 78, wherein the missense mutation results in S38F, L39F, W35R, W36R, T37I, T37A, R78Q, S34L, F80P or D33G in the HBV S protein encoded by the HBV S gene .
80. The method of any one of claims 59-79, wherein the polynucleotide programmable DNA binding domain comprises a Cas12 polypeptide.
81. The method of any one of claims 59-80, wherein the polynucleotide programmable DNA binding domain comprises Cas12a, Cas12b, Cas12c, Cas12d, Cas12e, Cas12g, Cas12h or Cas12i.
82. The method of any one of claims 59-81, wherein the polynucleotide programmable DNA binding domain comprises Bacillus ectomuranschen Cas12b, Bacillus thermomylophilus Cas12b, Bacillus spp. V3-13 Cas12b or Alicyclobacillus acidophilus Cas12b has a sequence of at least about 85% amino acid sequence identity.
83. The method of claim 82, wherein the polynucleotide programmable DNA binding domain comprises a sequence that has at least about 85% amino acid sequence identity to Bacillus exomurana Cas12b (bhCas12b).
84. The method of any one of claims 59-83, wherein the polynucleotide programmable DNA binding domain is a nuclease inactive variant or a nickase variant.
85. The method of claim 84, wherein the nuclease-inactive variant or nickase variant is nuclease-activated bhCas12b comprising the amino acid substitutions D952A, S893R, K846R and E837G or their corresponding amino acid substitutions.
86. The method of any one of claims 59-85, wherein the adenosine deaminase domain is capable of deaminating adenine in deoxyribonucleic acid (DNA).
87. The method of any one of claims 59-86, wherein the adenosine deaminase is TadA deaminase.
88. The method of claim 87, wherein the TadA deaminase is TadA*7.10, TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7 , TadA*8.8, TadA*8.9, TadA*8.10, TadA* 8.11, TadA*8.12, TadA*8.13, TadA*8.14, TadA*8.15, TadA*8.16, TadA*8.17, Ta dA*8.18, TadA*8.19, TadA*8.20, TadA*8.21, TadA*8.22, TadA*8.23 or TadA*8.
24.
89. The method of claim 88, wherein the TadA deaminase is TadA*8.
13.
90. The method of any one of claims 59-89, wherein the one or more guide RNAs comprise CRISPRRNA (crRNA) and a trans-encoding small RNA (tracrRNA), wherein the crRNA comprises an HBV Nucleic acid sequence A nucleic acid sequence that is complementary to a nucleic acid sequence.
91. The method of any one of claims 59-90, wherein the base editor forms a complex with a single guide RNA (sgRNA) comprising a nucleic acid sequence complementary to an HBV nucleic acid sequence.
92. The method of any one of claims 59-91, comprising editing two or more nucleobases.
93. The method of any one of claims 59-92, comprising contacting the HBV genome with two or more guide RNAs targeting two or more HBV nucleic acid sequences.
94. The method of claim 92 or claim 93, comprising two or more guide RNAs targeting three, four or five nucleobases of the HBV genome.
95. The method of any one of claims 59-93, wherein the guide RNA comprises the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaAuAaggcua GUccGUUAucAAcuugaaaaagugGcaccgagucggugcususu (SEQ ID NO:317), wherein a, c, u or g represents a base with 2'O-methyl (M) modification, and as, cs, us or gs represents a base with 2'-O-methyl 3'-sulfur Phosphate substituted (MS) modified bases.
96. The method of any one of claims 59-93, wherein the guide RNA comprises the following scaffold sequence: GUUUUAGAGCUAGAAAUAGCAAGUUAAAA UAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUmU*mU*mU* (SEQ ID NO: 422), where mA*, mC*, mG* and mU* represent bases modified with 2'-O-methyl 3'-phosphorothioate.
97. The method of claim 63 or claim 64, wherein the cell is contacted with the one or more guide RNAs and the base editor at a first time point and a second time point.
98. The method of claim 97, wherein the first and second contacting the cells are separated by at least one week.
99. The method of claim 97, wherein the first and second contacting the cells are separated by at least two weeks.
100. A composition comprising a base editor combined with a guide RNA, wherein the guide RNA comprises a nucleotide sequence from 5' to 3' selected from one or more of the following, or 1 thereof , 5' and / or 3' truncated fragments of 2, 3, 4 or 5 nucleotides: ACAAGA AUCCUCACAAUACC (SEQ ID NO: 405), UCGCUGGAUGUGUC UGCGGC (SEQ ID NO:406), CACCUGUAUUCCCAUCCCAU (SE Q ID NO:407), GGGGCCAAGUCUGUACAGCA (SEQ ID NO:408), GCUGACGCAACCCCCACUGG (SEQ ID NO:409), GGAGC UACUGUGGAGUUACU (SEQ ID NO:410), UUCUUCUAGGGGA CCUGCCU (SEQ ID NO:411), GAGGACAAACGGGCAACAUA (SEQ ID NO:412), UUGUCAACAAGAAAAACCCC (SEQ ID NO:413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO:414), CCGG GCAACGGGGUAAAGGU (SEQ ID NO:415), ACACAGAAAGGC CUUGUAAG (SEQ ID NO:411) NO:416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO:417).
101. The composition of claim 100, wherein the guide RNA comprises the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGUccG UUAucAAcuugaaaaagugGcaccgagucggugcususu (SEQ ID NO:317), wherein a, c, u or g represents a base with 2'O-methyl (M) modification, and as, cs, us or gs represents a base with 2'-O-methyl 3'-sulfur Phosphate substituted (MS) modified bases.
102. The composition of claim 100, wherein the guide RNA comprises the following scaffold sequence: GUUUUAGAGCUAGAAAUAGCAAGUUAAAAUAAG GCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCGGU GCUmU*mU*mU* (SEQ ID NO: 422), where mA*, mC*, mG* and mU* represent bases modified with 2'-O-methyl 3'-phosphorothioate.
103. The composition of any one of claims 100-102, wherein the base editor comprises an adenosine deaminase.
104. The composition of claim 103, wherein the adenosine deaminase is capable of deaminating adenine in deoxyribonucleic acid (DNA).
105. The composition of claim 104, wherein the adenosine deaminase is TadA deaminase.
106. The composition of claim 105, wherein the TadA deaminase is TadA*7.10, TadA*8.1, TadA*8.2, TadA*8.3, TadA*8.4, TadA*8.5, TadA*8.6, TadA*8.7, TadA*8.8, TadA*8.9, TadA*8.10, TadA *8.11, TadA*8.12, TadA*8.13, TadA*8.14, TadA*8.15, TadA*8.16, TadA*8.17, Ta dA*8.18, TadA*8.19, TadA*8.20, TadA*8.21, TadA*8.22, TadA*8.23 or TadA*8.
24.
107. The composition of claim 106, wherein the TadA deaminase is TadA*8.
13.
108. The composition of any one of claims 100-106, wherein the base editor (i) Contains nuclease-inactive bhCas12b; or (ii) Contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to: MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLYDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSST DGSSGSETPGTSESATPESSGAPKKKRKVGIHGVPAAATRSFILKIEPNEEVKKGLWKTHEVLNHGIAYYMNILKLIRQEAIYEHHEQDPKNPKKVSKAEIQAELWDFVLKMQKCNSFTHEVDKDEVFNILRELYEELVPSSVEKKGEANQLSNKFLYPLVDPNSQ SGKGTASSGRKPRWYNLKIAGDPSWEEEKKKWEEDKKKDPLAKILGKLAEYGLIPLFIPYTDSNEPIVKEIKWMEKSRNQSVRRLDKDMFIQALERFLSWESWNLKVKEEYEKVEKEYKTLEERIKEDIQALKALEQYEKERQEQLLRDTLNTNEYRLSKRGLRGW REIIQKWLKMDENEPSEKYLEVFKDYQRKHPREAGDYSVYEFLSKKENHFIWRNHPEYPYLYATFCEIDKKKKDAKQQATFTLADPINHPLWVRFEERSGSNLNKYRILTEQLHTEKLKKKLTVQLDDRIYPTESGGWEEKGKVDIVLLPSRQFYNQIFLDIEEKGK HAFTYKDESIKFPLKGTLGGARVQFDRDHLRRYPHKVESGNVGRIYFNMTVNIEPTESPVSKSLKIHRDDFPKVVNFKPKELTEWIKDSKGKKLKSGIESLEIGLRVMSIALGQRQAAAASIFEVVDQKPDIEGKLFFPIKGTELYAVHRASFNIKLPGETLVKSR EVLRKAREDNLKLMNQKLNFLRNVLHFQQFEDITEREKRVTKWISRQENSDVPLVYQDELIQIRELMYKPYKDWVAFLKQLHKRLEVEIGKEVKHWRKSLSDGRKGLYGISLKNIDEIDRTRKFLLRWSLRPTEPGEVRRLEPGQRFAIDQLNHLNALKEDRLKKM ANTIIMHALGYCYDVRKKKWQAKNPACQIILFEDLSNYNPYKERSRFENSRLMKWSRREIPRQVALQGEIYGLQVGEVGAQFSSRFHAKTGSPGIRCRVVTKEKLQDNRFFKNLQREGRLTLDKIAVLKEGDLYPDKGGEKFISLSKDRKCVTTHADINAAQNLQK RFWTRTHGFYKVYCKAYQVDGQTVYIPESKDQKQKIIEEFGEGYFILKDGVYEWVNAGKLKIKKGSSKQSSSELVDSDILKDSFDLASELKGEKLMLYRDPSGNVFPSDKWMAAGVFFGKLERILISKLTNQYSISTIEDDSSKQSMKRPAATKKAGQAKKKK(SEQ ID NO:418).
109. The composition of any one of claims 100-108, further comprising a lipid.
110. The composition of claim 109, wherein the lipid is a cationic lipid.
111. The composition of any one of claims 100-110, further comprising a pharmaceutically acceptable excipient.
112. A pharmaceutical composition for treating HBV infection, comprising: (i) a base editor or a nucleic acid encoding said base editor and one or more guide RNAs (gRNA) comprising a nucleic acid sequence complementary to an HBV gene in a pharmaceutically acceptable excipient, wherein the one or more guide RNAs comprise a nucleotide sequence from 5' to 3' selected from one or more of the following, or 1, 2, 3, 4 or 5 nucleotides thereof. ' and / or 3' truncated fragment: ACAAGAAUCCUCACAAUACC (SEQ ID NO:405), UCGCUGGAUGUGUCUGCGGC (SEQ ID NO:406), CACCUG UAUUCCCAUCCCAU (SEQ ID NO:407), GGGGCCAAGUCUGU ACAGCA (SEQ ID NO:408), GCUGACGCAACCCCCACUGG (SEQ ID NO:409), GGAGCUACUGUGGAGUUACU (SEQ ID NO:405) NO:410), UUCUUCUAGGGGACCUGCCU (SEQ ID NO:411), GAGG ACAAACGGGCAACAUA (SEQ ID NO:412), UUGUCAACAAGA AAAACCCC (SEQ ID NO:413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO:414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO:410) NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416) and CACGCACGCGCUGAUGGCCC (SEQ ID NO:417).
113. The pharmaceutical composition of claim 112, wherein the base editor (i) Contains nuclease-inactive bhCas12b; or (ii) Contains an amino acid sequence that is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 100% identical to: MSEVEFSHEYWMRHALTLAKRARDEREVPVGAVLVLNNRVIGEGWNRAIGLHDPTAHAEIMALRQGGLVMQNYRLYDATLYVTFEPCVMCAGAMIHSRIGRVVFGVRNAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLCRFFRMPRRVFNAQKKAQSST DGSSGSETPGTSESATPESSGAPKKKRKVGIHGVPAAATRSFILKIEPNEEVKKGLWKTHEVLNHGIAYYMNILKLIRQEAIYEHHEQDPKNPKKVSKAEIQAELWDFVLKMQKCNSFTHEVDKDEVFNILRELYEELVPSSVEKKGEANQLSNKFLYPLVDPNSQ SGKGTASSGRKPRWYNLKIAGDPSWEEEKKKWEEDKKKDPLAKILGKLAEYGLIPLFIPYTDSNEPIVKEIKWMEKSRNQSVRRLDKDMFIQALERFLSWESWNLKVKEEYEKVEKEYKTLEERIKEDIQALKALEQYEKERQEQLLRDTLNTNEYRLSKRGLRGW REIIQKWLKMDENEPSEKYLEVFKDYQRKHPREAGDYSVYEFLSKKENHFIWRNHPEYPYLYATFCEIDKKKKDAKQQATFTLADPINHPLWVRFEERSGSNLNKYRILTEQLHTEKLKKKLTVQLDDRIYPTESGGWEEKGKVDIVLLPSRQFYNQIFLDIEEKGK HAFTYKDESIKFPLKGTLGGARVQFDRDHLRRYPHKVESGNVGRIYFNMTVNIEPTESPVSKSLKIHRDDFPKVVNFKPKELTEWIKDSKGKKLKSGIESLEIGLRVMSIALGQRQAAAASIFEVVDQKPDIEGKLFFPIKGTELYAVHRASFNIKLPGETLVKSR EVLRKAREDNLKLMNQKLNFLRNVLHFQQFEDITEREKRVTKWISRQENSDVPLVYQDELIQIRELMYKPYKDWVAFLKQLHKRLEVEIGKEVKHWRKSLSDGRKGLYGISLKNIDEIDRTRKFLLRWSLRPTEPGEVRRLEPGQRFAIDQLNHLNALKEDRLKKM ANTIIMHALGYCYDVRKKKWQAKNPACQIILFEDLSNYNPYKERSRFENSRLMKWSRREIPRQVALQGEIYGLQVGEVGAQFSSRFHAKTGSPGIRCRVVTKEKLQDNRFFKNLQREGRLTLDKIAVLKEGDLYPDKGGEKFISLSKDRKCVTTHADINAAQNLQK RFWTRTHGFYKVYCKAYQVDGQTVYIPESKDQKQKIIEEFGEGYFILKDGVYEWVNAGKLKIKKGSSKQSSSELVDSDILKDSFDLASELKGEKLMLYRDPSGNVFPSDKWMAAGVFFGKLERILISKLTNQYSISTIEDDSSKQSMKRPAATKKAGQAKKKK(SEQ ID NO:418).
114. The pharmaceutical composition of claim 112 or claim 113, wherein the base editor comprises bhCas12b or a bhCas12b variant comprising the amino acid substitutions D952A, S893R, K846R and E837G.
115. The pharmaceutical composition of any one of claims 112-114, wherein the one or more gRNAs and the base editor are formulated together.
116. The pharmaceutical composition of any one of claims 112-115, wherein the one or more gRNAs and the base editor are formulated separately.
117. The pharmaceutical composition of any one of claims 112-116, further comprising a vector suitable for expression in mammalian cells, wherein the vector comprises a polynucleotide encoding the base editor.
118. The pharmaceutical composition of claim 117, wherein the vector is a viral vector.
119. The pharmaceutical composition of claim 118, wherein the viral vector is a retroviral vector, an adenoviral vector, a lentiviral vector, a herpesvirus vector or an adeno-associated virus vector (AAV).
120. The pharmaceutical composition of any one of claims 112-119, further comprising ribonucleoprotein particles suitable for expression in mammalian cells.
121. The composition of any one of claims 112-120, wherein the guide RNA comprises the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaAuAag gcuaGUccGUUAucAAcuugaaaaagugGcaccgagucggugcususu (SEQ ID NO:317), wherein a, c, u or g represents a base with 2'O-methyl (M) modification, and as, cs, us or gs represents a base with 2'-O-methyl 3'-sulfur Phosphate substituted (MS) modified bases.
122. The composition of any one of claims 112-120, wherein the guide RNA comprises the following scaffold sequence: GUUUUAGAGCUAGAAAUAGCAAGUU AAAAUAAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUmU*mU*mU* (SEQ ID NO: 422), where mA*, mC*, mG* and mU* represent bases modified with 2'-O-methyl 3'-phosphorothioate.
123. A method of treating HBV infection, comprising administering the composition of any one of claims 100-111 to a subject in need thereof.
124. A method of treating HBV infection, the method comprising administering the pharmaceutical composition of any one of claims 112-123 to a subject in need thereof.
125. The method of any one of the preceding claims, wherein the HBV has genotype A or genotype D.
126. The method of any one of the preceding claims, wherein the method reduces the level of a marker selected from the group consisting of: hepatitis B surface antigen, hepatitis B E antigen, hepatitis B virus total DNA , hepatitis B 3.5kb RNA and hepatitis B covalently closed circular DNA.
127. The method of any one of the preceding claims, wherein the method edits the hepatitis B S antigen site and pre-core site.
128. The method of any one of the preceding claims, wherein the editing efficiency is about 30% at the S antigen site and about 60% at the pre-core site.
129. Use of the composition of any one of claims 100-111 for treating HBV infection in a subject.
130. Use of the pharmaceutical composition of any one of claims 112-123 in treating HBV infection in a subject.
131. The use of claim 129 or 130, wherein the subject is a mammal.
132. The use of any one of claims 129-131, wherein the subject is human.
133. A guide RNA comprising a nucleotide sequence from 5' to 3' selected from one or more of the following, or the 5' and 1, 2, 3, 4 or 5 nucleotides thereof. / or 3' truncated fragments: ACAAGAAUCCUCACAAUACC (SEQ ID NO:405), UCGCUG GAUGUGUCUGCGGC (SEQ ID NO:406), CACCUGUAUUCCCAU CCCAU (SEQ ID NO:407), GGGGCCAAGUCUGUACAGCA (SE Q ID NO:408), GCUGACGCAACCCCCACUGG (SEQ ID NO:409), GGAGCUACUGUGGAGUUACU (SEQ ID NO:410), UUCUU CUAGGGGACCUGCCU (SEQ ID NO:411), GAGGACAAACGGG CAACAUA (SEQ ID NO:411) NO:412), UUGUCAACAAGAAAAACCCC (SEQ ID NO:413), CCCAAGGUCUUACAUAAGAG (SEQ ID NO:414), CCGGGCAACGGGGUAAAGGU (SEQ ID NO:415), ACACAGAAAGGCCUUGUAAG (SEQ ID NO:416) and CACGCACGCG CUGAUGGCCC (SEQ ID NO:417) .
134. The guide RNA of claim 133, wherein the guide RNA comprises the following scaffold sequence: gUUUUAGagcuagaaauagcaaGUUaAaAuAaggcuaGU ccGUUAucAAcuugaaaaagugGcaccgagucggugcususu (SEQ ID NO:317), wherein a, c, u or g represents a base with 2'O-methyl (M) modification, and as, cs, us or gs represents a base with 2'-O-methyl 3'-sulfur Phosphate substituted (MS) modified bases.
135. The guide RNA of claim 133, wherein the guide RNA comprises the following scaffold sequence: GUUUUAGAGCUAGAAAUAGCAAGUUAAAAU AAGGCUAGUCCGUUAUCAACUUGAAAAAGUGGCACCGAGUCCGGUGCUmU*mU*mU* (SEQ ID NO: 422), where mA*, mC*, mG* and mU* represent bases with 2'-O-methyl 3'-phosphorothioate modification.
136. A pharmaceutical composition comprising (i) a nucleic acid encoding a base editor; and (ii) the guide RNA of any one of claims 133-135.
137. The pharmaceutical composition of claim 136, further comprising a lipid.
138. The pharmaceutical composition of claim 136 or claim 137, wherein The nucleic acid encoding the base editor is mRNA.
Citation Information
Patent Citations
Electrical connector
EP0010831A1
Reovirus compositions and methods of use
US20100055131A1
Subcutaneous sensor inserter and method
US20160058344A1
System And Method For Providing A Content Delivery Network Via A Motor Vehicle
US20190044935A1
Safe Serve Utensil Sanitizing Cover
US20200016285A1
Cited By
Epigenetic editing tool targeting hepatitis b virus gene
WO2026124637A1
